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Breast cancer is the most common cancer among women worldwide. While 
incidence continues to rise as Western lifestyles are adopted, mortality rates have 
declined due to advancements in treatment and earlier detection through regular 
mammography screening. In this thesis, we explore issues pertaining to the accurate 
detection of breast cancer and risk assessment for individualized screening. 
Breast cancer is most treatable in its early stages therefore it should be identified 
as soon as possible. Analogue screen-film and full-field digital mammography (FFDM) 
are effective for both routine screening and symptomatic breast diagnosis. However, 
their benefits may be limited among younger women who tend to have dense breasts. 
Tissue overlap in two-dimensional (2D) images may obscure a tumor or produce an 
image that wrongly suggests an abnormality, leading to unnecessary recall. This may be 
resolved by stereoscopic digital mammography (SDM) which produces three-
dimensional (3D) images. We compared the effectiveness of SDM and FFDM in terms of 
lesion conspicuity and characterization. Our results showed that 3D is most suited for 
detecting mass lesions by improving margin clarity, and reduces the need for additional 
mammographic views. Abnormalities that are malignant or develop in denser breasts are 
more easily seen.   
Population-based mammography screening lowers mortality by around 20%. Yet, 
the controversies surrounding its age-dependent approach makes mass screening 
complex and resource-intensive. A balance between the benefits, harms and cost can 
be achieved by implementing a risk-based tailored screening programme that allocates 





The incorporation of mammographic density and common genetic variants to 
established risk models has been proposed. Mammographic density may be measured 
differently on digital versus analogue images, hence affecting the validity of existing risk 
models. Moreover, a standardized measure that is objective and automated is needed 
for large-scale application. Through a case-control study, we analyzed the relationship of 
quantitative density and subjective BI-RADS from processed digital images, with breast 
cancer risk. The added value of these measures and the substitutability of BI-RADS 
were examined too. Dense and total areas obtained using automated software, were 
associated with risk of the disease. Their combined use in place of BI-RADS did not 
significantly alter model discriminatory accuracy. 
Genetic variants identified in Western populations may not confer similar risks in 
Asians. We conducted a nested case-control study to investigate the cumulative effect of 
51 SNPs in conjunction with conventional risk factors. Classification of absolute five-year 
risk was improved for 6.2% of women. In a prospective cohort, we estimated risk by 
including known risk factors, mammographic density, and simulated genotypes across 
75 SNPs. At 2.5% absolute 10-year risk, our model correctly identified 0.9% more 
women who would develop breast cancer versus one containing classical risk factors 
only. Thus, mammographic density and common genetic variants can modestly improve 
the predictive ability of an established risk assessment model among females in 
Singapore. Our findings have highlighted the potential feasibility of employing such a 
model in the targeted prevention of breast cancer for a developed Asian country where 
screening is not well-received. 
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OUTLINE OF THESIS 
 
The aim of this thesis is twofold. Firstly, it explores the potential benefit of 3D 
mammography in improving detection accuracy of breast lesions. Secondly, it 
investigates the use of an individualized risk assessment method for targeted 
mammography screening in Singapore. 
Chapter 1 introduces epidemiology as a core practice within public health, and 
cancer as a significant problem that the world faces today. The top cancer among 
women is breast cancer [1]. An overview of the disease and its epidemiology is provided 
in Chapter 2 followed by a discussion on its detection, management and risk 
assessment. These approaches are intended to fulfill the three tiers of prevention, 
namely, tertiary, secondary and primary prevention. In this context, tertiary prevention 
refers to the long-term management of breast cancer when it is symptomatic as well as 
any complications, secondary prevention is the treatment of breast cancer in the early 
stages, and primary prevention seeks to protect people from the disease altogether. The 
research goals are then stated in Chapter 3, and the various studies that fulfill them are 
illustrated in the next few chapters.  
This thesis focuses on the detection and risk assessment of breast cancer - both 
‘upstream’ processes in the management of the disease. Early detection of breast 
cancer is achieved primarily through mammography, which is also part of the triple 
assessment in breast cancer diagnosis. However, the problem of tissue overlap in 
conventional mammography often leads to unnecessary recall and high false positive 
rates. Chapter 4 describes how stereoscopic digital mammography, a novel imaging 
technique, could improve the identification and characterization of breast lesions from 





Another problem that is encountered among Asian populations in particular is the 
low receptivity of screening mammography. Given its poor uptake and accuracy, a 
reliable risk assessment model to facilitate a tailored screening programme, where only 
women at higher risk are recommended regular screening, is pertinent. Presently, 
mammographic density and common genetic variants are two of the most frequently 
discussed variables that are associated with breast cancer. The former can be altered 
with anti-estrogen drugs to lower a woman’s risk of the disease, while recent advances 
in genotyping technology have prompted the discovery and application of numerous 
common genetic variants at reduced costs.  
Mammographic density is obtained from mammograms to help estimate a 
woman’s risk of breast cancer. Since women with denser breasts are more likely of 
developing the disease [2, 3], this opened up the possibility of using mammographic 
density together with established risk factors of breast cancer in risk assessment models. 
With the advent of technology, the use of automated quantitative measures in digital 
mammography instead of the current, subjective BI-RADS measure in risk assessment 
is considered in Chapter 5.  
Genetic research has benefitted from technological advancements too. GWAS 
have enabled the identification of a massive number of putative genes that are linked to 
breast cancer. In Chapter 6, the value of numerous common genetic variants with 
statistically significant effects was determined in the presence of other established risk 
factors. Since both mammographic density and common genetic variants were 
independently associated with breast cancer, Chapter 7 considers the potential 






The thesis concludes with Chapter 8 highlighting the key findings and suggesting 
possible work for the future. Finally, the afterword in Chapter 9 takes a broader 
perspective by contemplating about potential avenues for enhancing etiological research 



















Around 400 BC, Hippocrates wrote that “Whoever wishes to study medicine 
properly should… consider the seasons of the year…the winds…the waters…and the 
way in which the inhabitants live…whether they are fond of drinking and eating in excess 
and given to indolence, or are fond of exercise and labour [4].” More than 2000 years 
later, the term “epidemiology” was coined and various branches of research pertaining to 
this field have emerged ever since [5, 6].  
Stemming from the word “epidemic”, epidemiology has often been defined as 
“the study of the distribution and determinants of disease frequency in man [7].” Three 
components are highlighted here: frequency, which refers to the quantification of disease 
occurrence in the population; distribution, which describes the pattern of disease 
affecting a subgroup of people within the population; and determinants, which could be 
physical, biological, social, cultural or behavioral factors that influence health. This 
definition is anchored on two fundamental assumptions. Firstly, diseases do not occur in 
a population purely by chance. Secondly, they are caused and prevented by certain 
elements of person, place or time [8] which should be identified systematically.  
The search for etiological factors of disease is not a modern idea, as evidenced 
in early writings of the Egyptians, Jews, Greeks and Romans [9]. Hippocrates and Galen, 
both prominent Greek physicians, noted that disease in a population was a result of 
atmospheric conditions or “miasma”, an individual’s susceptibility to illness and lifestyle 
[10]. However, in 1854, the popular “miasma theory” was displaced by John Snow, 
whose investigations found poor water quality and not “bad air” to be the culprit behind 





waste systems were managed, and his study is now deemed as the first in modern 
epidemiology. 
Over the years, epidemiology has shifted gears from being a discipline that 
interweaves etiology and public health matters, to one that focuses on study 
methodology and clinical outcomes for the individual instead. The end of World War II 
saw the start of such major, pioneering projects. Doll and Hill employed a case-control 
design [12] to better understand the impact of smoking on lung cancer. Their method 
soon became a milestone for the study of diseases with long induction periods. In an 
attempt to untangle the effects of genes and the environment on cancer, research on 
Japanese migrants to Hawaii and California revealed that dietary and other lifestyle 
factors affect one’s risk of stomach and colon cancer to a larger extent [13]. Cohort 
studies such as the Framingham Heart Study led to the development of multiple logistic 
regression [14], one of the most important modeling techniques in modern epidemiology. 
The U.S. Nurses’ Health Study [15] highlighted the versatility of a multi-purpose cohort in 
examining associations between various outcomes and exposures.  
Suffice to say, epidemiologic investigations have been pivotal in controlling the 
spread of infectious diseases and the discovery of risk factors for chronic illnesses. Yet, 
achievements in the field have not spared it from criticism.  
Since the 1980s, a lot of effort has been placed in search of genetic markers of 
susceptibility to disease [16]. What started off as a targeted hunt for candidate genes 
became an agnostic approach in the form of genome-wide association studies (GWAS), 
following the completion of the Human Genome Project in 2003 [17]. While candidate 
gene studies rely on some background knowledge of the gene of interest, GWAS tend to 





one to question the validity of findings as testing a huge number of genetic variants 
increases the likelihood of false positives. Also, most surrogate markers do not correlate 
with actual determinants perfectly [19].  
Unlike the TP53 tumor suppressor gene whose notorious involvement with 
cancer was discovered much earlier on, common genetic variants contribute only a 
minute effect to an individual’s risk of disease [20]. Similarly, environmental factors that 
are strongly associated with illnesses have already been established over the past five 
decades, leaving subtler effects of other causal agents to be ascertained [21]. When 
effect size is small in an observational study, false positives and false negatives tend to 
occur due to measurement errors such as misclassification, bias and confounding [22]. 
In a bid to minimize these errors, and to integrate new genetic markers with traditional 
non-genetic factors, epidemiologists have developed novel complex statistical tools [21]. 
As more sophisticated methods are used to evaluate factors of lesser significance 
nowadays, reports have consequently become more difficult to interpret and understand 
especially for the common man. 
Non-replicability or conflicting findings is another product of studies with modest 
effect sizes [18]. This could be attributed to genuine heterogeneity among populations or 
bias, which is inherent in observational study designs [18].  Although meta-analysis aims 
to address these inconsistencies, it is subjected to publication bias against null findings 
and has attracted its share of skepticism too [18]. Unfortunately, the dissemination of 
contradictory results by over-zealous journalists who report them in isolation of other 
studies has created an “epidemic of anxiety” [21].  
While infectious diseases become less of a problem, chronic non-communicable 





advancements in biotechnology have altered the way epidemiologists think about health 
and sickness - we evaluate risk factors at the individual instead of population level, and 






























Cancer is one of four main types of non-communicable diseases, the other three 
being cardiovascular diseases, chronic respiratory diseases and diabetes [24]. 
According to the World Health Organization’s (WHO’s) GLOBOCAN 2012 report, 14.1 
million people were newly diagnosed with cancer, 32.6 million were still alive within 5 
years of diagnosis, and 8.2 million died of their condition in that year [1]. Regardless 
whether cancer is viewed from a public health or clinical point of view, its malignant 
nature has prompted the relentless search for causes and preventive strategies via 
epidemiological studies [22]. 
 
 Derived from “karkinos”, the Greek word for crab which Hippocrates used to 
describe solid breast tumors with finger-like projections [25], cancer in the modern day 
refers to a complex family of diseases that differ by site, morphology, clinical behavior 
and response to therapy [22]. Although there are several hundred kinds of cancer, all 
exhibit signs of malignancy which reflect the break-down of a cell’s defence system: 
uninhibited cell proliferation in the absence of cell-cycle control, growth despite inhibitory 
factors, evasion from apoptosis, a change in cell-environment interactions such as 
angiogenesis, as well as invasion into normal tissues and metastasis [26]. While 
malignant cells invade tissues and can be fatal, their benign counterparts remain in a 
single enveloped cluster and pose less of a problem. 
  
 Cancer often results from a culmination of a series of genetic mutations - 
changes in our genomic sequence that are acquired through the germline or facilitated 
by exogenous agents [27]. Between 5% and 10% of cancer is attributable to genetics 





oncogenes, tumor-suppressor genes and DNA repair genes [28, 29]. In a normal cell, 
oncogenes stimulate appropriate cell growth as required for cellular replication and 
tissue maintenance. When mutated, they are constantly activated and cells continue to 
grow without appropriate growth signals [28]. Tumor-suppressor genes function in an 
opposite way compared to oncogenes. They work to keep cell numbers controlled by 
inhibiting the cell cycle or promoting programmed cell death, hence, mutations will result 
in unrestrained increase in cell numbers even when growth-stimulatory signals are not 
present [28]. Unlike oncogenes and tumor-suppressor genes which direct 
carcinogenesis by regulating cell counts, DNA repair genes minimize the amount of 
genetic aberrations such that a mutation would lead to an accumulation and higher rates 
of gene defects that could potentially be cancerous [29]. While oncogenic mutations 
require one of two alleles to be mutated, cancer results only after both alleles of the 
tumor-suppressor or DNA repair genes are inactivated [29]. Proposed by Armitage and 
Doll, this two-hit theory of carcinogenesis suggests that one mutagenic event in each 
allele is necessary to facilitate the growth of neoplastic lesions; an individual may inherit 
a germline mutation first, then acquire a second somatic mutation later, or may get two 
successive somatic mutations without inheriting any [30]. 
 
 Somatic mutations are genetic aberrations that can be caused by exogenous 
carcinogens. These include occupational exposures, viruses and lifestyle-related factors 
such as smoking and diet [31]. While studies have noted the substantial causal effect of 
smoking in carcinogenesis, a smaller than expected effect of diet in adulthood on cancer 
was observed [32]. Although exogenous agents induce mutations through different 
pathways, all of them disrupt processes that ensure fidelity in DNA replication [33]. 
People who had inherited the first ‘hit’ will be more susceptible to cancer upon exposure 





 On a cellular level, cancer seems to originate based on a monoclonal model 
where a single normal cell becomes cancerous through numerous mutagenic events [34]. 
When DNA is subjected to exogenous carcinogens, cells undergo initiation - the first of a 
three-step carcinogenesis process. Although the irreversible damage to DNA is 
necessary, it is not sufficient for tumor formation. This is followed by tumor promotion, a 
reversible process that enables initiated cells to be expressed, leading to the generation 
of precursor lesions and benign tumors. Finally, through the build-up of genetic 
aberrations, benign tumors progress to form a malignant homogenous mass [26]. This 
can then develop into a heterogeneous cluster of cells as more mutations accumulate 
[33]. Eventually, an increasingly aggressive disease and metastasis result [35].  
 
 Metastasis is the migration of tumor cells from a primary mass to distant sites in 
the body. These cells multiply without survival and growth signals from the original 
environment, overcome inhibitory factors and build a vascular network in their new 
location. As secondary tumor masses develop, they can interfere with the daily functions 
of many organ systems. Hence, metastasis is often deemed as the most advanced 
stage and complication of cancer [33].  
 
 The stage of tumor development is often used to determine prognosis and 
appropriate therapy for a patient. Several components are used to stage a disease: size, 
extent of invasiveness into normal tissue, number of positive lymph nodes affected by 
disease spread and evidence of distant metastases. Higher stages mean worse 
prognosis [36]. Apart from stage, tumor grade is another commonly used prognostic 
indicator. Grading assesses the extent to which a tumor resembles normal tissue at the 





differentiated tumors that do not look like normal tissue are considered more malignant 
[33].  
 
 Research on cancer aims to provide effective clinical management and 
prevention so that incidence and mortality rates can be reduced. Worldwide, men suffer 
mostly from lung, prostate and colorectal cancer, while a majority of female patients are 
victims of breast, colorectal and cervical cancer [1]. Expectedly, studies on these 
frequent cancers have been plentiful. However not all knowledge garnered in the field 

















2.1 History of breast cancer 
The Edwin Smith Surgical Papyrus [37] appears to contain the earliest reference 
to breast cancer. Believed to have been written by Imhotep, the physician-architect who 
designed the step pyramid in Egypt in 3000 BC, it cited the diagnoses and treatment of 
eight cases of ailments of the “breast”, as well as first mentions regarding the suturing of 
wounds and cauterization with fire drills. Following that, Greek physicians of the 
Hellenistic period provided vivid details of the disease. “Karkinoma” referred to malignant 
growths, “scirrhous” described hard, solid tumors, “cacoethes” implied an early or 
probable malignancy, and a “hidden” cancer meant one that was not ulcerating the skin. 
Hippocrates remarked that solid tumors in the breast become firmer, are pus-free and 
can disseminate to other parts of the body. He noted that over time, the patient feels 
pain that originates from the breast to the neck and shoulder blades, acquires a bitter 
taste, loses appetite, craves water, and eventually becomes thin and weak. As he 
noticed that breast cancer tended to occur among women whose menstruation had 
ceased, Hippocrates tried to restore bleeding in younger patients. This observation was 
later corroborated by Galen who also recognized the higher occurrence of breast cancer 
among post-menopausal women. Treatment of “hidden” cancers was discouraged, 









2.2 Clinical features and prognosis 
In ancient times, the understanding of a disease was largely attained from a 
physician’s conjecture based on his observations of a patient. Breast cancer then was 
studied as a single disease that appeared in various forms, mainly visible or hidden, 
while advances in modern biology have revealed its heterogeneous nature [39].  
Varying subtypes of breast cancer exhibit distinct phenotypic and genotypic traits, 
and can translate to differences in clinical outcome. Tumors are classified according to 
their stage, grade, histology, and molecular profile.   
 
2.2.1 Stage 
 The practice of grouping cancer cases into early and late stages arose from the 
knowledge that patients tend to die of a disease if the cancer had spread beyond the 
organ of origin. This broad categorization gave the physician an indication of the 
patient’s prognosis and the course of treatment needed, if any. Today, the spread and 
extent of breast cancer is determined by a TNM system that was developed by a French 
doctor, Pierre Denoix, between 1943 and 1952. It has since been adapted for use in 
many cancers [40].  
 The TNM system uses the following components in staging: size of the primary 
tumor (T), number of affected lymph nodes (N), and absence or presence of distant 
metastasis (M). It ensures that patients within each category are similar in terms of their 
likelihood to survive the disease, and that rates across the categories are well-
differentiated. A higher stage corresponds to greater tumor size and spread, hence 
worse prognosis. Stage 0 represents the accumulation of hitherto non-invasive 





[40]. Supported by several findings [41-44], it is generally accepted that most breast 
tumors, if left untreated, would advance through the stages and continue to grow in 
malignancy [39].  
 
2.2.2 Grade 
The grade of a tumor indicates the aggressiveness of the disease and is 
assigned by examining the resemblance of tumor cells to healthy breast tissue under a 
microscope. This was first noted by a German physiologist, Johannes Müller who 
commented that the proportions of cancer cells contrasted those of normal cells [45]. 
Presently, the grade of a breast tumor cell is allocated the Nottingham Histologic Score, 
an amended Bloom-Richardson Scale [46] which looks at three morphologic features of 
breast tumor cells, namely, the formation of tubular structures, nuclear pleomorphism 
and cell division activity (Figures 2.1-2.3) [47]. Each feature is scored from 1 to 3 
according to the degree of differentiation, then summed to give a combined histologic 
grade based on the characteristics mentioned above [47]. The higher the tumor grade, 













                       
 
 
Figure 2.1 Grade I breast cancer. Tubules (structures that look like large rings) 
are well-formed, nuclei (dark circles) are uniform in shape and size, mitotic 
activity is absent. 
Figure 2.2 Grade II breast cancer. Solid clumps of tumor cells, moderate 








Studies have found that patients who are younger [48, 49], pre-menopausal [50] 
or have a positive family history [51, 52] are more likely to be diagnosed with higher-
grade breast cancers compared to their older, post-menopausal counterparts. Although 
there seems to be substantial correlation between tumor grade and stage especially 
among lower-grade tumors [53], the former remains an important independent predictor 
of five-year survival [54] and treatment response [55].  
 
2.2.3 Histology 
Another pathological breakthrough since the invention of the compound 
microscope is the ability to identify the organization and growth pattern of cancer cells. 
Ductal and lobular carcinomas constitute the two most common histological types of 
breast cancer [39]. A large majority of in-situ cancers are ductal carcinomas in-situ 
(DCIS) [56]. They occur in the milk ducts of the breast and are precursors of invasive 
cancers [57, 58]. On the other hand, lobular carcinomas in-situ (LCIS) - abnormal cells 
that grow in the lobules or milk-producing glands at the end of breast ducts, only place 
Figure 2.3 Grade III breast cancer. Tubule formation is absent, marked variation 





the woman at higher risk of breast cancer and are not viewed as true cancers [39, 56]. 
While DCIS frequently shows up on a mammogram, and has been on the rise in 
countries with nation-wide screening programmes [59, 60], LCIS is non-symptomatic and 
cannot be visualized on a mammogram [39].  
Among women diagnosed with invasive breast cancer, up to three quarters are 
invasive ductal carcinoma (IDC) [61]. Invasive lobular carcinomas (ILC) take up 
approximately 10% with the remainder being rare histological variants [61]. Unlike 
tumors in IDC which form discrete solid masses that are palpable and visible on a 
mammogram, those in ILC grow in sheets or linear strands that appear as subtle 
thickening of the breast, resulting in a later stage of presentation due to harder detection 
[62]. However, the hormone-dependent nature of tumors in ILC [63] allows for better 
response to therapy and a reduction in mortality risk among patients [64]. It is therefore 
unsurprising that the risk factor that has a contrasting influence between these two 
histological types is the use of combined hormone therapy [65].    
 
2.2.4 Molecular profile 
 Advancements in the field of molecular biology have allowed prognosis and 
treatment decisions to be made at a higher level of resolution compared to the past. 
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2) are the main markers that are assessed in a clinical setting [66]. 
Immunohistochemistry (IHC)-based methods are employed to ascertain ER, PR, and 
HER2 status of the tumour, while the more accurate Fluorescence In-Situ Hybridization 





  The ER is a nuclear protein that serves as a transcription factor [68]. It exists in 
two main forms - ERα and ERβ, where the former exists predominantly [39]. When ERs 
are bound to estrogen, a steroid reproductive hormone, a signaling cascade that 
regulates cell proliferation is activated [68]. In the development of breast cancer, this 
binding initiates uninhibited cell growth and tumor promotion [69]. As ERs are present in 
about 75% of breast tumors [70], they become an attractive therapeutic target  such that 
ER-positive cancers have better prognosis [71]. Also, ER-negative tumors tend to be of 
higher grade [72], and occur among younger patients [73] or those who are carriers of 
germline mutations [74]. While ER status is highly correlated with PR status and often 
used to predict a patient’s survival and response to treatment, the latter is of less clinical 
importance [75]. HER2 positivity, on the other hand, has been instrumental in ensuring 
optimal use of trastuzumab (HerceptinTM), a targeted drug which was first marketed in 
1998 [76]. HER2 is a transmembrane tyrosine kinase receptor that mediates cell-cell 
signaling [77]. It is overexpressed in about 20% of breast cancer cases [78] and has 
been linked to higher levels of cell proliferation, motility, tumor invasiveness, aggressive 
metastases, rapid angiogenesis and suppression of programmed cell death [79]. 
Compared to patients with ER-positive breast tumors, women with HER2-positive tumors 
usually encounter a faster rate of mortality [80] as their tumors are often of higher 
histologic grade, are ER and PR negative, and have affected lymph nodes [76]. This 
prognostic outlook has improved though, with the recent administration of trastuzumab 
[81].  
Since the discovery of these biomarkers, breast cancer cases are assigned one 
of four categories nowadays: ER positive (ER+/HER2-), HER2 positive (ER-/HER2+), 





cases are associated with the best prognosis while triple negative ones have the poorest 

























2.3 Burden of disease 
 The global burden of breast cancer can be measured in terms of incidence and 
mortality. Incidence rates are an indication of the average risk of developing a disease, 
and are often age-standardized because of the strong association between age and 
cancer, and a need to account for diverse demographics of populations. Mortality is a 
function of incidence and the proportion of deaths among patients with cancer. It reflects 
the average risk of dying from cancer in the population and is dependent on incidence 
trends, natural history of the disease, treatment efficacy and health service quality. A 
decrease in cancer incidence signifies effective primary prevention in the population 
while a reduced cause-specific mortality rate implies heightened awareness, earlier 
detection and improved treatment for breast cancer [39] 
 Based on the GLOBOCAN 2008 report [83], breast cancer is the most frequent 
cancer among females and the second most common cancer worldwide. Approximately 
1.4 million new cases were diagnosed in 2008, accounting for more than 20% of all 
cancers among women. It is also responsible for 6% of cancer deaths in the world and 
14% among females, making it the leading cause of mortality for women with cancer.  
Breast cancer ranks as the top female cancer in both developed and developing 
regions, with around 690,000 newly diagnosed cases in each region in a year (Figure 
2.4). Incidence rates tend to be high in developed countries with few exceptions such as 
Japan, and lower in most developing countries. Western Europe reported a rate of 89.9 
per 100,000 versus 19.3 per 100,000 in Eastern Africa (Figure 2.5) [83].  
As with incidence, breast cancer also caused the most number of cancer deaths 
among females regardless of geography - 189,000 and 269,000 deaths in developed 





the former, mortality rates are consistent across the regions (Figure 2.5), as better 











Figure 2.4 Estimated number (thousands) of new cancer cases (incidence) and deaths 
(mortality) in women in developed and developing regions of the world in 2008. Breast 





















Figure 2.5 Estimated age-standardized incidence and mortality rates (per 100,000) for 
breast cancer. Incidence rates in more developed regions are about twice of those in 
less developed regions, while mortality rates across regions are fairly constant [83]. 
 
Besides disparities in incidence and mortality, countries also differ by patient 
characteristics and clinical presentation of the disease. In contrast to Caucasian women, 
breast cancer tends to occur at a younger age in Asians. More than half of the patients 
are aged 50 or younger [85], and close to two-thirds are premenopausal [86, 87]. 
Tumors are more likely to present at a later stage [88] and higher grade [89]. Although 
DCIS cases are few among Asians [90], invasive carcinoma tend to be ductal in nature 
[91]. The proportion of receptor-positive tumors in Asians remains undetermined in light 
of contradictory isolated findings [92-94].  
Singapore has one of the highest incidence rates for breast cancer in Asia [95] 






in the country and was the highest ranking cancer among women (Figure 2.7) [96]. 
Among the four main ethnic groups, Chinese had the highest crude incidence rate of 
99.0 per 100,000 which dropped to 64.3 per 100,000 after adjustment for age. 
Unadjusted incidence rates for Malays, Indians and Others were around 70 per 100,000 
but became 58.7, 61.4 and 73.3 per 100,000 after age standardization [96]. Over the 
past four decades, the incidence of breast cancer in Singapore has tripled with a 3% 
annual increase [97]. Now, 1 in 16 women will develop breast cancer over the course of 
their lifetime with most being diagnosed between the ages of 55 and 59 years old [97]. 
Even though the five-year survival rate has improved slightly, the largest percentage of 
cancer deaths among women is still attributed to breast cancer, where the age-
standardized mortality rate has risen from 9.3 to 14.2 per 100,000 per year [96]. 
 
 
Figure 2.6 Estimated age-specific incidence rates (per 100,000 female population) for 
breast cancer by country in 2008. Singapore has the highest age-standardized incidence 









































Figure 2.7 The ten most frequent cancers in Singapore females (%) from 2009 to 2013. 
Breast cancer constitutes almost 30% of all female cancers in Singapore [96]. 
 
With the “westernization” of lifestyles such as late child-bearing, having fewer 
children as well as the consumption of exogenous hormones and calorie-dense foods, 
the incidence rate of breast cancer in developing countries is expected to rapidly 
approach that of affluent nations [98]. For developed countries, an increasing incidence 
rate together with improved survival would mean a growing strain on the healthcare 










2.4 Breast cancer etiology 
 The uneven geographical distribution of breast cancer as well as ethnic 
variations in breast cancer incidence within a country like Singapore has prompted the 
search for cultural risk factors of breast cancer. This hypothesis has been tested in 
several migrant studies where disparities in incidence rates have been found between 
migrants and residents of their home country [99-102], suggesting an association of 
breast cancer with environmental and lifestyle factors [103]. Also, the aggregation of 
breast cancer in families has highlighted the possible involvement of a hereditary 
component in addition to a shared environment [104].  
 
2.4.1 Reproductive and hormonal factors 
 Scientists have shown that changes in reproductive factors may explain the 
higher rate of breast cancer incidence among Asian migrants to the West. These include 
factors such as having fewer or no children, having one’s first child at a later age, not 
breastfeeding, and the consumption of oral contraceptives (OCs) or hormone 
replacement therapy (HRT) [105]. These actions influence a woman’s exposure to 
circulating levels of estrogens and progestogens in the body - hormones that enhances 
the mitotic activity of breast epithelial cells. The more times the cells divide, the more 
likely a mutation will occur, hence altering one’s susceptibility to breast cancer [106].  
 Intuitively, one would expect an early age at menarche and late menopausal age 
to be risk factors as they lengthen the duration that a woman is exposed to high 
estrogen levels over the course of her life [107, 108]. Hsieh et al. reported a reduction in 
cancer risk by 10% for every two-year delay in onset of menstruation and a 17% higher 





analysis found that postponement of menarche by an extra year lowers pre- and post-
menopausal breast cancer risk by 9% and 4%, respectively  [109]. Risk is also increased 
by 3% for an additional year before menopause [110] such that women who are 
menopausal only after age 55 are twice as likely to get breast cancer compared to those 
who stop menstruating before they are 45 years old [111]. 
 As a corollary to diminishing circulating estrogens levels after menopause [112], 
the incidence of breast cancer follows a distinct age-specific pattern. It increases rapidly 
with age up to around age 50, then plateaus and rises at a much slower rate after that. 
This phenomenon, known as a Clemmensen’s hook, represents the overlapping of two 
curves corresponding to pre- and post-menopausal breast cancer, with a drastic change 
in the slope occurring when menopause begins [113]. According to the Surveillance, 
Epidemiology, and End Results (SEER) database, women aged below 50 have a 1 in 53 
chance of developing breast cancer, which becomes 1 in 43 when they are 50 to 59 
years old, and 1 in 29 from ages 60 to 69 [114].   
The association of breast cancer with childbearing dates back to three centuries 
ago when Ramazzini, an Italian physician, postulated that nuns were more likely to have 
breast cancer because they were celibate [115]. His speculation on the relationship 
between parity and the disease was later quantified [115] and established after 
consistent findings in subsequent population-based studies [116-120]. Although little is 
known about the underlying biological mechanisms, the protective effects of having 
children may be explained by a sustained reduction in endogenous estrogens after high 
hormonal exposure during pregnancy. A permanent decrease in prolactin which 
stimulates milk production, or change in estrogen metabolism may be responsible for 
lower breast cancer risk [121, 122]. At the cellular level, childbearing is thought to induce 





resistant to carcinogenesis [123]. Some groups have refined pregnancy’s link to breast 
cancer in recent years, noting a transient increase in risk shortly after childbirth [124-126] 
and peaking at five years before falling after that [127, 128]. This is supported by animal 
experiments where temporary and long-term structural changes in breast tissues were 
observed [129]. Therefore, high hormonal levels during pregnancy promote growth of 
preclinical tumors, and a subsequent elevated resistance to mutagenic events clarify this 
dual effect of childbearing on breast cancer risk [130].  
Given the hormone-related protective effect of parity, it can be deduced that age 
at first live birth will also play a role in determining a woman’s risk of breast cancer. This 
may be a resultant of a shorter time period between the start of breast cell proliferation 
at menarche and its termination at pregnancy when the cells differentiate, hence lower 
cumulative exposure to carcinogenic agents [131, 132]. According to an international 
collaborative study by MacMahon and colleagues [133], females who had their first child 
after the age of 35 had thrice the probability of breast cancer versus those who gave 
birth before the age of 18. As with a study in Shanghai [134], it also revealed that women 
whose first birth occurred after age 30 were at higher risk compared to their nulliparous 
counterparts, while those who delivered their first baby before 20 years old had half the 
likelihood of disease . Others have equated one more year of age at first birth to 5% and 
3% increases in pre and post-menopausal breast cancer correspondingly [109].  
 Another factor that attempts to justify the discrepancy in incidence rates of breast 
cancer between the East and the West is breastfeeding. This practice is thought to delay 
the return of regular menstrual cycles, decrease the amount of endogenous estrogens 
and boost prolactin production [135]. Unlike Caucasians, Asian mothers experienced 
prolonged lactation in the past. Now, it is suspected that their adoption of shorter 





cases in the region. Amidst an array of contradictory findings regarding the relation 
between breastfeeding and breast cancer [136-139], a recent combined analysis of 47 
studies spanning 30 countries has reported a 4.3% lower risk of breast cancer for every 
year of breastfeeding [140].  
 Large collaborative work have also been undertaken to clear any doubts 
pertaining to the impact of OCs and HRT. In a meta-analysis of 54 studies conducted 
across both developed and developing nations, users of combined OCs containing 
estrogen and progestogen experienced up to 24% greater risk of developing breast 
cancer. This elevated hazard was not maintained 10 or more years after OC 
consumption had been discontinued [141]. Closer attention should be accorded to the 
detrimental use of HRT among post-menopausal women. HRT can exist in unopposed 
estrogen-only or combined estrogen-and-progestin formulations. Women who have been 
prescribed HRT without progestin have a 23% higher risk of breast cancer than non-
users at age 70, whereas those who opt for combined preparations increase their risk by 
67% [110, 142]. Additional susceptibility is also noted in the current and prolonged 
usage of combined HRT [143, 144], where a 2.3% hike is recorded every year on 
average [110]. When HRT is stopped, its supportive role in carcinogenesis diminishes 
and disappears at the end of five years [110, 143]. HRT’s overall impact on breast 
cancer development can be modified by an individual’s body mass index (BMI) and 
whether its initial use occurred closer to menopause [110, 145]. Interestingly, prior usage 
of OCs or HRTs seemed to provide a protective effect against metastatic and more 
advanced cancer which could possibly be an artifact of tighter surveillance among OC 





2.4.2 Family history and genes 
A hereditary component of breast cancer has been recognized since 1866 when 
French physician, Paul Broca, identified 10 cases of the condition within four generations 
of his wife’s family [147]. Later epidemiologic studies have shown that the added risk of 
breast cancer conferred by a positive family history depends on the degree of kinship, 
number of affected relatives and the age at which they were diagnosed.  Out of all breast 
cancer patients, about a quarter have an affected relative [148, 149]. For women with 
affected first-degree relatives (mothers, sisters, daughters), a two- to three-fold risk has 
been identified in contrast to 1.5 times for those with second-degree (aunts, 
grandmothers, grand-daughters) family history [150]. An analysis of 58,000 cases and 
100,000 controls obtained relative risks of 1.80, 2.93 and 3.90 for one, two and three or 
more affected first-degree relatives, compared to a negative family history [151]. A 70% 
and 30% greater risk was also measured for women with mothers or sisters who were 
diagnosed before and after age 50, as presented in the Nurses’ Health Study [152]. 
Multiple segregation analyses of the clustering of breast cancer in families and 
individuals with genetically-determined syndromes, as well as modern high-throughput 
multi-gene testing platforms have led to the discovery of cancer predisposing genes of 
varying penetrance. Penetrance of a gene is defined by the probability that an individual 
carrying it will present the trait that it encodes [153]. In other words, a woman carrying a 
high penetrance gene for breast cancer will most probably develop the disease.  
The earliest breast cancer susceptibility genes that were identified are BRCA1 
[154] and BRCA2 [155]. These are uncommon, but highly penetrant genes that have an 
autosomal dominant mode of inheritance [156]. BRCA1 and BRCA2 proteins are tumor 
suppressors that maintain genomic stability [157]. BRCA1 participates in a series of DNA 





degradation, and remodels chromatin to facilitate DNA repair [158]. Specifically, 
experiments have demonstrated its repression of estrogen receptor transcriptional 
activation mechanisms [159-161]. BRCA2, on the other hand, coordinates homologous 
recombination during meiosis and DNA repair [162]. Germline mutations of the BRCA 
genes are accountable for up to 80% of breast cancer in high-risk families (≥4 cases) 
[163, 164] but less than 10% in unselected populations [165]. Penetrance of these genes 
by age 70 was approximately 80% [163] in the former and 45% to 65% in the latter [166]. 
Since BRCA mutations mostly account for breast cancer cases in high-risk 
families only, the rest of the familial aggregation may be attributed to defects in key 
dominant and recessive genes, and common, low penetrant variants [167-169]. These 
include high-penetrance genes implicated in rare, inheritable syndromes notably, TP53 
in the Li-Fraumeni syndrome [170-172], PTEN in Cowden syndrome [173], STK11 in 
Peutz-Jeghers syndrome [174] and CDH1 in hereditary diffuse gastric cancer syndrome 
[175]. Carriers of the aforementioned mutations are much more vulnerable to tumor 
growths in many sites apart from the breast, and a younger age of onset [176-179]. 
Moderate-penetrance mutations in other DNA repair-related genes  have also been 
found to confer a 15% to 40% lifetime risk of breast cancer [180]: a woman with one 
defective ATM gene has twice the risk of breast cancer versus the average person [181]; 
a homozygous deletion in CHEK2 multiplies the risk by six times relative to a 
heterozygous one [182]; PALB2 mutations accord a 5.3 times elevated risk in carriers 
compared to non-carriers [183]. GWAS during the last decade have enabled an efficient 
and hypothesis-free search for common genetic variants. These variants or single 
nucleotide polymorphisms (SNPs) are common alterations in DNA that usually occur 
outside functional genes. They exist frequently in the population, have low penetrance 





Considering that family-based investigations found no further susceptibility genes [184], 
and the relative risks from SNPs are small [185], some studies have proposed a 
polygenic component with many low penetrant genetic variants [167, 168] where their 
cumulative effect of common polymorphisms may hold the answer to the missing 
heritability of breast cancer. Between 2007 and 2008, the association of breast cancer 
with eight common genetic variants was confirmed [186-190], out of which FGFR2 
exhibited the largest per allele odds ratio of 1.26 [186]. It was also the only locus with a 
known function, coding for a transmembrane receptor that is essential in modulating cell 
proliferation, survival, migration and differentiation for tumor growth [191]. The SNP in 
CASP8 is the sole variant identified from a candidate-gene study and whose minor allele 
is protective for breast cancer [190]. Due to the small effect sizes and frequent presence 
of SNPs within the population, it has been estimated that these eight variants, together 
with rare mutations in major genes will only account for 25% of excess familial risk, 
leaving the rest unexplained [192]. 
 
2.4.3 Anthropometric and lifestyle factors  
Although family history was one of the first factors to be associated with breast 
cancer, not all who had affected relatives developed the disease, and not all who 
developed the disease had affected relatives. The limited power of genetics in this 
respect has been illustrated in a population-based analysis on 45,000 pairs of twins 
which derived a minor influence of inherited elements on breast cancer susceptibility, 
suggesting a principal non-genetic or lifestyle contribution [193].  
 Alcohol is the most established dietary risk factor for breast cancer [194, 195] 





drinkers [196]. In a pooled analysis of six cohort studies, breast cancer incidence rose 
linearly by 10% for every 10g (1 drink) of alcohol, over the range reported by light to 
moderate drinkers [197]. Experiments on human breast cells have proposed the 
involvement of alcohol in breast carcinogenesis through the detection of DNA damage 
when the cells were subjected to an environmental carcinogen  [194]. Other groups have 
also found that alcohol represses the expression of BRCA1 while promoting the 
transcription for ERα [198, 199]. These cause a heightened responsiveness of cells to 
circulating estrogens and a sub-optimal maintenance of genomic integrity.  
 High levels of physical activity have often been linked to a lower risk for breast 
cancer despite some inconsistencies [200].This inverse relationship seems to work 
through the regulation of endogenous estrogen levels [201], and is stronger for post-
menopausal cancer [200, 201]. A recent review of 62 cohort and case-control studies 
has found that exercise decreases one’s risk of breast cancer by 25% to 30% on 
average [202]. However, findings from the Nurses’ Health Study II did not show any 
overall association between physical activity and risk in premenopausal women. Instead, 
the possibility of effect modification by adiposity was raised [203]. 
 The association of BMI with risk of breast cancer differs by menopausal status. 
An increased risk of breast cancer in overweight and obese post-menopausal women 
has been reported [204, 205], with one measuring an increased 2% risk per unit BMI 
[206]. This effect is especially marked in women who experienced large weight gains 
after 18 years old [207]. Among pre-menopausal women, however, no or minimal 
protective effect has been found [208]. In a multi-centre prospective cohort comprising 
women from nine European countries, obese post-menopausal women whose BMI 
exceeded 30 were 30% more susceptible to breast cancer in relation to women with BMI 





attenuation after adjustment for estrogen [209, 210], implying a hormone-related 
underlying mechanism. When a woman reaches menopause, estrogens are obtained 
mainly from adipose tissue, resulting in a positive linear relationship between BMI and 
estrogen levels. Moreover, women who are overweight have low levels of sex hormone-
binding globulin and more aromatase [209, 211], an enzyme that catalyzes the 
biosynthesis of estrogen, hence a higher level of circulating estrogens in the body that 
could stimulate malignant growth in breast tissues [212].  
Given the modifiability of these factors, breast cancer prevention would be most 
convenient and effective through the implementation of these lifestyle-based preventive 
measures.  
 
2.4.4 Benign breast disease 
 The relationship between benign breast pathology and breast cancer has long 
been a subject of interest. Benign breast disease is a histologically heterogeneous group 
that can be classified into three main categories: non-proliferative breast disease, 
proliferative breast disease without atypia and proliferative disease with atypia [213]. 
Non-proliferative lesions such as cysts confer little or no added risk of breast cancer 
[214]. Women who had fibroadenomas or ductal hyperplasias - proliferative disease 
without atypia, were about twice as likely of developing breast cancer compared to the 
general population [215]. This risk was doubled again for women with atypical 
hyperplasia [216]. Atypical hyperplasia, which falls under the third category of benign 
breast disease, refers to an accumulation of abnormal cells in a breast duct or lobule 
which may eventually become cancerous. In a study of 280,000 women [217], subjects 





without proliferative disease, while those without atypical hyperplasia had 1.3 times. 
These associations were altered by a positive family history and breast size [216].  
 
2.4.5 Mammographic density 
Another factor whose effect on breast cancer can be affected by breast size is 
mammographic density. This was derived from a study consisting of women from a 
multi-centre, population-based case control group, which noted an elevated risk among 
women with denser breasts that was attenuated by a larger breast size [218]. Earlier 
investigations in post-menopausal and lean pre-menopausal women have also found a 
similar positive association [219-221]. 
Mammographic density refers to the radio-dense areas that appear white on a 
mammogram through which the radiographic appearance of the breast is reflected. 
Breasts consist of a mixture of fat, connective and epithelial tissues. Fat is radiologically 
lucent, and makes up the non-dense tissue that appears dark on mammograms. In 
contrast, connective and epithelial tissues are radiologically dense, and appear light on a 







Figure 2.8 Example of a mammogram. Mammographic density refers to the white 
(radio-dense) areas on a mammogram which represent epithelial and connective tissue 
[222]. 
 
Numerous ways have been devised to characterize mammographic density. In 
the early days, parenchymal patterns were used to describe the appearance of breasts 
on a mammogram. The most commonly used visual classification method was the Wolfe 
pattern developed by US mammogram expert John Wolfe in 1976. Four categories of 
increasing mammographic densities were created: N1, for breasts that contain mostly fat; 
P1, for breasts with prominent ducts in less than a quarter of the breast; P2, for breasts 
with prominent ducts in more than a quarter of the breast; and DY, for breasts with 
diffuse or extensive nodular densities, obscuring an underlying duct formation (Figure 
2.9) [223]. Subsequently, other classification methods such as the Tabar pattern [224], 
Boyd’s six-category assessment of percent density [225] and Breast Imaging Reporting 
and Data System (BI-RADS) [226] were created too with a common aim to segregate 
breasts by their tissue composition and expected risk of cancer. Today, the four-
category semi-quantitative BI-RADS method is conventionally applied in clinics. Breasts 





tissue as BI-RADS II, those that are heterogeneously dense as BI-RADS III and breasts 








Figure 2.9. Example of mammograms rated according to Wolfe’s classes - P1, P2 and 









Figure 2.10 Example of mammograms rated according to BI-RADS. BI-RADS I to IV 
represent breasts of increasing mammographic density [228]. 
P1 P2 DY 





The invention of computer-assisted interactive threshold methods such as 
Cumulus [229], Madena [230] and ImageJ [231], has permitted the automated, objective 
assessment of absolute and percent mammographic densities. These methods require 
the extra step of digitizing analogue images, which can be bypassed with the entry of 
digital mammograms. Also, none of them takes into account the thickness of the breast, 
hence neglecting its 3D aspect. This issue was recognized so volumetric approaches for 
density measurement have been proposed by several groups lately [232, 233]. 
Quantitative measures are now often used in place of subjective approximations to 
evaluate the relationship of mammographic density with breast cancer. As digital images 
appear less dense compared to analogue ones (Figure 2.11), the extent to which 
existing methods yield similar risk estimates when applied to digital mammograms 









Figure 2.11 Digitized and digital images from the same individual. Mammographic 
density tends to appear less extensive when assessed from digital images versus 
digitized ones. 





Mammographic density is a strong, independent risk factor of breast cancer. 
Several groups have reported a four- to six-fold higher risk among women with the 
highest mammographic density than women with very low densities [2, 225]. This 
increased susceptibility can last for a decade [234]. When percent mammographic 
density (PMD) was used, its association with breast cancer incidence was not affected 
by age, menopausal status or ethnicity [235] and was not a product of the “masking” of 
lesions by dense breast tissue [235]. Given the many measures and categorization of 
mammographic density, estimates of its effect size on breast cancer have been varied 
although all exhibit a similar direction of association [3, 236]. A systematic meta-analysis 
[2] comprising 14,000 cases and 226,000 non-cases from 42 studies found a higher 
relative risk for PMD compared to BI-RADS and Wolfe’s classification. However, it 
remains inconclusive for PMD versus absolute dense area [237].  
 The exact mechanisms for the heightened risk are not clear, but data have 
presented a greater number of epithelial cells from which breast cancer originates in 
dense areas of the breast [238]. Therefore, it is believed that the uninhibited proliferation 
of these cells may influence the probability of genetic damage that can result in cancer. 
Collagen, a product of stromal cells, as well as an altered expression of stromal proteins, 
are also found in higher levels [239]. Through stromal-epithelial interactions and 
mechanical properties, they may promote tumor formation and invasion [240, 241]. 
Metalloproteinases that are involved in remodeling of the stromal matrix and exist in 
larger amounts in dense breasts can also release growth factors for carcinogenesis 
[242].  
 Mammographic density is dependent on a strong genetic and a modifiable non-
genetic component. Increasing age, parity, and menopause are correlated with a 





and North American twins has found that genetics could explain around 60% of the 
residual variation in PMD that could not be explained by non-inherited factors [243]. 
Their findings have later been corroborated by other cohort studies [244, 245]. Non-
inherited factors that are correlated with mammographic density have been examined by 
several groups. They have presented a decreasing trend in mammographic density as a 
woman ages [246, 247] - a seemingly self-contradictory observation since a woman’s 
risk increases with age. This can be resolved by the Pike model [248] which hinges on 
the concept of cumulative breast tissue exposure to mitotic activity and genetic damage, 
and not chronological age, in being the true predictor of breast cancer risk. Furthermore, 
breast tissue age is related to the action of hormones on the breast at the genetic and 
cellular level [249]. Women who are nulliparous, have few children or are older at first 
live birth tend to have denser breasts [235, 250]. A longitudinal study by Boyd and 
colleagues has shown that PMD was reduced by 8% on average among post-
menopausal women [251]. Mammographic density also becomes more extensive by 5% 
to 6% following the administration of hormone therapy, as demonstrated in placebo-
controlled randomized trials in the US [252-254]. For women undergoing tamoxifen 
treatment, a reduction in mammographic density was noted especially among those who 
were pre-menopausal [255]. An inverse association of BMI with mammographic density  
is likely due to heavier women having large breasts with substantial amount of fatty, non-
dense tissue [256]. This justifies the weakened relationship between mammographic 
density and breast cancer risk that was mentioned earlier.  
The amenability of mammographic density via the above factors makes it a 







2.4.6 Ionizing radiation 
Breast tissues are one of the most sensitive to ionizing radiation. This has been 
demonstrated in a cohort of Hiroshima and Nagasaki atomic bomb survivors [257] as 
well as a report on new breast cancer cases ten years after the Chernobyl accident in 
Belarus and Ukraine [258]. Present-day sources of radiation include occupational and 
medical diagnostic procedures. Studies have noted a dose- and age-dependent 
relationship between radiation exposure and breast cancer. For instance, women treated 
with therapeutic chest radiation at a young age presented a higher risk of breast cancer 
which decreased when lower radiation dose was used [259, 260]. Also, a review of 
epidemiological studies that addressed radiation-induced breast cancer did not find an 














2.5 Detection and diagnosis   
The detection and diagnosis of breast cancer has evolved since the revolution in 
diagnostic imaging. What was previously detected by pain and physical changes in the 
breast can now be identified and characterized using modern technological procedures. 
 
2.5.1 Diagnostic mammography 
Mammography is the primary imaging modality for breast cancer screening and 
diagnosis. As its purpose suggests, it can be divided into two groups - diagnostic and 
screening, of which the latter will be discussed in Section 2.7. Otherwise termed 
“consultative” or “problem-solving mammography”, diagnostic mammography is 
performed when there are clinical findings such as a palpable lump, localized pain, 
nipple discharge, or an abnormal screening mammogram that requires thorough 
examination [262]. They include supplemental imaging tailored to the patient, such as 
spot compression of an area of the breast tissue or magnified images, which are taken in 
addition to standard craniocaudal (CC) and mediolateral oblique (MLO) views [263]. The 
CC image of the breast is taken top-down, while the MLO image is captured outwards 
from the middle of the chest at a 30 to 60 degrees angled view (Figure 2.12) [228]. In 
this way, the nature of the clinical abnormality can be better defined, unexpected lesions 


























Figure 2.12 CC and MLO views of a right breast from digital mammography [228]. 
  
 BI-RADS is the standard system for reporting mammographic findings [265]. 
Unlike the four-category classification that is used to describe breast tissue composition, 
BI-RADS final assessment categories directly represent recommended protocols for 
patient management [265]. As the BI-RADS category for a lesion increases, so does its 
















Table 2.1 BI-RADS report final assessment categories and their recommended patient 





 Besides assigning BI-RADS for patient follow-up, breast lesions which present 
mainly as masses, calcifications or asymmetries, are also characterized. A mass is a 
space-occupying lesion that is seen on two different planes [265]. It is described by its 
shape and margin, where the latter is the more important indicator of the probability of 
malignancy [266]. Shape-wise, a mass can be round, oval, lobular or irregular, with most 
round masses being benign and irregular masses being most likely cancerous. Margins 
can be seen as circumscribed, obscured (by adjacent tissue), microlobulated, indistinct 
or spiculated, in decreasing order of benignancy (Figure 2.13) [228, 267]. Examples of a 
benign lobular, circumscribed mass, as well as a malignant irregular mass with 


































Figure 2.14 Examples of masses. (a) Benign mass with a lobular shape and 
circumscribed margin. (b) Malignant mass with an irregular shape, spiculated and 
partially obscured margin (arrow) [228]. 
 
Increasing probability of 
malignancy 





 Calcifications, another common feature on abnormal mammograms, are 
described in terms of their morphology and distribution. Based on morphology, they can 
be grouped as typically benign, intermediate concern or higher probability of malignancy. 
Typically benign calcifications tend to appear large and coarse, whereas amorphous, 
pleomorphic, or fine, linear or branching calcifications are highly suggestive of cancer 
(Figure 2.15). Calcifications can be distributed in one of five ways: diffuse or scattered, 
regional, clustered, linear, or segmental. Linear and segmental formations are more 
inclined to be malignant, while diffuse or scattered calcifications that occur randomly 
throughout both breasts are almost always benign (Figure 2.15) [268]. A breast 
containing benign, rod-like calcifications that are regionally distributed, and another 
having malignant pleomorphic calcifications that are clustered together are shown 







































Figure 2.16 Examples of calcifications. (a) Benign rod-like calcifications in a regional 




Subtle signs of malignancy can be detected in the form of an architectural 
distortion or asymmetry in the breast [269]. Architectural distortion refers to the 
appearance of radiating spicules without a central mass. It is hard to detect and cannot 
be differentiated from a surgical or radial scar (Figure 2.17). An asymmetrical 
distribution of fibroglandular tissue observed in both breasts of a woman warrants a 
detailed examination. This is also challenging to identify, however, since minor 
differences are not unusual (Figure 2.18) [267]. 
 
 







Figure 2.17 Architectural distortion in a right breast. A spot compression image (right) 






Figure 2.18 Asymmetry in breasts. Right and left MLO digital mammogram views show 








 While mammography may be the main tool for detection of breast lesions, its 
performance is generally compromised by dense breast tissue, inferior technical quality, 
and interpretation flaws. The sensitivity of mammography is dependent on the relative 
amounts of fat and fibroglandular tissue in the breast [228]. Since both fibroglandular 
tissue and lesions appear white on mammograms, dense breasts can conceal lesions, 
making them harder to detect (Figure 2.19) [267]. This limitation has been addressed by 
the switch to digital mammography [270], which optimizes image acquisition and display 
by separating both processes. Image processing of digital data allows the degree of 
contrast in the image to be manipulated, so that dense areas of the breast can be 
demarcated more clearly.  However, improvements may be absent or unsubstantial [271, 
272]. Incorrect positioning and underexposure of the breast to x-rays during 



















Figure 2.19 Breast composition and sensitivity of mammography. a) A breast comprising 
mainly fat makes it easier to detect small lesions. b) A dense breast comprising mainly 
fibroglandular tissue makes detection harder [267]. 
 
a) Fatty breast, high 
sensitivity of mammography 
b) Dense breast, low 





2.5.2 Diagnostic ultrasound 
 In addition to mammography’s lower resolution in dense breasts, there are 
certain clinical features that it cannot recognize. Breast ultrasound is an essential 
adjunct to mammography in this respect. It effectively differentiates cysts from solid 
masses, and can clarify the nature of ambiguous lesions on mammograms [273]. This is 
accomplished and improved through supplemental processing techniques that allow a 
clear visualization of cystic contents, good representation of the internal structure of solid 
lesions, as well as enhanced lesion conspicuity and margin depiction [274, 275]. 
Moreover, ultrasound enables the examination of palpable masses not visible in dense 
breasts, inflammatory, or certain lobular invasive cancers, mammographic asymmetry, 
and peripheral, small carcinomas in particular [276, 277]. As with mammography, 
ultrasound is liable to interpretation and diagnostic errors. Inter-observer variability has 
been demonstrated in three radiologists who reviewed images of 162 masses [278]. 
Malignant masses may resemble benign ones in certain ways, hence leading to false-
negative conclusions [228]. 
 
2.5.3 Diagnostic magnetic resonance imaging (MRI) 
 Magnetic resonance imaging (MRI), a procedure which was deemed to have 
minimal reliability in detecting and diagnosing lesions [279], is now considered an 
integral part of the management of breast cancer [280]. This is because of the 
introduction of an intravenous MR contrast medium which enables lesions to be detected 
easily through rapid contrast enhancement [281]. With contrast-enhanced MRI, lesions 
that appear suspicious on a mammogram can be re-evaluated with accuracy [282]. 
Today, MRI resolves inconclusive findings, determines the extent of disease, and is 





breast augmentation [283].  Despite the provision of a 3D view of the breast [284], MRI 
is not devoid of sensitivity and specificity issues. Normal tissue and benign conditions 
especially fibroadenomas can appear as cancerous on an MRI, resulting in unnecessary 
biopsies [285]. Compared to mammography which is effective in detecting 
microcalcifications, MRI is limited in its ability to differentiate benign calcifications from 
malignant ones [286]. It cannot characterize these lesions according to size, shape and 
distribution - features associated with lesion malignancy [287].  
 
2.5.4 3D mammography  
The problem of tissue overlap is a major barrier that conventional 2D 
mammography cannot overcome. Breast thickness is projected onto a single plane such 
that a true malignant lesion is obscured by overlying tissue and often goes undetected 
[288]. This is especially so in breasts which are mammographically dense [235]. 
Conversely, a coincidental alignment of normal fibroglandular tissue or calcifications at 
various depths within the breast may mimic a true lesion [289], causing a false-positive 
diagnosis [270].   
The evolution of 2D mammography from screen-film to full-field digital 
mammography (FFDM) has given rise to the development of digital breast 
tomosynthesis (DBT) and stereoscopic digital mammography (SDM) - 3D 
transformations of FFDM. DBT is a novel imaging technology that produces tomographic 
and volumetric 3D images [290]. An x-ray tube rotates in an arc of 15 to 50 degrees 
across the breast. Coupled with a digital detector, a series of 1mm-thick, low-dose cross-
sectional images are produced via a mathematical algorithm, thereby reconstructing a 
quasi-3D mammogram with layers of breast tissue that a radiologist can scroll through 








Figure 2.20 Schematic of digital breast tomosynthesis [290].  
  
 
DBT’s impact on diagnostic performance has been evaluated by several groups. 
Its specificity tends to be higher than that for 2D mammography [292-294] but this may 
not be the case for sensitivity. Few studies have reported a reduction in sensitivity 
ranging from 4% to 9% for DBT compared to 2D mammography, but were not 
statistically significant [294-296]. Others have obtained higher sensitivity [292, 293, 297, 
298], visibility and better characterization of lesions [299, 300].They required only half 
the contrast level needed with 2D mammography, allowing improved detection of 





used alone or together with 2D mammography, a lower recall rate was attained under 
either circumstance [292, 302-304]. DBT has also displayed a higher diagnostic 
accuracy than digital spot compression views, and improved lesion characterization, 
hence removing the need for additional 2D views. Most importantly, these advantages 
apply to women with mammographically dense breasts [299].  
 SDM also works to address the drawbacks of 2D mammography: masking of 
malignancy by overlaying normal tissue, false impression of a tumour, and the inability to 
derive volumetric information for lesion characterization. In SDM, stereo pair images are 
used. A stereo pair comprises two images that are captured with an x-ray tube that 
rotates by 10 degrees between the acquisitions while the breast remains stationary. The 
stereo images are viewed on two five-megapixel, grayscale monitors mounted one 
above the other, and separated at an angle of 110 degrees. A glass plate with half-
silvered coating bisects the 110 degree angle between the monitors. One image is 
presented on the vertical monitor and is transmitted through the glass plate, while the 
other is displayed on the upper monitor and reflected from the top of the glass plate. As 
the images of each stereo pair are cross-polarized, a radiologist wearing a pair of cross-
polarized glasses sees the reflected image only with his right eye, and the transmitted 
image with his left (Figures 2.21 and 2.22). The fusion of both images by the visual 




































 SDM offers a direct in-depth, 3D view of the breast’s internal structure, potentially 
increasing detection accuracy. This allows a lesion to be differentiated from normal 
tissue, in line with but at different depths in the breast volume, thereby promoting 
sensitivity in diagnosis. Specificity is also raised as fibroglandular tissue or calcifications 
that superimpose on top of one another to resemble a lesion can now be discerned. 
Besides that, a volumetric perspective can more correctly characterize lesions - 
microcalcifications and architectural distortions in particular. The spatial arrangement of 
calcium elements or radial-orientation of spiculations is crucial in determining the need 
for further examination of these breast abnormalities. In 2D mammography, this data can 
only be derived from the cognitive merging of orthogonal planar images. Researchers of 
a prospective clinical trial have recorded similar sensitivity levels, and a 5% greater 
specificity for detecting lesions in dense breasts with SDM compared to 2D 
mammography. Also, the number of patients recalled for diagnostic workup was 12.9% 












 The declining mortality rate of breast cancer in developed countries over time 
has been attributed to improved treatment methods, and earlier detection of the disease 
through mammographic screening [39]. Treatment administered depends largely on 
stage at diagnosis, hormone receptor status, HER2 expression levels, patient preference 
and comorbidity. It either addresses loco-regional or systemic disease, and is directed at 
curing early stages of breast cancer and relieving pain in metastatic disease [306]. In 
this section, a brief overview of the therapies for breast cancer is given. 
 
2.6.1 Loco-regional therapy 
 The purpose of localized treatment of breast cancer is to completely eliminate 
any detectable tumor in the breast and lymph nodes. This is achieved through surgery 
and radiotherapy. In surgery, the entire breast may be removed through mastectomy, or 
the tumor and its surrounding tissue may be excised through breast-conserving surgery 
(BCS). Chest wall and regional lymph node radiation may be given after mastectomy to 
patients with tumors larger than 5cm, a close or positive tumor margin, and more than 3 
affected lymph nodes [307]. On the other hand, whole-breast irradiation is performed on 
patients who undergo BCS [306].  
 Although BCS is the most popular treatment presently, not all early stages of 
breast cancer can be handled this way. Women with tumors larger than 5cm or 
extensive cancer spread would not be suitable for BCS [308]. Also, those with a strong 
family history and have a high inherited risk for breast cancer may be better off with a 







2.6.2 Systemic therapy 
 Systemic therapy can be broadly classified into chemotherapy, endocrine, and 
biologic therapy and its goal differs from that of loco-regional treatment. In an adjuvant 
setting, it eradicates micrometastatic disease that can linger in patients with invasive 
cancer after surgery, thereby reducing recurrence and improving overall survival.  
 Adjuvant chemotherapy is the standard therapy for women with invasive cancers 
larger than 1cm. It is often initiated after surgery and before radiotherapy. The regimen 
typically consists of two to three cytotoxic drugs from the anthracycline drug class, which 
inhibit topoisomerase II enzyme in DNA replication [310]. However, anthracyclines 
cannot be used in patients with pre-existing heart conditions as they can cause 
irreversible heart failure [311]. Non-anthracycline based regimens are prescribed to 
these patients instead, but are not as effective [312].  
 Following chemotherapy, endocrine therapy may be administered along with or 
after radiotherapy. Since most breast tumors are ER- or PR-positive, patients tend to 
respond to hormonal interventions. Tamoxifen, a selective estrogen receptor modulator 
(SERM) that competes with the human sex horomone, 17β-estradiol at the receptor site 
and blocks cell proliferation [313], has been extensively studied. Despite lowering the 
rate of breast cancer mortality by a third [312], its pro-estrogenic effects on the 
endometrium have promoted carcinogenesis at this site among post-menopausal 
women [314]. Nevertheless, tamoxifen continues to be the standard endocrine treatment 
for ER-positive breast tumors in pre-menopausal women [306]. A second line of drugs 
for endocrine therapy are aromatase inhibitors (AIs). AIs prevent the synthesis of 
estrogens by inactivating the aromatase enzyme which catalyzes this process [315]. 
Even though they do not promote endometrial cancer, AIs can have an adverse effect on 
bone health leading to fractures and joint pain [316]. They do not work in pre-





 The discovery of over-expressed HER2 protein in 25% to 30% of human breast 
cancer cells [318] has inspired the application of adjuvant biologic therapy. Unlike 
chemotherapy, a biologic drug is designed to specifically counteract the effects of a 
genetic defect in a tumor without inflicting damage on normal, healthy tissues. One such 
medication is trastuzumab, a monoclonal antibody that binds to the extracellular domain 
of HER2, thereby preventing proliferation of tumor cells [319]. It is especially useful in 
treating patients with HER2-positive breast tumors, a cancer subtype often associated 
with poor prognosis and high risk of recurrence. Although trastuzumab has become 
standard therapy for HER2-positive breast cancers, it causes symptomatic congestive 
heart failure in up to 4% of patients [320], and is particularly toxic to older women with 
pre-existing heart disease [321]. 
 Due to their low risk of relapse, patients with tumors that are smaller than 5mm, 
node-negative, or of favorable histology are exempted from adjuvant drugs. Systemic 
therapy is also the principal mode of treatment for metastatic breast cancer, albeit with a 
different intention of maximizing quality of life and prolonging survival [322]. 
 
2.6.3 Systemic neo-adjuvant therapy 
 In contrast to adjuvant therapy, neo-adjuvant therapy serves to reduce the size of 
large primary tumors for BCS in patients with locally advanced breast cancers [323]. It 
may also halt the spread of cancer to the axillary lymph nodes and furnish physicians 
with clues on treatment response [324]. Anthracycline-based neo-adjuvant 
chemotherapy has been reported to be most effective in small, high grade and HER2-
positive tumors [325]. Regimens that exclude anthracyclines were also found to be 
particularly useful in patients who do not respond to endocrine therapy [326]. Even if 





chemotherapy is still recommended [323]. With regard to the comparison between AIs 
and tamoxifen, a randomized trial has demonstrated a better response in patients taking 




















 Besides treatment, screening plays a major role in preventing breast cancer 
deaths too, as alluded previously. It works by detecting and treating the disease early so 
that optimal response to therapy is achieved. This strategy is based on the prevailing 
notion that breast cancer begins as a cell that multiplies and grows until metastasis 
occurs, leading to death of the affected individual [328]. However, opponents to this idea 
think that breast cancer is systemic from the start, therefore screening would not 
significantly reduce mortality rates in a population [329]. Moreover, the slower mortality 
rates reported could be an artifact of studies that are liable to lead-time, length and 
selection bias. Lead-time bias refers to an earlier detection of the cancer but no change 
in time of death. Since a longer duration of cancer is observed, it gives a false 
impression of an extended survival time when in fact, it remains unchanged [330]. 
Additionally, researchers of a Finnish comparative cohort study have found histological 
differences between screen- and clinically-detected tumors indicative of slower cancer 
progression in the former [331]. In other words, screening tends to detect slower-growing 
cancers which exist for a longer time pre-clinically compared to those that are more 
aggressive, hence a length bias . As healthier women are more inclined to participate in 
optional screening programmes. comparison studies may also be subjected to a healthy-
screenee effect [332].  
 The early detection of disease alone cannot justify the implementation of mass 
screening programmes. Cole and Morrison have proposed that cancer screening should 
fulfill three criteria before it is introduced: treatment for screen-detected cases is more 
effective than clinically-detected ones, having the disease results in severe morbidity-
related aftereffects or death, and there is a high prevalence among people who are 





screening be encouraged? This section addresses the costs and benefits of five 
screening methods.  
 
2.7.1 Screening mammography 
 First performed using gross mastectomy specimens then in patients [334, 335], 
the concept of adopting mammography to screen for breast lesions in asymptomatic 
women was subsequently proposed by Gershon-Cohen and colleagues in the 1950s 
[336]. In their paper as well as Egan’s, the possibility of using mammography for 
screening preclinical breast cancer was evaluated with favourable results [336, 337]. 
This sparked an interest in the potential of mammography screening to reduce breast 
cancer mortality rates. 
 The efficacy of mammography screening has been demonstrated in a number of 
randomized prospective trials [338-342]. Overall, mammography reduces breast cancer 
mortality by around 20% [330, 343]. Among women who were 50 years or older at 
recruitment, a consistent 25% reduction in mortality was recorded after seven years from 
first screen [330, 344, 345], with effects appearing as early as four years following the 
point of initiation [342, 345]. On the contrary, their younger counterparts who were 40 to 
49 years of age may not benefit until 10 years later, and to a smaller extent of 15% [330, 
345, 346]. Also, not all studies are in agreement with one another. While a randomized 
controlled trial of 51,000 Swedes found a 30% reduction in mortality after 14 years of 
follow-up [347], and a more recent UK study on 161,000 participants saw a 17% 
decrease after 10 years [340], an investigation on 50,000 women in Canada recorded a 





 Some have attempted to explain this discrepancy in effect of mammographic 
screening between the two age groups. Firstly, to account for the longer duration before 
screening benefits younger women, Konig et al. have presented a computer simulation 
model supporting the view that majority of the reduction in mortality happens after a 
woman turns 50 [348]. Secondly, the abrupt change in screening effect at this age has 
been connected to the approximate time of menopause, where hormonal fluctuations 
alter a woman’s susceptibility to breast cancer [349]. Lastly, the “mortality paradox” [350] 
as outlined in the example above seems to suggest a discriminatory response to therapy 
between pre- and post-menopausal women [351]. Alternatively, it may be due to the 
more aggressive nature of tumors in younger patients [352] or the ineffectiveness of 
mammography in detecting them [351]. Whatever the case may be, the fact of the matter 
is that females younger than 50 years old have less to gain from routine screening.  
  In conjunction with age-related complications, the poor sensitivity of 
mammography to dense breast tissue becomes a false reassurance to the affected 
individual. Out of 100 women aged 40 to 49 years old with breast cancer, 25 are missed 
by screening mammography in contrast to 15 in the older age group [353]. This may 
stop the women from seeking medical help even when symptoms appear [354]. 
Conversely, mammography may lead to a large number of false positives and 
unnecessary diagnostic evaluations which adversely impact the level of anxiety and 
quality of life. Around two diagnostic tests are carried out per abnormal screening result, 
on average [355]. Since prevalence of breast cancer is lower among younger females, 
this translates to a smaller positive predictive value (PPV), where a relatively large 
proportion are subjected to further diagnostic tests to find a few confirmed cancers [356]. 
For every cancer detected in a woman below 50 years old, 45 additional procedures will 





is considered over a 10-year period, a 40-year old has a 30% probability of at least one 
abnormal screening result that requires further examination, and a 7% chance of 
undergoing at least one breast biopsy. For someone 10 years older, the likelihood of 
having at least one abnormal screening examination and at least one breast biopsy are 
26% and 10% respectively [354, 357]. On top of that, the cumulative risk of a false-
positive result over a decade can reach 56% [358, 359]. Efforts have been made to 
tackle this issue regarding sensitivity. With the advent of digital mammography, 
investigators have found better utility for younger, pre- or peri-menopausal women with 
dense breasts [270] while film screen mammography continues to be used for the others 
[360]. 
 Another concern that sceptics have raised about mammography screening is that 
not only does it advance the time of breast cancer diagnosis, it may be detecting 
cancers that would probably have remained asymptomatic for the rest of a woman’s life 
[361]. A review of population-based mammographic screening programmes in seven 
European countries have estimated the extent of overdiagnosis to be up to 10% [362]. 
Yet, between 46% and 58% have been reported based on a meta-analysis of studies 
from the Nordic countries, Canada, Australia and the UK [361]. Besides posing no threat 
to an individuals’ life expectancy, these cancers may even undergo spontaneous 
regression later on without the need for medical attention [363]. The problem is 
exacerbated when mammography is highly sensitive to DCIS cases [364] and detects a 
significant proportion of it through routine screening [365]. Although DCIS is often 
presumed to become invasive if left untreated, this only occurs in 25% of them after a 
period of 15 years [366]. Moreover, less than 3% of them will die of invasive breast 





diagnosed with DCIS are undergoing surgery for a condition that is unlikely to harm or 
even kill them.     
 As mentioned in an earlier section, radiation is a cause of breast cancer. Since 
low doses of radiation are used in mammography, screening may increase a woman’s 
risk of the disease. Simulation using data from the Netherlands and Sweden showed 
that one breast cancer death is induced for every 242 deaths prevented with 
mammography screening among women aged 50 to 69. The balance was tilted 
drastically to 97 lives saved per death induced when younger women were included for 
screening as well [368]. Routine mammography screening may not be suitable for 
carriers of cancer susceptibility genes too. Individuals, who are heterozygous for a 
defective gene such as ATM or BRCA, are vulnerable to low levels of radiation [369, 
370]. Thus, to detect breast cancer among this high-risk group of women, MRI is the 
preferred mode of screening. 
 
2.7.2 Screening MRI 
MRI has been recommended as a screening tool for women who have over 20% 
lifetime risk of breast cancer such as those with a strong family history or had received 
radiotherapy to the chest in the past [371]. Compared to mammography, it is able to 
correctly identify about 40% more true breast lesions but 9% more benign breast 
abnormalities as well [372, 373]. Since MRI has lower specificity and cannot detect all 
breast cancers that are found through mammography, the implementation of both 
methods together was expected to perform better [372]. However, a prospective multi-





and a meta-analysis of North American and European studies showed a three- to five-
fold increase in unnecessary patient recall rates [375]. 
 
2.7.3 Screening ultrasound 
 An alternative adjunct screening method to mammography is breast ultrasound. 
As with MRI, it is a supplementary tool for finding lesions in high-risk women and those 
with mammographically dense breasts due to superior sensitivity [376]. In a large 
prospective cohort comprising 2725 women with these characteristics, the inclusion of 
ultrasound to conventional mammography screening improved breast cancer detection 
by 55% but increased the number of false positives substantially. The PPV also dropped 
from 22% to 9%, indicating a rise in number of diagnostic workup that is not needed 
[377]. Unlike MRI where the machine is expensive, ultrasound is costly because of the 
amount of professional resources wasted in identifying a malignant tumor out of many 
false positive cases [378].  
 
2.7.4 Clinical breast examination (CBE) 
 For developing countries where screening equipment is not readily available, 
clinical breast examination (CBE) by medically-trained personnel is a more feasible 
mode of screening, if the compliance level in a population is satisfactory [379]. CBE 
readily detects tumors larger than 1cm, and around 39% of lesions that are smaller [380]. 
In addition to its greater ability in searching for bigger tumors, CBE is also more effective 
in identifying cancers among younger women and can perform as well as mammography 
among older women. A study on 31,000 female residents of America aged 40 to 65 





compared to 42% by mammography. The proportion shifted to 61% and 19% 
respectively for those younger than that [381]. This observation was corroborated by the 
Canadian breast screening study which recorded 32% of cancers found by CBE in 
females aged 40 to 49 versus 18% in the 50 to 59 age group [338, 339]. Furthermore, 
CBE can identify 5% to 10% of all breast cancers that mammography fails to recognize 
[382]. Like mammography though, the false positive rate is highest among women aged 
40 to 49 at 6%, and decreases to 3.5% for those between the ages of 50 and 59 [358].  
 
2.7.5 Breast self-examination (BSE) 
 Unlike CBE, breast self-examination (BSE) does not require regularly involve a 
medical staff. Despite being an inexpensive, non-intrusive and convenient screening 
method, the appeal of BSE has been marred by the lack of favorable outcomes in 
mortality and heightened medical attention that is uncalled for. A population-based non-
randomized trial in the UK could not find prolonged survival among communities who 
practised BSE [383]. Likewise, randomized controlled trials in Russia [384] and China 
[385] have reported comparable lengths of survival between BSE and the control group 
beyond 10 years of follow-up. Not only was there no reduction in mortality rate, a 
displacement of late-stage cancers for early-stage ones was not present either [386]. 
Moreover, women who performed BSE visited the doctor more frequently, tend to be 
referred for additional diagnostic tests, and were almost twice as likely of getting benign 







2.7.6 Cost-effectiveness of screening 
 Whether mass screening should be implemented or not does not depend solely 
on costs (direct and indirect) or efficacy, but rather a balance. In the context of screening 
mammography, assuming that breast cancer mortality is reduced by 15%, and 
overdiagnosis is 30%, for every 2000 women screened over 10 years, one death will be 
avoided and 10 individuals will be treated unnecessarily [330]. In monetary terms, 
among women below the age of 50, one breast cancer death is prevented for every 
2500 screened annually, over a decade. This translates to an incremental cost-
effectiveness of USD105,000 per year of life saved and a two-day gain in life expectancy. 
Using the conventional threshold of USD50,000 per life-year saved, and an increase in 
life expectancy by 30 days, the effect of screening among the younger population does 
not seem worthwhile. The reverse is true for older women, though. The cost per life-year 
drops to USD21,000, life expectancy is longer by 14 days and one breast cancer death 
is averted for every 270 women screened biennially, over two decades [388]. Such 
considerations are especially pertinent for developing countries that face serious 
limitations in healthcare resources and an impending spike in breast cancer cases. One 
reason for the modest cost-effectiveness of screening is the huge population that has to 
be screened in order to identify the minority affected with cancer. This problem is made 
more complex by the differing sensitivity and specificity of the various screening 
methods for women of different age groups. It is hoped that a targeted strategy, based 
on each woman’s predicted risk for breast cancer, can solve the current dilemma that 







2.8 Risk assessment 
Presently, a two-pronged approach in breast cancer prevention is used. Females 
at risk of carrying a germline mutation in a predisposing gene such as BRCA are offered 
formal genetic testing and prophylaxis for those who test positive. The majority who are 
ineligible for genetic testing or obtained a negative result are often recommended routine 
screening mammography. In view of the controversies in screening, it may be better to 
quantify the risks of all women so that individualized measures can be taken for disease 
prevention.  
A risk assessment model fulfills this role by predicting a woman’s chance of 
developing breast cancer over a given span of time [389]. In order to attain an accurate 
estimation, all known risk factors for breast cancer should be taken into consideration 
[390]. This implies that as more predictors are being discovered, the model needs to be 
continually refined and its performance re-evaluated. 
Numerous ways have been employed to gauge the accuracy of models, of which 
calibration and discrimination are two fundamental aspects that are commonly appraised 
[391]. Calibration reflects how close predicted probabilities are to actual observed risks 
[392] and is often measured using the Hosmer-Lemeshow “goodness-of-fit” test [393]. 
While well-calibrated models can accurately estimate population risk and are sufficient 
for policy-making, the risk for each woman needs to be calculated too so that 
personalized actions can be taken [390]. Discrimination represents a model’s ability to 
distinguish people who will and will not develop the disease of interest. It is determined 
by the area under the receiver-operating characteristic curve (AUC) or concordance (c) 
statistic, which are functions of sensitivity and specificity [394]. A model with an AUC of 
0.5 means it operates no better than chance, while an AUC of 1.0 signifies perfect 





improvement in this statistic indicates a stronger model, by convention [395]. Yet, the 
insensitivity of AUC makes it a poor marker of change in model performance [391]. What 
is most important for risk assessment in a clinical setting is not the sensitivity and 
specificity of a statistical model on which the AUC is based. Rather, it is whether a model 
can stratify individuals into more appropriate, clinically relevant risk groups. Pencina et al. 
has proposed a Net Reclassification Improvement (NRI) index which accounts for a shift 
in risk category of each individual in the right direction [396]. It is derived by summing the 
differences in proportion of individuals moving up a risk category minus the proportion 
moving down for those with the disease, and the proportion of individuals moving down a 
risk category minus the proportion moving up for those without the disease. Since the 
relatively insensitive AUC or c statistic may exclude novel and significant risk predictors 
from statistical models, NRI may be a more suitable indicator of the value of these 
additions to current models.  
Several statistical models for predicting breast cancer risk have been designed 
and validated in the last two decades. Over the years, emphasis has been placed on 
phenotypic risk predictors of breast cancer namely reproductive and hormonal exposure, 
previous benign breast disease, as well as limited information on family history of the 
disease. With the rise of genetics in today’s post-genomic era, there appears to be a 
growing dependency on common genetic variants and diminishing reliance on family 
history. This is not entirely unexpected as multiplex genetic assays have become readily 
accessible but knowledge on family history may be incomplete or inaccurate [397]. 
Furthermore, over 80% of all breast cancers occur in women with no family history of the 
disease [398]. A new trend has now emerged where family history and common genetic 





non-genetic factors can potentially provide the greatest accuracy for estimating risk in an 
individual. 
Here, we highlight a few established breast cancer risk assessment models. 
 
2.8.1 Gail and other established models 
 The Gail model, otherwise known as the Breast Cancer Risk assessment Tool 
(BCRAT), is the most well-known and widely used model for breast cancer risk 
assessment [399]. It was developed by Dr. Mitchell Gail and his colleagues in 1989 
using nested case-control data from the Breast Cancer Detection and Demonstration 
Project (BCDDP), comprising 300,000 women who underwent screening between 1973 
and 1980. The model was later modified to omit incidence rates for in-situ cancers, 
replace age-specific incidence rates from the BCDDP with that from the SEER database, 
and include composite incidence rates for African-American patients [400]. In both 
versions of the model, six factors namely, age, age at menarche, age at first live birth, 
number of breast biopsies, history of atypical hyperplasia, and number of affected first-
degree relatives were used to estimate a woman’s risk for breast cancer [399, 400]. 
Since the Gail model only considers first-degree relatives, it may underestimate the risk 
for women with a strong family history as observed in two studies [401, 402]. Neither 
does it perform well among women who do not participate in annual screening 
mammography [403]. Nevertheless, validation studies have shown that the model is 
well-calibrated overall but has modest discriminatory accuracy ranging from 0.58 to 0.63 
[400, 403-408].   
 Unlike the Gail model which focuses primarily on non-genetic risk factors, the 





control study, looks at family history alone albeit a much more detailed one [409]. It 
records the number of affected first- and second-degree relatives and the age at which 
they were diagnosed with breast and ovarian cancer [410]. According to the model, 
having a first-degree relative with ovarian cancer and another with breast cancer in her 
thirties puts a woman at a 40% risk of developing breast cancer by age 79. As the 
relative’s age of diagnosis for breast cancer increases, her risk decreases. Despite 
working with a more comprehensive record of family history, the exclusion of non-
genetic factors and the poor reflection of lifetime risks for women living in modern times 
restrict the routine use of the Claus model today [389]. Given the lack of reproductive 
factors in this model, it is therefore unsurprising to find a large discrepancy in risk 
estimations between the Gail and Claus models especially for women who are 
nulliparous, have had multiple benign breast biopsies, and a strong paternal or first-
degree family history [411]. 
 An alternative method to approximate a woman’s susceptibility to breast cancer 
is to determine her chance of having a mutation in high penetrance genes such as 
BRCA. Since BRCA carriers are up to 80% more likely of developing hereditary breast 
cancer [412], the BRCAPRO model which calculates the likelihood of a BRCA mutation 
could also be used to obtain breast cancer risk [413]. Apart from collecting information 
on affected relatives, the model recognizes those who are free of breast cancer too. 
However, non-BRCA mutations, reproductive as well as lifestyle factors are not 
accounted for, hence an underestimation of risk in women without a strong family history 
or in breast-cancer-only families [390]. 
 In view of the model limitations above, an integration of extensive genetic and 
non-genetic information is needed. The Tyrer-Cuzick model was developed using data 





trial that explores the impact of tamoxifen in 7152 high risk women [414]. It accounts for 
the effects of familial and personal risk factors namely, age, age at menarche, age at 
first birth, menopausal status, previous benign breast disease, BMI and HRT. Compared 
to the Claus and BRCAPRO models which focus on BRCA mutations only, the Tyrer-
Cuzick model addresses all other unexplained familial clustering of breast cancer 
through a hypothetical genetic component, BRCAu.  
 The performance of these risk models have been evaluated in a prospective 
study of 1933 women who participated in the Family History Evaluation and Screening 
Programme in the UK [401]. Over a mean follow-up of 5.27 years, the ratios of expected 
to observed numbers of breast cancer were 0.48, 0.56, 0.49 and 0.81 for the Gail, Claus, 
BRCAPRO and Tyrer-Cuzick models, respectively. In terms of discriminatory accuracy, 
the corresponding AUCs were 0.735, 0.716, 0.737 and 0.762. Although the Tyrer-Cuzick 
model performed the best among all, it may overestimate risk in women who once had 
benign breast disease [415]. The other three models projected lower susceptibilities with 
a huge error margin. This miscalculation was particularly obvious for women who have 
one first-degree relative with breast cancer, did not have any children or had their first 
child after the age of 30, or whose period began after 12 years old [389, 401]. Similar 
findings have also been reported in a recent retrospective study [415].  
 
2.8.2 Mammographic density in risk assessment 
Although risk assessment methods such as the Gail and Tyrer-Cuzick models 
have been shown to estimate lifetime risk accurately, they are unable to tell a woman 
specifically if she will develop breast cancer or not within a fixed span of time. To solve 





Mammographic density is a major risk factor with high population attributable risk [235]. 
Studies have presented similar AUCs for models containing only breast density and Gail 
or other established models [416-418]. Also, its addition into existing models has 
suggested a gain in performance [405]. Tice and colleagues had observed an 
improvement in AUC from 0.67 to 0.68 when the BI-RADS measure of mammographic 
density was added to the Gail model in a large screening population [418]. This change 
was statistically significant but clinically unimportant, however. After the Gail model was 
modified to contain only age, race, family history and previous breast biopsy, BI-RADS 
increased AUC by 0.05 [419]. Furthermore, their proposed model could reclassify 34% 
of women into more appropriate five-year risk categories. Likewise, Barlow et al. noted a 
rise in AUC from 0.605 to 0.62 when the BI-RADS density measure was entered into a 
model which consists of the following: age, ethnicity, first-degree family history, age at 
first birth, prior breast procedures, BMI, menopause type, current HRT use and previous 
mammography outcome [420]. Apart from BI-RADS, the value of PMD, a quantitative 
measure of mammographic density was explored. Chen and coworkers found a 
significant increase in AUC from 0.602 to 0.664 for the same BCDDP population that the 
original Gail model was based on [421]. In one of the latest reports on the IBIS study, the 
application of visually-assessed PMD to the Tyrer-Cuzick model enhanced AUC from 
0.51 to 0.62 and effectively reclassified 15.7% of high-risk women [422]. Models with 
PMD were found to be superior to those that used absolute dense area in risk 
assessment, according to a recent meta-analysis of several case-control studies [423].  
Despite improvements in discriminatory accuracy, the variability in the methods 
and measurement of mammographic density restricts the routine use of these models in 
populations. The advent of digital technology has prompted the displacement of 





to enhance diagnostic capability and quantification of mammographic density [417]. 
While studies have demonstrated the advantages of FFDM over analogue 
mammography in lesion detection and characterization [424-426] among younger 
women in particular [427, 428], the disregard of grayscale information via thresholding 
techniques may incur precision errors [390]. Also, the interactive aspect of this method 
depends on a trained reader’s visual assessment of the image to determine the cut-off 
value for a pixel to be considered black (non-dense) or white (dense); this is labor-
intensive, time-consuming, and introduces inter- and intra-reader variability. In the 
context of a population-based risk assessment programme, a fully-automated 
measurement of mammographic density would be more practical. Regardless whether 
screen-film mammography or FFDM is used, obtaining a 2D image for a 3D breast 
structure subjects one to precision and reproducibility issues. Differences in 
compression or positioning of the breast, film exposure and the amount of breast tissue 
captured on the image may influence density assessments on 2D mammograms [222, 
429].  
Thus, volumetric measures of the breast may bridge this gap and enable a more 
accurate prediction of breast cancer than current 2D methods. This has been supported 
by a comparison study between PMD and fibroglandular volume which displayed 
improved classification of risks when the latter was applied [430]. Yet, a reduction in 
measurement error is not good enough. For implementation in population-wide 
programmes, a reproducible and automated approach to measure mammographic 
density is needed. The creation of novel ways of examining breasts in 3D is underway. 
Quantra and Volpara are fully-automated software that have been designed for use with 
digital mammograms. Both have exhibited sufficient robustness in initial investigations 





assessments and high correlation with MRI data, displaying its potential to be used in 
objective breast cancer risk models [433]. This agreement with MRI has also been 
recorded for other 3D techniques [434]. 
Further validation of risk models especially those involving volumetric features of 
mammographic density and in premenopausal women are necessary. Even though 
adding mammographic density to established models leads to more accurate individual 
estimates of absolute risk, the improvement is modest.  
 
2.8.3 Common genetic variants in risk assessment 
 A polygenic component for breast cancer susceptibility has long been proposed 
because high penetrance genes such as BRCA have only been detected in a minority of 
the population [435]. This idea first appeared in the Breast and Ovarian Analysis of 
Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model which 
estimated risk through BRCA mutations and the multiplicative effect of many genes 
carrying minute effects [436]. The authors have presented more accurate predictions 
with the BOADICEA than the Claus and BRCAPRO models. Now, a modified version 
includes data from additional population-based studies, an age dependency in the 
polygenic component, as well as adjustment for birth-cohort effects [437]. Compared to 
the BRCAPRO and Tyrer-Cuzick models, the BOADICEA model could most accurately 
predict mutation carrier probabilities and differentiate carriers from non-carriers in a large 
number of families attending genetic clinics in the UK. It also estimated the familial 
relative risk for an individual well. A prospective validation study in Australian women 






 Large-scale multi-national GWAS collaborations involving huge numbers of 
breast cancer cases and controls have uncovered more than 70 risk SNPs to date [439]. 
Although each SNP has minimal effect on disease susceptibility, they can influence 
one’s risk when considered cumulatively in a polygenic risk score [435]. While SNPs 
alone have lower discriminatory power compared to the Gail model, they enhance model 
performance modestly when used together with non-genetic factors [440]. In a nested 
case-control cohort of 1600 patients aged 50 and above, the addition of seven SNPs to 
the Gail model produced a statistically significant gain in AUC from 0.56 to 0.59, and 
reassigned 19.5% of women with moderate risk into more appropriate five-year risk 
groups [441]. Dite et al. found a similar increase in AUC among younger women. For 35- 
to 39-year old women, 2.1% of cases were classified into a higher risk stratum, in 
contrast to 10.9% of cases and 4.0% of controls for those aged 40 to 49. The small 
proportion of women who were allocated higher predicted risks could be explained by a 
low absolute risk of breast cancer in younger individuals [442].  
With the discovery of more common genetic variants, their introduction into 
established models was expected to lead to greater predictive values. Wacholder et al. 
reported a 0.04 higher AUC in a model comprising 10 SNPs and conventional risk 
factors. A net 12.1% of breast cancer patients were reassigned to a larger risk category 
[443]. Others who evaluated the effectiveness of 15, 18 or 67 SNPs on the Claus and 
Tyer-Cuzick models drew the same conclusions on model discrimination too [444-446].  
 
2.8.4 Mammographic density and common genetic variants in risk assessment 
 Besides single-mindedly inserting novel SNPs as they are revealed, an 





into existing risk assessment models. This approach appears promising as the separate 
assessment of breast cancer risk using the Tyrer-Cuzick model, PMD, and SNPs are not 
associated, implying the inclusion of new, independent information that boosts predictive 
accuracy [444]. A case-control study conducted by Darabi and colleagues investigated 
the performance of PMD and 18 SNPs when they were both added to the Gail model 
simultaneously. Their proposed model widened the spread of predicted five-year 
absolute risks, increased AUC from 0.55 to 0.62, and reclassified about 20% of women 
to more correct risk categories [447].  
One should point out, however, that this method works only when PMD and 
SNPs are unrelated to the traditional predictors, and will fare poorly if a variable is an 
intermediate in a biological pathway that links genetics to breast cancer [448]. Since 
mammographic density shares a genetic component with breast cancer risk [243, 244, 
449] and is associated with other epidemiologic risk factors [450], it may clarify the 
unimpressive changes in predictive ability even when mammographic density, multiple 
SNPs and established risk factors have been considered altogether. This heritability 
holds true for volumetric mammographic density as well, but to a lesser extent [451]. 
 
2.8.5 Risk assessment in Singapore 
Annual screening mammography is generally recommended to women aged 50 
years and older. However, the fact that younger women are also afflicted with breast 
cancer should not be ignored. According to the latest Singapore Cancer Registry data, a 
sizable number of females who were diagnosed with breast cancer were in their 40s. 
From 2009 to 2013, women aged 45 to 54 formed 30% of those who developed breast 





Specifically in Asia, the development of risk assessment methods is crucial not 
solely because of sensitivity or specificity-related issues. Screening programs are 
expensive to set up and maintain as they require adequate facilities and trained 
manpower. Therefore, their success depends largely on high participation and retention 
rates [452]. Unfortunately, due to cultural attitudes, lack of encouragement and time, 
receptivity towards screening mammography has not been satisfactory [453]. Only 39.6% 
of women aged 50 to 64 have undergone regular breast screening as reported in the 
Singapore National Health Survey in 2010 [454]. This is in contrast to higher attendance 
rates of above 60% in the West [455, 456], and has not changed for the better compared 
to six years before [457].  
Where the incidence rate and uptake of screening is significantly lower, a small 
number of breast cancers have been detected through population-based mammography. 
Therefore, evidence to justify the implementation of routine screening mammography in 
the region appears to be lacking. This further strengthens the case for screening to be 
tailored to each woman’s risk of breast cancer, particularly for individuals without prior 
breast disease or a strong family history. Not only can closer surveillance be provided, 
primary preventive measures such as lifestyle modifications and prophylactic drugs may 
also be applied. Since risk assessment models developed using data from other 
countries may not be generalizable to the local population [458], validation or an 







3 STUDY OBJECTIVES 
The studies conducted in this thesis investigate the use of mammography and 
genetics in breast cancer detection and risk assessment. It is hoped that the following 
research can provide an unbiased evaluation amidst the controversies surrounding their 
application in population-wide screening and risk prediction. 
Specifically, the work done addresses these issues: 
 Can 3D images of the breast increase the accuracy in detecting and 
characterizing lesions? 
 Can quantitative mammographic density derived from digital mammograms be 
used in the risk prediction of breast cancer, and how does it compare to the 
conventional and subjective BI-RADS measure? 
 To what extent can common genetic variants improve risk assessment in breast 
cancer? 
 How much value can mammographic density and common genetic variants 










4 2D versus 3D mammography in breast cancer detection 
4.1 Motivation 
Breast cancer mortality has been decreasing in many parts of the world [98]. 
Although improvements in treatment may have contributed to this decline in breast 
cancer deaths, earlier detection of the disease has played a substantial role too [459]. 
The most important tool in early detection is breast screening mammography [460] 
which reduces the death rate by up to 45% based on reports from randomized clinical 
trials [338, 339, 461-466].  
Analogue screen-film and FFDM have been shown to be effective for both 
routine screening and symptomatic breast diagnosis [460]. In fact, it has been deemed 
as the most reliable way for detecting non-palpable breast lesions [342, 462, 464]. 
Despite this, concerns arise regarding the imprecision of mammography [467], over-
diagnosis [468] and limited benefit among younger women who tend to have denser 
breasts [469]. This is largely due to tissue overlap in 2D images where mammographic 
evidence of a tumor may be completely or partially obscured. Conversely, normal 
structures that overlay one another may produce an image that wrongly suggests an 
abnormality, leading to unnecessary recall and further assessment. 
Improvements in the overall image quality of mammograms can lead to better 
accuracy and timeliness of breast cancer detection, as well as lower rates of interval 
cancers [459]. This can be achieved with novel imaging technology such as DBT and 
SDM. As mentioned in Section 2.5.4, an x-ray fan beam sweeps in an arc across the 
breast, producing tomographic images and enabling the production of volumetric, 3D 
data. DBT allows the radiologist to scroll through a series of images, visualizing the 





especially in women with dense breasts [290]. While DBT has already been approved for 
both diagnostic and screening, little data has been published on 3D SDM. SDM is a 
novel imaging technology that enables the production of stereoscopic images and 
volumetric 3D images. It reduces the extent of tissue overlap that is inevitable in 2D 
images, thereby enhancing the differentiation of lesion types as well as the sensitivity 
and specificity of mammography. 
In this study, we evaluate the effectiveness of SDM in comparison to existing 
FFDM in terms of lesion conspicuity and characterization - aspects that influence patient 
















4.2 Materials and methods 
4.2.1 Study design and subjects 
Study subjects in this pilot study are patients from KK Women’s and Children’s 
Hospital who underwent diagnostic mammography from October 2012 to June 2013. 
They were selected if they had any mass, focal asymmetry or calcification in the breast. 
A total of 39 women were enrolled in this study and 51 lesions were depicted in these 
patients: 30 masses, 2 masses with calcifications, 6 focal asymmetries and 13 
calcification clusters. The lesion of interest was recorded for each case on a data form 
so that readers knew which lesion to evaluate. This study was approved by the 
Centralised Institutional Review Board.   
 
4.2.2 Mammogram acquisition and assessment of mammographic characteristics 
and density 
FFDM and SDM images were acquired using a Fujifilm AMULET f digital 
mammography system (Fujifilm Corporation, Tokyo, Japan). For 2D FFDM images, each 
image is stored according to DICOM protocol, with a bit resolution of 12-bit per pixel. 
Processed images of the left and right CC and MLO standard views were used in this 
study.  In SDM, an additional low dosage image was also taken at 4 degrees to the 
plane of origin for each standard view (Figure 4.1) [470]. As mentioned in Section 2.5.4, 
a standard mammography image and its corresponding 4-degree image are treated as a 
stereo-pair in SDM. Without undergoing any reconstruction process, an image of a 
stereo-pair is displayed on one of the 5-megapixel grayscale monitors while its paired 
image is viewed on the other monitor. Light coming from the top monitor is reflected on 





polarization of light coming through the half mirror is rotated by 90 degrees. By wearing 
a pair of polarized glasses, the viewer’s visual system fuses the stereo-paired images 
into an in-depth, 3D image of the breast.  
 
              
Figure 4.1 Image acquisition in SDM. 
 
Three breast radiologists with varying experience ranging from 5 to 13 years of 
reading mammograms were involved in the visual assessment of breast characteristics 
and identification of each lesion. They were blinded to the final histology (benign or 
malignant) of the patients. The following information was collected with the use of SDM: 
conspicuity (no lesion visible, lower conspicuity than 2D, similar to 2D, higher 
conspicuity than 2D), finding type (mass, mass and calcifications, focal asymmetry, 
calcifications only) mass shape (oval, round, irregular, lobulated), margin (circumscribed, 
indistinct, spiculated, micro-lobulated), calcifications morphology (punctate, amorphous, 
coarse heterogeneous, linear/branching, pleomorphic), distribution (group, loosely 
grouped, linear, segmental, regional, scattered), density (BI-RADS 1,2,3,4), lesion’s 





work-up (additional views, ultrasound) are required. BI-RADS categories from 2D and 
3D visual assessment of mammograms were also recorded. The radiologists used the 
American College of Radiology (ACR) BI-RADS [265] on both breasts, where possible, 
according to standard protocol. Density was divided into four classes : BI-RADS 1, 
almost entirely fatty, <25% glandular tissue; BI-RADS 2, scattered fibroglandular 
densities, 25-50% glandular tissue; BI-RADS 3, heterogeneously dense, 51-75% 
glandular tissue; BI-RADS 4,  extremely dense, >75% glandular tissue.  The likelihood 
of malignancy of a lesion was grouped according to the follow BI-RADS lexicon: 
Category 1, negative; Category 2, benign; Category 3, probably benign; Category 4, 
suspicious abnormality; and Category 5, highly suggestive of malignancy. Before 
embarking on reading SDM, on-site training was provided by an applications specialist 
from Fuji, reviewing 20 test cases.  
 
4.2.3 Statistical analyses 
The diagnostic performance of 2D FFDM and 3D SDM, in terms of lesion 
conspicuity, was compared on the following bases: final histology, finding type, density 
and lesion malignancy. The Kruskal Wallis test was used together with the Tukey (equal 
variance) or Games-Howell (unequal variance) post-hoc test. The agreement of lesion 
characteristics when visualized under 2D versus 3D was assessed using simple kappa. 
The inter-rater visual reproducibility between using 2D and 3D mammography to assign 
BI-RADS categories for lesion malignancy was summarized by weighted kappa (Kw). 
McNemar’s test was also used to compare the two methods based on final histology and 






The level of agreement between 2D and 3D visual assessment was performed 
using STATA version 12. All other statistical analyses were performed using SPSS 



















4.3.1 Patient demographics and lesion histology 
A total of 39 female patients were recruited for this study. They were aged 38 to 
71, with a mean age of 49.1 years.  Among these women, 25 had a single lesion, 10 had 
two lesions each, and the remaining 2 women reported three lesions each. A total of 51 
lesions were depicted: 30 masses, 2 masses with calcifications, 6 focal asymmetries and 
13 calcification clusters.  
 
4.3.2 Lesion conspicuity and characteristics 
The assessment of mammography in 3D was compared to the existing practice 
of identifying lesions from 2D FFDM in terms of lesion conspicuity with final lesion 
histology, finding type, density and lesion malignancy.  
Table 4.1 shows that approximately 60% of malignant and 50% of benign lesions 
were better visualized when mammograms were assessed in 3D. Less than 15% of 
benign lesions appeared less obvious on 3D compared to 2D (p=0.215). Numbers 
presented in the tables reflect the number of lesions read by the three radiologists, 









Table 4.1 Conspicuity of lesions when assessed three-dimensionally by final histology  
(p = 0.215). 
 Benign Malignant Unknown Total 
No lesion visible 1 (0.8%) 0 (0%) 0 (0%) 1 (0.7%) 
Lower conspicuity than 2D 18 (14.3%) 1 (4.8%) 0 (0%) 19 (12.4%) 
Similar to 2D 44 (34.9%) 7 (33.3%) 4 (66.7%) 55 (35.9%) 
Higher conspicuity than 2D 63 (50.0%) 13 (61.9%) 2 (33.3%) 78 (51.0%) 
Total 126 (100%) 21 (100%) 6 (100%) 153 (100%) 
 
Conspicuity of the lesions was also analyzed based on the type of lesions (Table 
4.2). We observed that masses were found in majority of the women (58.9%), and it 
tended to be seen more clearly under 3D (p < 0.001). Mass conspicuity was significantly 













Table 4.2 Conspicuity of lesions when assessed three-dimensionally by finding type     
(p < 0.001). 































2 (33.3%) 7 (38.9%) 7 (17.9%) 0 (0%) 78 
(51.0%) 
 
Out of 78 mass lesions that were more conspicuous under 3D, radiologists rated 
the margin (Table 4.3) and shape (Table 4.4) to be better appreciated for 66 (p < 0.001) 
and 36 (p < 0.001) lesions respectively. A similar observation was not made at other 











Table 4.3 Conspicuity of mass lesions and how well their margins are visualized in 3D  
(p <0.001). 
 Margin in 3D 
Not Applicable Better Same Worse Total 
No lesion visible 0 (0%) 0 (0%) 1 (100%) 0 (0%) 1 (100%) 
Low conspicuity 14 (73.7%) 1 (5.3%) 2 (10.5%) 2 (10.5%) 19 (100%) 
Similar to 2D 28 (50.9%) 5 (9.1%) 20 (36.4%) 2 (3.6%) 55 (100%) 
High conspicuity 10 (12.8%) 66 (84.6%) 2 (2.6%) 0 (0%) 78 (100%) 
Total 52 (34.0%) 72 (47.1%) 25 (16.3%) 4 (2.6%) 153 (100%) 
 
Table 4.4 Conspicuity of mass lesions and how well their shapes are visualized in 3D   
(p < 0.001).  
 Shape in 3D 
Not 
Applicable 
Better Same Total 
No lesion visible 0 (0%) 0 (0%) 1 (100%) 1 (100%) 
Low conspicuity 14 (73.7%) 1 (5.3%) 4 (21.1%) 19 (100%) 
Similar to 2D 28 (50.9%) 3 (5.5%) 24 (43.6%) 55 (100%) 
High conspicuity 10 (12.8%) 36 (46.2%) 32 (41.0%) 78 (100%) 






 Among women whose breast densities fall within BI-RADS 2 to 4, about a third 
of the lesions appeared as clearly as when visualized in 2D, and about half of them 
appeared more visible under 3D although no statistical significance was achieved (p = 
0.938) (Table 4.5). The same conclusion cannot be drawn for women with density class 
1 due to limited sample size. 
 
Table 4.5 Conspicuity of lesions when assessed three-dimensionally by density             
(p = 0.938). 
 BIRADS 1 BIRADS 2 BIRADS 3 BIRADS 4 Total 
No lesion visible 0 (0%) 0 (0%) 1 (1.8%) 0 (0%) 1 (0.7%) 
Lower conspicuity 
than 2D 
0 (0%) 3 (10.7%) 8 (14.5%) 8 (12.1%) 19 (12.4%) 
Similar to 2D 2 (50.0%) 10 (35.7%) 16 (29.1%) 27 (40.9%) 55 (35.9%) 
Higher conspicuity 
than 2D 
2 (50.0%) 15 (53.6%) 30 (54.5%) 31 (47.0%) 78 (51.0%) 
Total 4 (100%) 28 (100%) 55 (100%) 66 (100%) 153 (100%) 
 
Similarly, for breast lesions which fall within categories 2 to 4, more than half of 
them appear equally or more obvious when assessed in 3D (p = 0.026) (Table 4.6).  
More than half of the suspicious BI-RADS 5 category lesions were more visible when 
assessed in 3D (66.7%). The results suggest that malignant lesions also tend to appear 
more conspicuous when viewed under 3D, although numbers are too small to be 





Table 4.6 Conspicuity of lesions when assessed three-dimensionally by BI-RADS 
category (p = 0.026). 
 Category 
1 









2 (33.3%) 7 (8.0%) 6 (22.2%) 4 (14.8%) 0 (0%) 19 (12.4%) 
Similar to 
2D 




3 (50.0%) 52 (59.8%) 7 (25.9%) 12 (44.4%) 4 (66.7%) 78 (51.0%) 
Total 6 (100%) 87 (100%) 27 (100%) 27 (100%) 6 (100%) 153 (100%) 
 
 
Although SDM may improve the visibility of lesions in general, radiologists 
describe the lesions that they observe in terms of mass shape, margin, calcifications 
morphology and distribution similarly when viewed under either mode of assessment, as 










Table 4.7 Visual assessment in 3D does not alter the observed characteristics of lesions. 
Characteristic Simple kappa p value 
Mass shape 0.96 <0.001 
Margin 0.81 <0.001 
Calcifications morphology 0.93 <0.001 
Distribution 0.91 <0.001 
 
 
4.3.3 Visual reproducibility 
Weighted kappa (Kw) values were calculated between the radiologists in order to 
determine the inter-rater visual reproducibility of BI-RADS when evaluating breast 
densities in 2D versus 3D (Table 4.8). Although Readers 1 and 3 seem to have higher 
agreement above chance in assigning BI-RADS scores, the radiologists did not differ 
substantially when assessing mammograms in 2D and 3D. There was 5% higher 
agreement between Readers 2 and 3 when SDM was used, but this difference was not 











Table 4.8 Visual reproducibility of BI-RADS categories for lesion malignancy between 
radiologists, when assessing mammograms in 2D versus 3D. 
 
 Kw for 2D (95% CI) Kw for 3D (95% CI) 
Reader 1 vs Reader 2 0.16 (0.00 - 0.36) 0.15 (0.00 - 0.35) 
Reader 1 vs Reader 3 0.58 (0.31 - 0.85) 0.55 (0.29 - 0.82) 
Reader 2 vs Reader 3 0.18 (0.00 - 0.41) 0.23 (0.00 - 0.46) 
 
 
4.3.4 Follow-up procedures required 
As noted in Table 4.9, assessing mammograms in 3D may help to reduce the 
number of women who require additional mammography for clinical follow-up. Out of 47 
lesions which required additional views initially, this procedure was no longer needed for 
7 (14.9%) of them when viewed in 3D (p = 0.016). Focal asymmetry and calcifications 
formed the majority of cases that still required additional views when viewed in 3D – 14 
out of 16, and 24 out of 27 respectively. Only 2 out of 90 ‘mass’ and none of the ‘mass + 
calcifications’ cases required additional views. This improvement was not evident for 
ultrasound, however (p=1.00) (Table 4.10). Almost all the lesions (98.1%) which require 
further evaluation with ultrasound when assessed on 2D similarly needed ultrasound 







Table 4.9 Visual assessment in 3D reduces the number of lesions that require additional 
views (p = 0.016). 
 
 Additional views not 
needed in 3D 
Additional views 
needed in 3D 
Total 
Additional views not 
needed in 2D 
106 (100%) 0 (0%) 106 (100%) 
Additional views 
needed in 2D 
7 (14.8%) 40 (85.1%) 47 (100%) 
Total 113 (73.9%) 40 (26.1%) 153 (100%) 
 
 
Table 4.10 Visual assessment in 3D does not alter the number of lesions that require 
follow-up ultrasound procedure (p = 1.00). 
 
 Ultrasound not 
needed in 3D 
Ultrasound 
needed in 3D 
Total 
Ultrasound not needed 
in 2D 
49 (96.1%) 2 (3.9%) 51 (100%) 
Ultrasound needed in 
2D 
1 (1.0%) 101 (99.0%) 102 (100%) 










Limited data has been published on the possible use of 3D mammography. In 
this study, we have demonstrated the potential value of 3D SDM over the existing 2D 
FFDM on the basis of a few factors. Around 90% of lesions, regardless of malignancy 
were as well seen or better seen in 3D compared to 2D. The conspicuity of mass lesions 
seems to be improved the most, given that close to 70% of them are better seen with 
SDM.  This could be attributed to a clearer mass margin where radiologists reported a 
better appreciation more than 80% of the time. Although more than half of calcification 
cases were as well or better seen in 3D, additional views were still preferred for women 
with this type of lesion. 
As the extent of tissue overlap is reduced when images are viewed three-
dimensionally, the need for additional views also diminishes as a result, thereby saving 
manpower, money and time. However, this advantage does not extend to the use of 
ultrasound as most radiologists still preferred further evaluation to ascertain the solid or 
cystic nature of the mass. 
Young women tend to benefit less from 2D mammography screening. This is 
partly due to a lower fat content in the breasts of women aged below 50, hence greater 
mammographic density [469], which in turn reduces the sensitivity of mammography 
[471] and timeliness of cancer detection. A greater proportion of lesions in 
heterogeneously dense and extremely dense breasts were better seen on 3D 
mammography. This method also enabled easier identification of approximately half of 
the malignant lesions. This is because through 3D visualization, real information about 
the breast is no longer condensed into only two dimensions as a consequence of 





Mammographic density has consistently been shown to be an independent and 
modifiable risk factor that can increase a woman’s risk of breast cancer by up to 6-fold 
[235]. Due to its strong association with breast cancer, risk models comprising BI-RADS 
as a predictor have been proposed [418, 419]. BI-RADS is a tool that is devised as a 
means to standardize communication in mammography reports [473]. Its original 
purpose is to indicate how difficult it is to spot a lesion in the breast and if further tests 
are required [474]. Given its subjective nature, inter-observer inconsistency is expected 
even between trained readers, calling its application in prediction models into question. 
Here, we did not find greater agreement between readers, suggesting that 3D SDM does 
not provide a more consistent view of tissue density and distribution in comparison to 2D 
FFDM.  
Our study is limited by its small sample size; we did not have cases of 
architectural distortion, and recruited very few women with low breast density or breast 
abnormalities that are most likely malignant. Intra-rater reliability was not assessed 
either. These restrict the conclusions we can draw based on breast lesion types, BI-
RADS density groups and categories for lesion malignancy.  
We also identified the lesions on FFDM before reviewing them on SDM. In order 
to reduce bias in our assessment when viewing known lesions on SDM, mammograms 
could have been randomized, and images reviewed without prior knowledge of the 
location and type of lesion. A randomized controlled trial can also be conducted where 
cases and non-cases are randomized into one of three ‘treatment’ arms: FFDM only, 
SDM only, and both FFDM & SDM. Important outcome measures such as recall rates 
may then be assessed Even though the above were not done, the radiologists did not 
favour SDM or FFDM and had no conflict of interest with the manufacturer of SDM.  
We have shown the potential efficacy that can be achieved with 3D SDM as a 





should be carried out in larger study populations to validate the current findings. 3D SDM 
may be able to enhance the visibility of breast lesions, as well as save labor and time by 
reducing unnecessary follow-up procedures. However, it requires a more expensive 
instrument and exposes the patient to a higher dose of radiation as non-standard views 
are taken to form stereo pairs. Perhaps, SDM may be used specifically among younger 
women with denser breasts (BI-RADS 3 or 4) and a positive family history, where the 
chance of obtaining a false negative result is substantially higher. Cost-effectiveness 
analyses should be performed to find a balance between the additional risks undertaken 
















5 Quantitative versus qualitative mammographic density in 
breast cancer risk assessment 
5.1 Motivation 
Mammographic density commonly refers to the radiographic appearance of a 
breast in terms of dark and light regions [475]. This proportion of dark and light regions, 
which reflects the composition of fat and fibro-glandular tissue [476], varies among 
individuals and has been shown to be associated with an increase in a woman’s risk of 
breast cancer by three to six-fold [2]. This association was first observed by Wolfe, who 
noted that women with denser mammographic patterns were at higher risk of breast 
cancer [223, 477]. The qualitative relationship has been observed consistently in 
subsequent studies [478-480], while other groups have analyzed mammographic density 
quantitatively and reached a similar conclusion [237, 481]. Mammographic density has 
conventionally been reported using the ACR-instituted BI-RADS [226]. Quantitative 
methods using computer-aided thresholding programs, such as the current gold 
standard, Cumulus, have been proposed [229, 231, 482, 483]. Regardless of the 
different measures of mammographic density (parenchymal pattern, BI-RADS, dense 
area or PMD), research groups have found the association between mammographic 
density and breast cancer to be greater than that of almost all other risk factors with the 
disease [2], and it behaves in a dose-dependent manner [484]. Additionally, women with 
higher PMDs have increased risks lasting for a decade from their date of mammography 
[485, 486].   
In recent years, FFDM has gradually replaced screen-film mammography in 
breast cancer screening protocols. FFDM systems produce both raw (i.e. “FOR 





images for clinical display. Due to the sheer size of the raw image and storage 
considerations, it is often discarded, leaving only the processed one for routine clinical 
examination. However, display formats of processed images differ across manufacturers 
according to their proprietary algorithms that are developed for the purpose of improving 
diagnostic capability [474]. This can in turn influence operator-assisted measurements of 
mammographic density especially on a continuous scale. Although BI-RADS density 
categories on either screen-film or digital images have not been found to differ [487], 
radiologists have noticed that processed breast images appear less dense than when 
they are viewed on screen films [474]. This could mean that mammographic density 
measured from processed FFDM images may not fare as well as screen film 
mammograms when being evaluated as a breast cancer risk factor. 
If quantitative measures of mammographic density are to be used for risk 
assessment and patient management in the clinical setting, it is essential to evaluate the 
impact of estimating it from FFDM on risk model performance. Therefore, the 
development of automated methods warrants an investigation into whether 
mammographic densities acquired from digital images can perform as well as existing 
measures in breast cancer risk prediction. Here, we estimated the associations of BI-
RADS categories and other quantitative density measures with breast cancer. We also 
studied the potential value of quantitative measures in addition to BI-RADS, as well as 









5.2 Materials and methods 
5.2.1 Study design and subjects 
Study subjects were obtained from the National University Hospital (NUH). 
Patients were selected from a review of the hospitals’ online medical records.  In total, 
559 women from NUH (135 cases, 424 controls) with full field digital mammograms 
available between July 2008 and July 2013 were used in this case-control study. Cases 
have been diagnosed with unilateral breast cancer. Controls are either free of breast 
conditions or have been diagnosed with benign breast abnormalities.  
 
5.2.2 Validation population 
A total of 2020 women from University Malaya Medical Centre (UMMC) 
comprising 89 cases, 1931 controls were used for validation purposes. These women 
had full field digital mammograms performed from January to December 2010. Cases 
and controls were defined in the same way as patients from NUH.  
This study was approved by the National Healthcare Group Domain Specific 
Review Board B2 and the Medical Ethics Committee of UMMC. 
 
5.2.3 Mammogram acquisition and estimation of mammographic density 
Mammograms from NUH were acquired using a Siemens MAMMOMAT 3000 
Nova machine (Siemens AG, Munich, Bavaria, Germany) which produces both raw and 
processed images; whilst mammograms from UMMC were acquired using the Siemens 
Mammomat Novation DR platform (Siemens AG, Medical Solutions, Erlangen, 





stored in the Digital Imaging and Communications in Medicine (DICOM) format, with a 
bit resolution of 12-bit per pixel. Left and right CC and MLO views of the processed 
images were retrieved from the hospital’s online database. The mammograms closest to 
date of diagnosis and before administration of treatment were selected.  
Breast  densities of the images were scored by trained radiologists, who were 
blinded to the case-control status of the patients. The radiologists used the BI-RADS on 
both breasts, where possible. The following categories for density measure were used: 
Category 1, almost entirely fat, <25% glandular tissue; Category 2, scattered 
fibroglandular densities, 25-50% glandular tissue; Category 3, heterogeneously dense, 
51-75% glandular tissue; and Category 4, extremely dense, >75% glandular tissue.   
Quantitative measures of mammographic density - PMD, total breast area, dense 
area, and non-dense area, were estimated from the processed DICOM images using a 
fully automated thresholding method [231]. To be consistent with images used in the BI-
RADS scoring, the mean measurement of both left and right images in the MLO view 
were used in the analyses. 
 
5.2.4 Statistical analyses 
We summarized the following patient characteristics accordingly: age at 
mammography, dense area, non-dense area, total breast area, PMD, by mean and 
standard deviation; ethnicity, BI-RADS and density quartiles by proportion. A t-test was 
used to compare the means for continuous variables, while chi-squared test was used to 
compare categorical variables between cases and controls. 
Among NUH patients, we assessed the association between individual measures 





adjustments for age at mammogram and ethnicity. Continuous mammographic density 
measures were grouped into quartiles based on the entire study population. To identify 
quantitative mammographic density measures that were useful for risk prediction on top 
of existing factors, forward step-wise regression was performed. This was carried out by 
first assigning age, ethnicity and BI-RADS to the model, then running forward variable 
selection on quantitative density measures using cut-offs of p=0.1 and p=0.15 for entry 
and exit from the model respectively. To find out if quantitative density measures were 
more useful than BI-RADS in risk prediction, BI-RADS was included with the other 
mammographic density measures for forward variable selection. BI-RADS’ 
substitutability was also studied by excluding it from the step-wise regression model 
completely. These models which contained mammographic density predictors were 
compared with the logistic regression model comprising age at mammogram, ethnicity 
and BI-RADS only. This was done by plotting receiver-operating curves (ROCs) and 
comparing the corresponding AUCs. The models were then validated on a population of 
female patients from UMMC.  
 Statistical analyses were performed using STATA version 12. Statistical tests 












A total of 135 out of 559 women from NUH were diagnosed with breast cancer as 
of July 2013. Tables 5.1 and 5.2 show the distribution of age at mammogram, ethnicity 
and various mammographic density measures. Patients from NUH tend to be older than 
healthy controls at time of mammography (Table 5.1), while no difference was observed 
for women from UMMC (Table 5.2). Majority of patients in NUH tend to be Chinese, 
while close to 50% of patients in UMMC were Malay. Dense area, summarized as a 
mean or in quartiles, was higher among cases. A similar trend was not observed for the 
other mammographic density measures except BI-RADS, where NUH cases tend to be 
















Table 5.1 Baseline characteristics of NUH patients. 
Characteristic Case (n=135) Control (n=424) P* 
Range of age at mammogram, years 26 - 91 25 - 84 - 
Mean age at mammogram (SD) 54.7 (11.8) 52.0 (8.4) 0.016 
Ethnicity, n (%)    
Chinese 82 (60.7) 160 (37.7) <0.001 
Malay 20 (14.8) 98 (23.1)  
Indian 10 (7.4) 95 (22.4)  
Others 23 (17.0) 71 (16.7)  
Mean dense area, cm
2
 (SD) 28.3 (14.0) 24.6 (14.4) 0.010 
Dense area in quartiles, n (%)    
Q1 (2.5 to 15.0 cm
2
) 22 (16.3) 117 (27.6) 0.007 
Q2 (15.0 to  22.5 cm
2
) 35 (25.9) 106 (25.0)  
Q3 (22.5 to 33.2 cm
2
) 36 (26.7) 104 (24.5)  
Q4 (33.2 to 101.3 cm
2
) 42 (31.1) 97 (22.9)  
Mean non-dense area, cm
2
 (SD) 114.1 (42.8) 114.6 (48.7) 0.921 
Non-dense area in quartiles, n (%)    
Q1 (17.9 to 82.5 cm
2
) 29 (21.5) 111 (26.2) 0.817 
Q2 (82.5 to 105.7 cm
2
) 38 (28.1) 102 (24.1)  
Q3 (105.7 to 140.8 cm
2
) 37 (27.4) 102 (24.1)  
Q4 (140.8 to 325.6 cm
2
) 31 (23.0) 109 (25.7)  
Mean total breast area, cm
2
 (SD) 142.4 (42.6) 139.2 (44.1) 0.463 
Total breast area in quartiles, n (%)    
Q1 (50.0 to 108.7 cm
2
) 27 (20.0) 112 (26.4) 0.459 
Q2 (108.7 to 134.6 cm
2
) 40 (29.6) 101 (23.8)  
Q3 (134.6 to 165.8 cm
2
) 33 (24.4) 106 (25.0)  
Q4 (165.8 to 334.5 cm
2
) 35 (25.9) 105 (24.8)  
Mean percent mammographic density 
(SD) 
21.4 (11.2) 20.0 (12.6) 0.249 
Mean percent mammographic density in 
quartiles, n (%) 
   
Q1 (0.7 to 11.2) 25 (18.5) 114 (26.9) 0.204 
Q2 (11.2 to 18.5) 39 (28.9) 102 (24.1)  
Q3 (18.5 to 27.9) 35 (25.9) 104 (24.5)  
Q4 (27.9 to 80.5) 36 (26.7) 104 (24.5)  

















*2-sided p values were derived from Chi-squared test for Ethnicity, linear-by-linear association 






Table 5.2 Baseline characteristics of UMMC patients. 
 
 
Characteristic Case (n=89) Control (n=1931) P* 
Range of age at mammogram, years 32 - 87 26 - 81 - 
Mean age at mammogram (SD) 54.8 (11.4) 55.0 (9.1) 0.891 

















Mean dense area, cm
2
 (SD) 30.4 (11.9) 26.8 (12.9) 0.010 
Dense area in quartiles, n (%) 
Q1 (3.1 to 17.5cm
2
) 
Q2 (17.5 to 24.5cm
2
) 
Q3 (24.5 to 33.8cm
2
) 















Mean non-dense area, cm
2 
(SD) 107.0 (42.5) 105.5 (51.6) 0.783 
Non-dense area in quartiles, n (%) 
Q1 (16.7 to 68.9cm
2
) 
Q2 (68.9 to 94.2cm
2
) 
Q3 (94.2 to 128.9cm
2
) 















Mean total breast area, cm
2
 (SD) 137.4 (44.7) 132.3 (51.2) 0.353 
Total breast area in quartiles, n (%) 
Q1 (30.4 to 96.9cm
2
) 
Q2 (96.9 to 122.4cm
2
) 
Q3 (122.4 to 158cm
2
) 















Mean percent mammographic density 
(SD) 
23.8 (9.9) 22.6 (10.7) 0.296 
Mean percent mammographic density in 
quartiles, n (%) 
Q1 (1.1 to 14.6) 
Q2 (14.6 to 21.9) 
Q3 (21.9 to 30) 

































*2-sided p values were derived from Chi-squared test for Ethnicity, linear-by-linear association 






Table 5.3 displays the association of individual mammographic density measures 
with breast cancer. Statistically significant linear trends are observed for dense area 
quartiles and BI-RADS. Total area quartiles were significantly associated with breast 
cancer with adjustment for age at mammogram and ethnicity. The odds ratios (ORs) for 
linear trend using dense area quartiles, total area quartiles and BI-RADS after 
accounting for age at mammogram and ethnicity are 1.34 (95% CI: 1.10 - 1.62), 1.23 (95% 
CI: 1.01 - 1.50) and 1.81 (95% CI: 1.37 - 2.39) respectively. The associations of 
continuous dense area and total area with breast cancer were significant but 
substantially weaker. Linear trends for non-dense area and PMD quartiles suggested 
that these measures conferred an increased risk of breast cancer, but the results did not 
achieve statistical significance. Continuous non-dense area did not reflect a similar or 
significant finding while the ORs for PMD were above 1, but were not statistically 
significant. After adjusting for age at mammogram and ethnicity, women with low non-
















Table 5.3 The association between individual mammographic density measures, before and after adjusting for age at mammogram 
and ethnicity. 
Characteristic Cases Controls Crude OR (95% CI) P Adjusted OR
#
 P Adjusted OR^ P 
Dense area (cm
2
) 135 424 1.02 (1.00-1.03) 0.011 1.02 (1.01-1.04) 0.001 1.02 (1.01-1.03) 0.008 
Dense area (quartiles) 
Q1 (2.5 to 15.0) 22 117 1.00 (Ref)  1.00 (Ref)  1.00 (Ref)  
Q2 (15.0 to  22.5) 35 106 1.63 (0.93-2.83) 0.086 1.82 (1.03-3.20) 0.039 1.82 (0.98-3.39) 0.058 
Q3 (22.5 to 33.2) 36 104 1.64 (0.94-2.87) 0.08 2.07 (1.16-3.68) 0.014 2.23 (1.18-4.20) 0.013 
Q4 (33.2 to 101.3) 42 97 2.01 (1.18-3.40) 0.01 2.48 (1.43-4.30) 0.001 2.60 (1.39-4.86) 0.003 
Linear 135 424 1.24 (1.05-1.46) 0.011 1.33 (1.12-1.59) 0.001 1.34 (1.10-1.62) 0.003 
Non-dense area (cm
2
) 135 424 1.00 (1.00 - 1.00) 0.921 1.00 (1.00-1.00) 0.452 1.00 (1.00-1.01) 0.277 
Non-dense area (quartiles) 
Q1 (17.9 to 82.5) 29 111 1.00 (Ref)  1.00 (Ref)  1.00 (Ref)  
Q2 (82.5 to 105.7) 38 102 1.20 (0.63-2.28) 0.576 1.17 (0.62-2.23) 0.629 1.75 (0.99-3.10) 0.055 
Q3 (105.7 to 140.8) 37 102 1.59 (0.86-2.95) 0.142 1.46 (0.79-2.73) 0.231 1.80 (0.99-3.28) 0.053 
Q4 (140.8 to 325.6) 31 109 1.35 (0.74-2.47) 0.334 1.11 (0.59-2.08) 0.746 1.67 (0.88-3.18) 0.118 
Linear 135 424 1.11 (0.92-1.32) 0.278 1.03 (0.86-1.25) 0.726 1.17 (0.96-1.43) 0.118 
Total area (cm
2
) 135 424 1.00 (1.00 - 1.01) 0.463 1.00 (1.00-1.01) 0.793 1.01 (1.00-1.01) 0.038 
Total area (quartiles) 
Q1 (50.0 to 108.7) 27 112 1.00 (Ref)  1.00 (Ref)  1.00 (Ref)  
Q2 (108.7 to 134.6) 40 101 2.02 (1.05-3.87) 0.035 1.99 (1.03-3.83) 0.039 2.02 (1.13-3.59) 0.017 
Q3 (134.6 to 165.8) 33 106 1.50 (0.79-2.87) 0.215 1.39 (0.72-2.68) 0.318 1.71 (0.93-3.14) 0.084 
Q4 (165.8 to 334.5) 35 105 1.66 (0.87-3.17) 0.124 1.46 (0.76-2.81) 0.261 2.16 (1.15-4.06) 0.017 
Linear 135 424 1.08 (0.90-1.30) 0.411 1.03 (0.86-1.25) 0.743 1.23 (1.01-1.50) 0.035 
Percent mammographic 
density (%) 








Percent mammographic density (quartiles) 
Q1 (0.7 to 11.2) 25 114 1.00 (Ref)  1.00 (Ref)  1.00 (Ref)  
Q2 (11.2 to 18.5) 39 102 1.39 (0.83-2.33) 0.213 1.62 (0.95-2.76) 0.076 1.78 (0.97-3.26) 0.064 
Q3 (18.5 to 27.9) 35 104 1.63 (0.95-2.80) 0.079 2.05 (1.16-3.62) 0.013 1.60 (0.86-2.98) 0.135 
Q4 (27.9 to 80.5) 36 104 1.18 (0.68-2.08) 0.556 1.56 (0.86-2.82) 0.142 1.47 (0.77-2.80) 0.239 
Linear 135 424 1.08 (0.91-1.28) 0.364 1.18 (0.99-1.42) 0.071 1.09 (0.90-1.32) 0.393 
BI-RADS 
1 8 62 1.00 (Ref)  1.00 (Ref)  1.00 (Ref)  
2 26 129 1.56 (0.67-3.65) 0.303 1.93 (0.81-4.61) 0.139 1.68 (0.69-4.08) 0.255 
3 82 200 3.18 (1.46-6.93) 0.004 4.34 (1.92-9.81) <0.001 3.61 (1.56-8.34) 0.003 
4 19 33 4.46 (1.77-11.3) 0.002 6.89 (2.59-18.3) <0.001 4.97 (1.82-13.6) 0.002 
Linear 135 424 1.74 (1.34-2.25) <0.001 1.98 (1.51-2.60) <0.001 1.81 (1.37-2.39) <0.001 
 
#Adjusted for age at mammogram 








The association among the various mammographic density measures in quartiles and 
breast cancer are presented in Table 5.4. Model 1 represents a logistic regression model 
comprising age at mammogram, ethnicity and BI-RADS only. When these factors were pre-
assigned to the model, total area was also selected into the model (Model 2). BI-RADS was 
chosen together with total area as significant predictors when the former was not pre-assigned 
but allowed to be selected into the model with the other various mammographic density 
measures. With the omission of BI-RADS as a predictor, dense and total area quartiles were 




















Table 5.4 The association between various mammographic density quartiles and breast cancer, after adjusting for all other variables 
in the model. 
Variables  Model 1
~
: OR (95% CI) P Model 2
#
: OR (95% CI) P Model 3^: OR (95% CI) P 






























































Total area (quartiles) 
Q1 (50.0 to 108.7cm
2
) 
Q2 (108.7 to 134.6 cm
2
) 
Q3 (134.6 to 165.8 cm
2
) 
Q4 (165.8 to 334.5 cm
2
) 




















Dense area (quartiles) 
Q1 (2.5 to 15.0 cm
2
) 
Q2 (15.0 to  22.5 cm
2
) 
Q3 (22.5 to 33.2 cm
2
) 
Q4 (33.2 to 101.3 cm
2
) 











~Model 1: Age, Ethnicity and BIRADS were assigned in Models 1 and 2 
#Model 2: (Age, Ethnicity, BIRADS) + Density measure(s) selected by step-wise forward regression, cut-off p value = 0.1 




Figures 5.1 and 5.2 demonstrate the effect of quantitative mammographic 
density measures on prediction model performance in NUH and UMMC patients. Overall, 
the AUCs for NUH patients were around 0.70 for the models (Figure 5.1). When 
adjusted for ethnicity, AUCs for NUH women were in the range of 0.59 to 0.76 while 
lower levels of model performance were reported for their UMMC counterparts (Figure 
5.2). Regardless of institution, the AUCs of all 3 models within each ethnic group did not 
differ significantly, with the exception of the Chinese patients from NUH. Model 2 had a 





Figure 5.1 Receiver-operating curves (ROCs) for Models 1 to 3 performed in NUH 
patients. Models containing BI-RADS as a risk predictor reported slightly higher AUCs 
compared to the model without. However, all 3 models were not significantly different 









Figure 5.2 ROCs for NUH (a-c) and UMMC (d-f) patients by ethnicity. Figures a, b and c 
showed how the models fared in Chinese, Malay and Indian NUH patients respectively. 
Figures d, e and f showed the corresponding models for UMMC patients. Models 1 to 3 are 
not significantly different from one another in each group of women, except for NUH Chinese 
patients (p = 0.037). Among NUH Chinese women, the difference between Models 2 and 3 




In this study, we have shown the individual associations of various 
mammographic densities with breast cancer (Table 5.3). As expected, dense area and 
BI-RADS presented a strong and significant dose-dependent relationship. The direction 
of association between PMD and breast cancer agreed with background knowledge, but 
did not reach statistical significance. Our findings are in line with published studies on 
various ethnic populations [486, 488, 489]. According to a meta-analysis by McCormack 
et al, women in BI-RADS Class 4 had 4.08 times the risk of breast cancer versus their 
counterparts in BI-RADS Class 1 [2]. This is slightly lower than the OR in our study. A 
stronger relation between breast cancer risk and PMD compared to BI-RADS has also 
been reported by the group [2]. However, our data showed otherwise. In fact, PMD was 
the least associated to breast cancer risk among the three mammographic density 
measures. This discrepancy could be due to our limited sample size, and that we have 
used processed, and not screen-film mammograms.  
Results on the association of non-dense area with breast cancer have been 
mixed. Experiments have shown that fat tissue increases the risk of breast cancer 
through the secretion of proteins that promote malignant cell growth and estrogen 
production [490, 491], while those of Pettersson et al [492] have suggested a protective 
function.  Based on our findings, we have not found statistically significant evidence to 
show that non-dense area confers a higher risk. A forward selection model was used to 
identify mammographic density measures that had a significant association with breast 
cancer based on our study population. We have shown in Table 5.4 that BI-RADS and 
total area are not redundant (Model 2). This suggests that BI-RADS did not represent 
the risk of breast cancer attributable to total breast area adequately, which is not unusual 
since radiologists look at the distribution and amount of dense tissues when assigning a 
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BI-RADS score. The current BI-RADS is a classification scheme that looks at breast 
composition in terms of parenchymal patterns as well as a broad categorization of PMD 
into one of the four groups: ≤25%, 26-50%, 51-75% and >75%. Its original purpose was 
not to predict risk of breast cancer, but rather to indicate how difficult it is to spot a lesion 
in the breast and if further tests are required [474]. Our findings suggest that total breast 
area can add value to current methods of risk assessment and intervention.  
BI-RADS was selected by the forward step-wise algorithm even when it was not 
pre-assigned into the model (Table 5.4). This emphasizes its important role in risk 
prediction which could be undertaken by dense and total area quartiles (Model 3). The 
inclusion of dense area highlights its huge overlap with BI-RADS, and suggests a 
potential application of quantitative dense area in situations where BI-RADS is 
unavailable or unreliable for predictive purposes. This is further illustrated in Figures 5.1 
and 5.2 where the ROCs for the respective models are largely similar and AUCs are not 
significantly different from one another. However, one should note that the AUCs of the 
models for NUH patients are likely to be over-estimated. The overall reduction in model 
performance among UMMC patients could be due to unknown covariates that vary 
between the two populations which were not accounted for in our study.  
We have investigated the impact of mammographic density measures in quartiles. 
Continuous scales may be of limited relevance in clinical practice, while the use of 
quartiles may raise a question regarding the external validity of our findings. Although we 
have applied our models to patients from UMMC, study subjects in this external 
population had similar densities and were expected to have a similar lifestyle - a rough 
representation of socio-economic status and uncontrolled factors. Hence, the results 
here require validation especially in populations where women have starkly different 
mammographic density ranges and standards of living. Also, as with most studies, the 
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digital mammograms we have collected from NUH originated from a single manufacturer, 
restricting the clinical generalizability of risk model performance across all FFDM 
systems. This could be partly responsible for the different AUCs observed among 
UMMC patients. Given the number of manufacturers, standardization steps may be 
required as an additional step in individualized risk prediction. Regardless, our results 
provide evidence on the usefulness of FFDM in characterizing the risk of breast cancer.  
 In our study, we accounted for the effect of age at mammography and ethnicity 
when estimating the ORs. Age was adjusted for because mammographic density 
changes over an individual’s lifetime with density decreasing as one gets older [493]. 
Ethnicity was adjusted because Chinese women in Singapore who had denser breasts 
were not at higher risk for breast cancer than those with less dense breasts, unlike their 
non-Chinese counterparts [494]. There is no concrete evidence to conclude that 
menopausal status alters the strength of the association between mammographic 
density and breast cancer risk [2]. Although BMI has been suggested to be a negative 
confounder [450], Boyd et al found that BMI and mammographic density work through 
separate pathways [495], and others reported that it did not affect the estimates for 
association [2, 496]. Even if BMI did play a confounding role in this study, the 
magnitudes presented here would be under-estimated since studies that controlled for 
body size [225, 237, 481, 485] tend to give larger relative risks than those that did not 
adjust for BMI [237, 497, 498]. Another reason for OR estimates that are lower than 
actual is that mammographic density is also a risk factor for benign breast disease 
(controls) [215]. This would in turn affect the generalizability of our study’s findings in the 
general screening population. 
 Limited work has been done to compare the difference between mammographic 
densities measured from raw and processed FFDM images [417, 499, 500] and even 
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fewer studies have assessed the feasibility of using quantitative measures from 
processed images for breast cancer risk prediction [417]. In our study, we have identified 
quantitative predictors that can be used in place of a subjective mammographic density 
measure, and estimated their performance in risk prediction. This is advantageous as 
these quantitative measures can be obtained through automated processes, and can be 











6 Common genetic variants in breast cancer risk assessment  
6.1 Motivation 
Breast cancer is a heterogeneous disease that is associated with genetic and 
environmental factors. Prior to genetic studies, investigations have mainly revolved 
around the presence of a family history, hormonal and reproductive-related risk factors 
[110, 141, 399] with the effects of other lifestyle factors being queried recently. To date, 
the risk of disease has been shown to increase with a woman’s age, age at menopause, 
age at first live birth, previous occurrence of atypical hyperplasia and family history [501]. 
The inherited predisposition to this malignancy has also been thoroughly studied to 
reveal two major susceptibility genes, BRCA1 and BRCA2 [154, 155], as well as other 
gene mutations of lower penetrance [186, 502-506]. However, these account for less 
than 5% of breast cancer cases, suggesting a more widespread relevance of common 
genetic variants in the population when considered cumulatively [167, 192, 436, 507]. In 
addition, migrant and twin studies have hinted of an environmental component that can 
possibly overwrite the genetic influences on breast cancer, suggesting a multi-factorial 
nature of breast cancer risk or gene-environment interactions [103, 193].  
In an attempt to increase the clinical utility of these findings, statistical models 
have been designed and validated to aid in personalized risk assessment. Notably, the 
Gail model is the most widely used for breast cancer risk prediction [399]. However, the 
model does not consider genetic factors directly and has limited discriminatory power 
[405]. On the contrary, other studies in general have until recently ignored hormonal and 
reproductive characteristics of individual women [413, 508]. Unfortunately, most of the 
models are still lacking in their predictive ability [443, 458, 509, 510] and may be 
inapplicable to Chinese populations. 
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Despite having a much lower breast cancer incidence in Asia than in Europe 
[511], a rapidly increasing trend towards rates in the West is a cause for concern [512]. 
Singapore women are reported to have one of the highest rates of breast cancer 
incidence in the region with an annual increase of more than 3% [513]. As the linkage 
disequilibrium patterns differ among ethnic groups [514], findings from GWAS done on 
Caucasian populations [186-188, 515-517] are potentially less relevant to Asian women 
[514, 518-520]. In this nested case-control study, we incorporated a set of established 
GWAS risk alleles into a model with well-known lifestyle factors and evaluated its impact 












6.2 Materials and methods 
6.2.1 Study design and subjects 
The subjects included in this study are women enrolled in the Singapore Chinese 
Health Study (SCHS), a population-based cohort study which has been described in 
detail previously [521]. Briefly, the cohort comprises 63,257 Chinese men and women 
between the ages of 45 to 74 who were recruited from 1993 to 1998. Participants were 
Singapore citizens or permanent residents who lived in government-built housing estates, 
and belonged to either of two major dialect groups: Hokkien or Cantonese. All 
participants were interviewed at baseline in their homes where they provided information 
on demographics, diet, level of physical activity, occupational exposure, smoking, and 
medical history. The women were also asked about their menstrual and reproductive 
history.  
Between April 1994 and December 1999, blood and single-void urine specimens 
were collected from a random 3% sample of study enrollees. Details of the biospecimen 
collection, processing and storage procedures have been described previously [522]. 
Between January 2000 and April 2005, we extended our biospecimen collection to all 
surviving cohort members and collected biospecimens from 32,575 participants, 
representing a consent rate of about 60% of surviving cohort participants at that time.  
Informed consent was obtained from all participants at baseline interview, as well 
as at time of biospecimen collection. The Institutional Review Board at the National 





6.2.2 Case ascertainment 
Incident breast cancer cases were identified through the population-based 
cancer registry in Singapore. As of 28 June 2010, 941 had developed breast cancer in 
this cohort and among them, 414 donated blood previously and were included in this 
study. Compared with breast cancer patients who did not donate a blood sample, those 
who donated were younger at diagnosis (54.9 versus 56.0 years).  Patients who did not 
donate blood samples were less educated (39.1% had no formal education) than those 
who did (25.1% had no formal education). There was also a higher proportion of family 
history of breast cancer among those who donated blood (n=11, 2.66%) compared to 
those who did not donate (n=4, 0.76%).  
 
6.2.3 Control selection 
For each of the 414 breast cancer cases, up to three control subjects were 
randomly selected among all female cohort participants who had donated blood samples, 
and who were alive and free of breast cancer history at the time of cancer diagnosis of 
their index case. The chosen controls were matched to the index case on age at study 
enrollment (±3 years), dialect group (Hokkien, Cantonese), menopausal status at sample 
collection, dates of study enrollment (±2 year) and of blood collection (±6 months). For 
the 414 cases, there were 6 cases where only two eligible controls were found for each 






6.2.4 SNP selection, genotyping and quality control 
We reviewed all published GWAS results related to breast cancer 
(http://www.genome.gov/gwastudies). SNPs from various studies [523-525] including 
more than 40 novel SNPs that were very recently identified from the Breast Cancer 
Association Consortium (BCAC) [439] and subsequently evaluated in a collaborative 
study on East Asian women [520] were evaluated for their application in breast cancer 
risk assessment. Due to differences in haplotype structure between Caucasian and 
Chinese populations, among SNPs in the same loci and having linkage disequilibrium 
(LD, r2) of more than 0.8 in HapMap Han Chinese in Beijing (CHB) population [526], the 
SNP with the greatest statistically significant association with breast cancer  was 
genotyped, to ensure that all SNPs analyzed for risk prediction were independent of 
each other. SNPs with minor allele frequencies (MAF) less than 5% according to the 
Singapore Genome Variation Project (SGVP) [527], were also excluded. 
Genotyping was done using the Sequenom iPLEX Gold MassARRAY system in 
96-well plates. MassARRAY Assay Design software was used to design amplification 
and extension primers. Multiplex PCR amplification was performed using Qiagen 
HotStart Taq DNA polymerase with 10ng of genomic DNA. Finally, primer extension 
reactions were carried out according to manufacturer’s guidelines. The investigators 
were blinded to the case/control status of the samples. 
Of the initial 69 SNPs, 7 SNPs (rs3803662, rs4808801, rs8100241, rs11199914, 
rs11814448, rs10069690 and rs1292011) could not be analyzed further as they 
produced poor, indistinguishable clusters which could result in unreliable genotype 
callings. The average call rate for all SNPs was 98%, however the minor allele 
frequencies of rs11571833, rs132390, rs1045485, rs614367, rs999737 and rs8170 fell 
below the 1% threshold and were removed from analysis due to low power to detect any 
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association with breast cancer. Deviation from Hardy-Weinberg equilibrium (P<0.0007) 
in controls was exhibited in the genotype distribution of rs7716600 and these SNPs were 
also discarded. Among the samples, 3 cases and 15 controls did not meet the minimum 
call rate of 90%. The entire matched set was removed from analyses in the former. 
Therefore, 55 GWAS SNPs and 1,623 subjects (411 cases and 1212 controls) were 
used for further data analyses. 
 
6.2.5 Statistical analyses 
The SCHS questionnaire contained demographic data, reproductive risk factors, 
as well as information on diet and lifestyle. Risk factors to be included in the prediction 
model were selected according to results reported from other studies done on the SCHS 
cohort and factors used in the original Gail model [399]. Variables in the model were: 
level of education (No formal schooling, primary school, or secondary school or above), 
age at first live birth (<20, 20-24, 25-29 or nulliparous, ≥30 years), age at menarche (≥14, 
12-13, <12 years), history of past breast biopsy (Yes, No), family history (Yes, No), BMI 
(<20, 20-23.9, 24-27.9, ≥28 kg/m2) and GRS in quartiles based on the controls. BMI was 
calculated as the weight divided by the squared height (kg/m2). Family history was 
limited to first-degree relatives only. The history of past breast biopsy (yes/no) was 
known for 218 (13.2%) women in the current nested case control sample. For the 
remaining women with unknown history of breast biopsy, we imputed the value of history 
of breast biopsy variable using the multivariate imputation by chained equations (MICE) 
package in R. Using BMI, estrogen and family history as predictors, biopsy status was 
predicted 5 times and the most frequent one was selected. The association between 
breast cancer and demographic, reproductive, and other baseline characteristics was 
investigated using the Student’s t-test and Mantel-Haenszel Chi squared test (linear by 
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linear association) for continuous and categorical variables respectively. Established risk 
factors namely, parity, age at first live birth, age at menarche, age at menopause, BMI, 
family history, history of past breast biopsy and estrogen use were examined for their 
independent associations with breast cancer risk. A GRS was derived for each individual 
to represent the cumulative effect of the genetic variants on a woman’s risk of breast 
cancer. The Cochran’s Q test [528], which is the weighted sum of the squared difference 
between individual and pooled effects across studies, was used to test for heterogeneity 
among the current and published studies, The P values were obtained by comparing the 
statistic with a chi-square distribution with k-1 degrees of freedom, where k is the 
number of studies. SNPs were included in the computation of GRS only if heterogeneity 
was not statistically significant. If not, they were removed on the basis of inconsistency 
among studies (rs11780156, rs6504950, rs6001930, and rs2981579). To account for 
multiple hypothesis testing, a false discovery rate (FDR) correction according to the 
Benjamini-Hochberg procedure [529] was applied. A total of 51 SNPs was included in 
the computation of GRS. All SNP selection criteria had been decided a priori. 
A fixed-effects meta-analysis of published GWAS and our study’s findings was 
performed in order to obtain reliable estimates for each SNP’s effect size in the form of 
pooled odds ratio (pOR) derived from published and local studies. We weighted the 
effect size estimates of each study using the inverse of the corresponding standard 
errors of the respective studies. The GRS for an individual woman is equivalent to the 
sum of (log pOR of SNP) x (Number of risk alleles that the individual carries for SNP) 
across all 51 SNPs. The GRS was normalized by dividing it by the average effect size of 
all SNPs in the population, as outlined previously [530]. Box plots were used to 
investigate the correlation between GRS and various breast cancer risk factors: age at 
first live birth, age at menarche, family history, past breast biopsy, BMI and education. 
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Conditional logistic regression was used to calculate the crude and adjusted ORs with a 
95% confidence interval for each risk factor. The P value for trend across categories was 
reported.   
Variables in the Gail model and BMI were used to construct the conditional 
logistic regression model. The models with and without a GRS were compared in terms 
of their ability to accurately assess a woman’s five-year absolute risk. The probability 
that an individual i would be free of breast cancer beyond a certain time point, Pi(t), was 
calculated as 1-(St)
Ci, where St is the proportion of people who were not diagnosed with 
breast cancer (survived) up to time point t. We estimated St using Kaplan-Meier survival 
curve, based on data from the SCHS cohort - the cohort that this nested case-control 
study is from. Since a five-year risk is required in this study, t = 5 years. The individual-
level coefficient, Ci is determined by the formula exp[∑βj(xij - µj)], where βj is the log OR 
of the risk conferred by a variable j, and xij refers to the value of variable j for individual. 
The average for the variable in the population, µj, was approximated using the average 
among controls. The benefit of adding genetic markers into the predictive model was 
assessed using an NRI index [396] that compares the risk classifications under models 
with and without GRS, to adjust the NRI index for over-fitting, the index was further 
corrected using a bootstrap procedure [531]. 
As there is general expectation of a more reliable risk prediction model as 
additional risk variants become identified [510], we tested this hypothesis by re-building 
the model with 6, 9, 11, 16 and 51(this study) SNPs. These SNPs were chosen in an 
order in which their association with breast cancer risk was established through time 
[447, 509, 510, 532]. 
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Conditional logistic regression for the association between SNPs and breast 
cancer risk, NRI calculation and histogram plots were performed using R version 2.13.0. 
All other statistical analyses were performed using SPSS version 21.0. Statistical tests 
were two-sided and P <0.05 was considered statistically significant. In the test for 

















In total, 411 cases and 1212 controls were used in the analyses. The distribution 
of subjects by background characteristics is shown in Table 6.1. As the cases and 
controls were matched on age and menopausal status, they were comparable in these 
aspects. Cases tend to be more well-educated (p=0.003), older at first live birth 
(p=0.022), report a younger age at menarche (p=0.033), tend to be current estrogen 
users (p=0.042) and fall under a higher GRS quartile (p<0.001) compared to controls. 
They also have higher BMI (p=0.066) and a positive family history of breast cancer 
(p=0.063). The remaining factors comprising sleep and dietary patterns did not differ 
significantly between the two groups. Figure 6.1 displays no statistically significant 













Table 6.1 Distribution of demographic and established risk factors for breast cancer in 
cancer patients (cases) and control subjects, the Singapore Chinese Health Study, 1993 
to 1998. 




Mean age, years (SD) 54.9 (7.6) 54.9 (7.5) 0.964 
Education level, n (%) 
None 
Primary 











Reproductive risk factors 




5 or more 
 
  56 (13.6) 
146 (35.5) 
131 (31.9) 
  78 (19.0) 
 






Mean age at first live birth, years (SD) 25.6 (4.9) 25.0 (4.7) 0.022 
Mean age at menarche, years (SD) 14.1 (1.7) 14.3 (1.8) 0.033 
Mean age at menopause, years (SD) 49.7 (4.4) 49.2 (4.3) 0.141 






    8 (1.9) 
  31 (7.5) 
 
1131 (93.3) 
    22 (1.8) 
    59 (4.9) 
 
0.042 
Other risk factors 





  11 (2.7) 
 
1196 (98.7) 
    16 (1.3) 
 
0.063 





  10 (2.4) 
 
1193 (98.4) 
    19 (1.6) 
 
0.252 
Mean body mass index, kg/m
2
 (SD) 23.5 (3.4) 23.2 (3.2) 0.066 
Marine n-3 omega fatty acids, g (SD) 0.90 (0.4) 0.90 (0.5) 0.299 






  79 (19.2) 

















  77 (18.7) 
  43 (10.5) 








Mean Isoflavanoids, mg (SD) 19.4 (20.4) 19.8 (17.3) 0.700 
Sleep duration, hours per day (SD) 7.0 (1.1) 7.0 (1.1) 0.685 
Genetic Risk Score in quartiles, n (%) 
First      (32.4– 43.6) 
Second (43.6 – 47.1) 
Third     (47.1 – 50.6) 
Fourth   (50.6 – 65.8) 
 
  80 (19.5) 











* 2-sided P values were derived from Chi-squared test for categorical variables and t test 
for continuous variables; the Mantel-Haenszel Chi-squared test for trend with one 




















Figure 6.1 Correlation of GRS with various breast cancer risk factors. No statistically 
significant correlation was observed between GRS and the following breast cancer risk 
factors: Age at First Live Birth, Age at Menarche, Family History, Past history of breast 
biopsy, BMI and Education. 
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The ORs of the 51 SNPs from the current study and their pooled estimates with 
previous GWAS studies are displayed in Table 6.2. The SNPs that tag the ESR1 loci - 
rs2046210 and rs3757318, presented ORs that were statistically significant at the 5% 
level. Associations with FOXQ1 (p=0.088) and TOX3 (p=0.098) displayed marginal 
significance. Apart from 2 tag SNPs for ESR1, another 6 SNPs (rs11552449, 
rs13387042, rs10759243, rs3903072, rs12422552, rs2236007) were also significantly 




















Table 6.2 The rare allele frequencies of 51 single nucleotide polymorphisms (SNPs) in breast cancer patients and control subjects 
and their association with risk of breast cancer.  
 








Per-allele OR (95% 
CI) 









rs11552449 A 0.596 0.556 0.85 (0.72, 0.99) 0.08 0.040 1.06 0.068 
1 FCGR1B rs11249433 G 0.029 0.026 0.85 (0.52, 1.39) 0.25 0.517 1.09 0.371 
2 INHBB- rs4849887 A 0.259 0.269 1.05 (0.87, 1.25) 0.09 0.634 0.92 0.561 
2 METAP1D/DLX1/
DLX2 
rs2016394 A 0.195 0.191 0.96 (0.79, 1.18) 0.10 0.727 0.95 0.790 
2 TNP1‡ rs13387042 G 0.907 0.883 0.77 (0.60, 0.99) 0.13 0.045 0.93 0.062 
2 DIRC3 rs16857609 C 0.376 0.367 1.07 (0.90, 1.27) 0.09 0.462 1.08 0.977 
3 ITPR1/EGOT rs6762644 G 0.098 0.096 0.97 (0.73, 1.29) 0.14 0.841 1.07 0.790 
3 SLC4A7 rs4973768 A 0.190 0.186 0.97 (0.80, 1.18) 0.10 0.757 1.11 0.473 
3 TGFBR2 rs12493607 G 0.278 0.262 0.91 (0.76, 1.09) 0.09 0.290 1.06 0.619 
4 TET2 rs9790517 A 0.613 0.635 1.09 (0.93, 1.29) 0.08 0.293 1.05 0.440 
4 ADAM29 rs6828523 A 0.275 0.271 0.99 (0.82, 1.18) 0.09 0.879 0.90 0.729 
5 5p12 (intergenic) rs4415084 C 0.441 0.434 0.96 (0.82, 1.14) 0.08 0.668 1.15 0.087 
5 MRPS30 rs10941679 G 0.499 0.519 1.09 (0.93, 1.29) 0.08 0.289 1.12 0.409 
5 MAP3K1‡ rs889312 C 0.589 0.577 0.96 (0.82, 1.14) 0.08 0.666 1.05 0.727 
5 RAB3C rs10472076 G 0.247 0.260 1.07 (0.89, 1.28) 0.09 0.465 1.04 0.500 
5 EBF1 rs1432679 G 0.631 0.642 1.05 (0.89, 1.24) 0.08 0.558 1.07 0.931 
6 FOXQ1† rs11242675 A 0.597 0.633 1.15 (0.98, 1.35) 0.08 0.088 - - 
6 ECHDC1/RNF14
6 
rs2180341 G 0.181 0.198 1.09 (0.90, 1.33) 0.10 0.365 1.31 0.100 
6 RANBP9 rs204247 G 0.588 0.611 1.10 (0.94, 1.29) 0.08 0.248 1.05 0.911 
6 FAM46A rs17529111 G 0.218 0.206 0.92 (0.75, 1.12) 0.10 0.404 1.06 0.675 
6 ESR1 rs3757318 A 0.276 0.316 1.20 (1.01, 1.42) 0.09 0.039 1.04 0.790 
6 ESR1‡ rs2046210 A 0.380 0.434 1.25 (1.06, 1.46) 0.08 0.008 1.27 0.970 
7 ARHGEF5 rs720475 A 0.046 0.041 0.90 (0.61, 1.33) 0.20 0.596 0.94 0.941 
  
 




8 RPL17P33 rs9693444 A 0.282 0.288 1.04 (0.87, 1.24) 0.09 0.691 1.07 0.977 
8 8q24 rs13281615 G 0.502 0.500 0.99 (0.84, 1.16) 0.08 0.872 1.07 0.215 
8 8q24 rs1562430 C 0.181 0.184 1.03 (0.83, 1.27) 0.11 0.820 0.87 0.273 
9 CDKN2A rs1011970 A 0.096 0.095 0.98 (0.75, 1.28) 0.14 0.875 1.07 0.639 
9 KLF4 rs10759243 A 0.431 0.476 1.20 (1.02, 1.41) 0.08 0.027 1.06 0.790 
9 KLF4 rs865686 C 0.057 0.067 1.19 (0.87, 1.64) 0.16 0.275 0.90 0.150 
10 ZNF365 rs10822013 T 0.500 0.517 1.07 (0.91, 1.25) 0.08 0.409 1.08 0.387 
10 ZNF365‡ rs10995190 A 0.012 0.013 1.14 (0.57, 2.30) 0.36 0.713 1.06 0.350 
10 ZMIZ1 rs704010 A 0.369 0.397 1.12 (0.95, 1.33) 0.08 0.169 1.08 0.473 
10 FGFR2‡ rs1219648 G 0.404 0.427 1.08 (0.92, 1.27) 0.08 0.343 1.14 0.560 
10 FGFR2 rs2981582 A 0.338 0.370 1.14 (0.96, 1.34) 0.08 0.128 1.26 0.451 




rs3903072 A 0.210 0.175 0.81 (0.66, 0.99) 0.10 0.039 0.95 0.268 
11 BARX2 rs11820646 A 0.489 0.509 1.09 (0.93, 1.28) 0.08 0.278 0.95 0.574 
12 ATF7IP rs12422552 C 0.273 0.325 1.29 (1.08, 1.53) 0.09 0.004 1.06 0.128 
12 PTHLH rs10771399 G 0.192 0.173 0.88 (0.71, 1.08) 0.11 0.221 0.86 0.729 
12 NTN4 rs17356907 G 0.253 0.247 0.98 (0.82, 1.18) 0.09 0.839 0.91 0.604 
14 PAX9/SLC25A21 rs2236007 A 0.297 0.255 0.83 (0.69, 0.98) 0.09 0.031 0.92 0.469 
14 CCDC88C rs941764 G 0.126 0.140 1.13 (0.90, 1.42) 0.12 0.308 1.06 0.931 
16 TOX3 rs4784227 T 0.245 0.274 1.17 (0.97, 1.41) 0.09 0.098 1.23 0.574 
16 TOX3 rs3112612 G 0.228 0.210 0.90 (0.74, 1.10) 0.10 0.300 1.13 0.066 
16 CDYL2 rs13329835 G 0.053 0.054 1.02 (0.70, 1.46) 0.18 0.938 1.09 0.351 
16 MIR1972-2/FTO rs17817449 C 0.140 0.118 0.83 (0.66, 1.06) 0.12 0.134 0.93 0.079 
18 AQP4‡ rs527616 G 0.267 0.266 0.99 (0.83, 1.19) 0.09 0.951 0.98 0.805 
18 CHST9 rs1436904 C 0.486 0.509 1.09 (0.93, 1.28) 0.08 0.287 0.96 0.225 
19 C19orf61:KCNN4
:LYPD5:ZNF283 
rs3760982 A 0.136 0.148 1.10 (0.87, 1.38) 0.12 0.437 1.06 0.994 
21 NRIP1 rs2823093 A 0.035 0.032 0.90 (0.57, 1.40) 0.23 0.631 0.92 0.994 
Chr, chromosome. 
† A pooled OR was not obtained for rs11242675 due to significant heterogeneity with other published studies. 
‡ A pooled OR with the Asian studies was obtained due to heterogeneity with the results of European studies.*P-value was derived 




The associations between breast cancer risk, established risk factors and GRS were 
evaluated. Compared to the lowest quartile, women in the highest GRS quartile were close to 
80% (OR= 1.75, 95% CI = 1.27 - 2.41) more likely to have breast cancer (Table 6.3). The 
magnitude of the association with GRS and the dose-response relationship remained almost 
unchanged even after adjusting for the established risk factors and education.  Age at first live 
birth and age at menarche presented statistically significant trends with breast cancer risk, but 
were no longer significant after adjustment. On the contrary, the association of BMI with risk 
became significant after other factors were considered. After accounting for GRS and the 
above-mentioned risk factors, neither a positive family history nor a previous breast biopsy was 































Genetic risk score, 
quartiles (range), mean 
First (32.4-43.6), 40.4 
Second (43.6-47.1), 45.4 
Third (47.1-50.6), 48.9 
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20 to <24 
24 to <28  
28 or higher 
P trend 
 
  51 (12.4) 
216 (52.6) 
102 (24.8) 
  42 (10.2) 
 
 167 (13.8) 
 659 (54.4) 
 305 (25.2) 
   81 (6.7) 
 
1.00 (ref) 
1.09 (0.77, 1.54) 
1.10 (0.75, 1.62) 
1.74 (1.07, 2.85) 









1.11 (0.78, 1.58) 
1.12 (0.76, 1.64) 
1.83 (1.12, 3.01) 









1.16 (0.81, 1.66) 
1.15 (0.78, 1.70) 
1.99 (1.21, 3.29) 








Table 6.3 The relation for genetic risk score and established conventional risk factors with risk of breast cancer. 
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(95% CI)‡ 
P value 
Genetic risk score, 
quartiles (range), mean 
First (32.4-43.6), 40.4 
Second (43.6-47.1), 45.4 
Third (47.1-50.6), 48.9 




  80 (19.5) 












1.26 (0.90, 1.75) 
1,47 (1.06, 2.04) 
1.78 (1.29, 2.44) 











1.25 (0.90, 1.75) 
1.49 (1.07, 2.06) 
1.74 (1.26, 2.40) 











1.26 (0.90, 1.76) 
1.47 (1.06, 2.04) 
1.75 (1.27, 2.41) 

















  56 (13.6) 
129 (31.4) 
175 (42.6) 










1.11 (0.77, 1.59) 
1.67 (1.16, 2.39) 
1.62 (1.03, 2.55) 











1.04 (0.72, 1.50) 
1.51 (1.04, 2.18) 
1.46 (0.92, 2.31) 











1.05 (0.73, 1.51) 
1.49 (1.03, 2.15) 
1.49 (1.03, 2.29) 























1.29 (1.00, 1.66) 
1.34 (0.95, 1.89) 








1.21 (0.93, 1.56) 
1.20 (0.84, 1.71) 








1.23 (0.94, 1.60) 
1.19 (0.83, 1.71) 











  11 (2.7) 
 
1196 (98.7) 
    16 (1.3) 
 
1.00 (ref) 
























































20 to <24 
24 to <28  
28 or higher 
P trend 
 
  51 (12.4) 
216 (52.6) 
102 (24.8) 
  42 (10.2) 
 
 167 (13.8) 
 659 (54.4) 
 305 (25.2) 
   81 (6.7) 
 
1.00 (ref) 
1.09 (0.77, 1.54) 
1.10 (0.75, 1.62) 
1.74 (1.07, 2.85) 









1.11 (0.78, 1.58) 
1.12 (0.76, 1.64) 
1.83 (1.12, 3.01) 









1.16 (0.81, 1.66) 
1.15 (0.78, 1.70) 
1.99 (1.21, 3.29) 







 Table 6.3 The relation for genetic risk score and established conventional risk factors with risk of breast cancer. 
ᶲ Adjusted for education 
‡ Adjusted for education and all other factors in the table 
 142 
 
An NRI index was used to assess the improvement in risk classification that 
would result from adding GRS to a model comprising established risk factors only. Table 
6.4 shows the distribution of women across the various five-year absolute risk categories 
from <1.0% to ≥2.5%. Approximately 1,400 women reported five-year cumulative risks of 
less than 1.5%, while only 5.4% of cases and 2.0% of controls were assigned into high-
risk groups of 2% or more. Among the 44 cases who were categorized as having a five-
year absolute risk of 1.5% - <2.0% under the model without GRS, 12 of them were 
shifted to higher risk groups while 13 were moved to the lower risk category of 1.0% - 
<1.5% when GRS was added to the model. Similarly, for about 46.1% of the controls 
who were initially estimated to have 1.5% - <2.0% risk based on established risk factors 
only, the new model with GRS indicated a lower risk of 1.0% - <1.5%, while shifting 12 
individuals to the 2.0% - <2.5% risk stratum. The reclassification improvement among 
cases was 11.2% (p<0.001), while that for controls was 2.2% (p=0.04), though the latter 
was not statistically significant. This led to an NRI of 13.4% (p=0.006), which decreased 
to 6.2% after correcting for optimism using a bootstrap method. This meant, that overall, 
6% of women were reclassified into more appropriate risk groups when a genetic 











Table 6.4 Reclassification of five-year absolute risk of breast cancer based on a risk 
model containing Gail variables with and without GRS on 411 breast cancer patients and 
1212 healthy women. 
 
Five-year risk 
without GRS (%) 
Five-year risk with GRS (%) 

































































































































Figure 6.2 demonstrates the change in model discriminatory power as GRS that 
represented the cumulative effect of 6, 9, 11, 16 and 51 (this study) SNPs were used in 

























Figure 6.2 Effect of increasing number of SNPs in breast cancer risk assessment. The 
rate of increase in model discriminatory power (difference in Log 5-year Absolute Risk) 
With GRS (16 SNPs) With GRS (51 SNPs) 
With GRS (9 SNPs) With GRS (11 SNPs) 
Without GRS 
 




between cases and controls diminishes as more SNPs are incorporated into the GRS. 
For instance, the change in improvement of model performance is minimal when the 
number of SNPs used in the GRS increased from 16 to 51. GRS is obtained by pooling 
the ORs of local and published studies. Y-axis is the density which reflects the frequency 



















We have evaluated a total of 51 SNPs and constructed a GRS to reflect their 
cumulative effect on breast cancer risk. The genetic score was independently associated 
with breast cancer risk after adjusting for education and other established risk factors. 
These common genetic markers, when considered in aggregate, together with 
reproductive factors and BMI, can improve the risk stratification for roughly 6% of 
Singapore Chinese women.  Similar to past SCHS studies [533, 534], cases tend to be 
more highly-educated compared to the controls, hence the adjustment for education in 
the conditional logistic regression model. However, BMI and family history did not differ 
significantly between the two groups although the direction of the associations was in 
agreement with prior knowledge. Failure to reach statistical significance is very likely due 
to the sample size, hence limiting our study’s power to detect an association. An 
attenuated effect of family history (OR = 1.78) after accounting for GRS was noted too. 
This could be due to the fact that risk variants which are directly or indirectly 
incorporated into the GRS are also traits that tend to be inherited together. 
To our knowledge, we have investigated the largest number of SNPs for use in 
risk assessment in an Asian population. Studies by Dai et al, Sueta et al, and Zheng et 
al have reported the discriminatory power of using 5, 7 and 8 SNPs respectively [518, 
535, 536]. All groups demonstrated the clinical utility that can potentially be achieved 
with the incorporation of common genetic variants to a model containing established risk 
factors. Locally, a group has reported the potential effect of combining 8 SNPs with 
clinico-pathological factors in risk prediction for a Singapore Chinese population [537]. 
Likewise, we have shown that common genetic markers, when considered in aggregate, 
together with reproductive factors and BMI, can improve the risk stratification for more 
than 5% of Singapore Chinese women. However, majority of the cases (79.6%) 
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presented low five-year cumulative risks of less than 1.5% after GRS was considered, 
with only 5.4% being assigned five-year cumulative risks of 2% or more. This suggests 
that other genetic, physiological and environmental factors not accounted for in this 
study, which includes novel factors yet to be identified, still account for a large proportion 
of risk for breast cancer in this population. 
To gauge how much value a genetic component can add to an individual’s risk 
assessment, we included the GRS into a model consisting of Gail variables and 
compared its performance with the model without GRS. Many of the studies published 
thus far have reported the accuracy of their models in terms of AUC values [538].  
However, AUC is insensitive even when strong predictors are added to the model [395], 
hence could partially account for insignificant increases in model discrimination. It also 
does not provide information about the actual risks predicted, therefore, its direct clinical 
relevance is limited [539]. Instead, we have quantified the degree of correct risk 
reclassification by calculating the NRI index [396]. Even though NRI depends on 
arbitrary cut-off points, it is robust to moderate changes [441]. Bootstrapping was 
performed to account for over-fitting of our data to the model, which could in turn lead to 
an overestimation of model performance. Although we attempted to incorporate all 
variables of the Gail model in our study, the low uptake of screening mammography 
meant that we did not have breast biopsy information for a majority of our participants. 
This problem of ‘missing data’ was overcome by imputing breast biopsy status based on 
BMI, estrogen use and family history - variables that differed between those who ever 
and never had a breast biopsy. 
SNPs that tagged the ESR1 gene which codes for estrogen receptor alpha 
(ESRα) presented statistically significant associations and consistent ORs in our study. 
This is in concordance with findings from other groups which showed substantial effect 
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sizes for SNPs in this region, highlighting a likely association with breast cancer among 
Chinese and Japanese women [540]. The study conducted among Singaporean 
Chinese also reported that rs2046210 recorded the largest magnitude, similar to our 
current study [537]. This is in agreement with a comparison study by Hein et al, which 
found significant association of the 6q25.1 locus in both Asians and Europeans but 
greater effects in the former [541]. Our study also supports the finding that the MAP3K 
SNP, rs889312, does not increase the risk of breast cancer among the Chinese [514, 
519, 537], contrary to that of European populations [186, 516]. However, unlike the other 
studies[186, 502, 514, 516, 518, 519], statistical significance was not observed here for 
another well-established susceptibility loci containing FGFR2.  
The OR of rs11242675 (FOXQ1) reported here was 1.15. This is contradictory to 
the findings of many published work which have reported statistically significant 
protective effects, but the risk effect we found is supported by the most recent BCAC 
study [439]. As a result, significant heterogeneity was observed among the various 
studies and a pooled OR was not applicable. Forkhead box Q1 (FOXQ1) is a 
transcription factor found on the 6p25 locus. Overexpression of the protein has been 
shown to enhance tumorigenicity and tumor growth through its angiogenic and anti-
apoptotic properties [542]. Its novel role in the metastasis of breast cancer has also been 
suggested [543]. In view of a plausible biological function of FOXQ1 in promoting cancer 
aggression, as well as marginal statistical significance that was a likely consequence of 
small sample size, rs11242675 was included in the GRS for risk assessment.   
Another SNP which was also considered in the GRS due to its marginally 
significant P value (P = 0.098) was rs4784227. Rs4784227 is situated at 16q12.1 [544] 
and has been predicted to interfere with the affinity of FOXA1, an essential component 
of ESRα signaling, to its binding site [545]. Its position in a regulatory region which 
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interacts with the TOX3 promoter enables it to disrupt the expression of this gene, which 
in turn alters chromatin structure and DNA-protein binding patterns essential for cell 
survival [544].  An OR of 1.17 was seen in our study. This effect size and direction were 
similar to the findings of others thus a pooled OR was used for GRS computation.  
It was observed, in Figure 6.2, that the marginal improvement in model 
performance was not proportional to the increase in additional SNPs used. Although the 
discovery of additional SNPs do not drastically improve the assessment of breast cancer 
risk, this is expected since the first few new SNPs discovered would have been 
associated with much larger effect sizes. Also, as the cost of genotyping continues to 
decrease, we expect the use of additional SNPs in risk assessment to be cost-effective 
in the near future. 
This study has several strengths. The study was nested within a population-
based prospective cohort that provides the use of questionnaire data collected before 
the occurrence of breast cancer to reduce recall and reverse causality bias. The 
inclusion of genetic variants in risk assessment is advantageous as it is not subjected to 
time-dependent errors in measurement, unlike environmental exposures such as BMI or 
smoking. We have also shown the strength of the association between GRS and breast 
cancer risk; it remains virtually unchanged even after all other established risk factors 
have been considered, highlighting the importance of genetics in this aspect.  
There are also several limitations in our study. The small sample size of 
approximately 1600 women has made it difficult to attain statistical significance for most 
of the SNPs that were identified in GWAS studies. Nevertheless, the direction of the 
effects of most SNPs was consistent with the published literature. Although a large 
proportion of women had their breast biopsy status imputed based on available 
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information, repeating the analyses without biopsy status did not alter the results 
substantially (data not shown). As all the subjects recruited were Chinese women, this 
could restrict the generalizability of our results. Studies will need to be conducted in 
larger populations and among women of other ethnicities to validate the effect of these 
polymorphisms. We were not able to consider two factors in this study: 1) the presence 
of copy number variations (CNVs) and their potential effects on breast cancer risk and 2) 
the various subtypes of the disease. Given the proximity of some SNPs to CNV regions 
[546], and the relation between CNVs and familial breast cancer [547], an effect of CNVs 
on risk of disease is not unlikely. However, modeling this poses difficulties and may not 
alter the results substantially [546]. Although further analysis by disease subtype would 
have been ideal, we were restricted by the study’s limited sample size and power. Finally, 
the breast cancer cases included in this study from the cohort had a higher prevalence 
for positive family history of breast cancer compared to cases that were not included in 












7 Mammographic density and common genetic variants in 
breast cancer risk assessment 
7.1 Motivation 
The primary goal of breast cancer screening is to enable early detection of 
disease so that prognosis can be improved by more timely intervention. Although 
screening offers the benefit of reduced mortality for potential patients, the level of over-
diagnosis and subsequent treatment of healthy individuals is worthy of concern: for 
every breast cancer death prevented, three women would be unnecessarily treated for 
the disease [548]. More importantly, a large majority of women who go for screening are 
never diagnosed with breast cancer. This suggests a need for re-allocation of resources 
so that women at higher risk of developing breast cancer are accorded more frequent 
supervision as a preventive measure.  
To facilitate the decision-making process, a woman’s risk is often assessed using 
her demographic and reproductive information, as well as the presence of a positive 
family history [538]. One of the most established prediction models used is the Gail 
model, which considers a woman’s family history, age, age at menarche, age at first live 
birth, and number of breast biopsies to provide an individualized estimate of breast 
cancer risk [399]. Subsequently, the model has been modified for use in other ethnic 
populations [407, 418, 421, 549]. Although these models were well-calibrated, their 
discriminatory power was relatively poor with AUCs of the ROC ranging from 0.53 to 
0.66 [538].  
In a recent study, Chay et al evaluated the applicability of the Gail model in 
Singapore. They found that the Gail model over-estimated the population’s 10-year 
breast cancer risk by 85% overall, with women aged 60-64 having a predicted incidence 
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that was thrice as high as observed [550]. This report highlights the need for an 
alternative model that is generalizable to Asian communities where the uptake of 
mammography screening and incidence of breast cancer is substantially lower [551]. 
Apart from the established reproductive factors, other variables have also been 
reported to be associated with breast cancer. Mammographic density has consistently 
been shown to be an independent and strong modifiable risk factor, increasing one’s risk 
of breast cancer by 3 to 6 times [237, 485, 486] for at least a decade [485]. Several 
groups have evaluated the impact of including mammographic density in breast cancer 
risk assessment, but have yielded modest results [418, 421]. 
Also, findings from GWAS have identified several common genetic variants that 
are associated with breast cancer risk [186, 188, 514, 517, 519]. Approximately 70 SNPs 
have been identified to date [439, 520] and some of these variants have been used 
cumulatively to estimate an individual’s probability of disease in an Asian context [509, 
518, 535-537]. Despite the increase in the number of predictive SNPs, the performance 
of the risk prediction models are still suboptimal to be clinically useful in individualized 
prevention [509].  
In this study, we aim to refine the Gail model by using effect sizes specific to our 
population, incorporating mammographic density and common genetic risk variants and 
evaluate the performance of the model in a prospective Singapore female cohort with 
large-scale mammography screening data available. In order to evaluate the potential 
improvement from genetics data, we simulated genotypes based on genotype frequency 
data relevant to the local population and averaged the results over the virtual genotype 
datasets. With the existing use of mammography and the decreasing costs of 
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genotyping, we hope to utilize these readily accessible resources to build an 


















7.2 Materials and methods 
7.2.1 Study design and subjects 
The subjects included in this study are women enrolled in the Singapore Breast 
Cancer Screening Programme (SBCSP), for which the study design has been described 
in detail previously [552]. The SBCSP was a prospective nationwide mammography 
screening project conducted between October 1994 and February 1997 among 
Singaporean women aged 50 to 64 years old. Eligible women were asked to complete a 
questionnaire regarding their demographic and anthropometric measures, family as well 
as reproductive history before being invited for a one-time mammogram examination. 
Out of 28,234 women, 3,974 did not have information on mammographic density 
because their mammograms were either unavailable, or the image quality of the 
scanned mammogram was too poor for the accurate assessment of mammographic 
density. Among those with measurements for density, 99 were detected with breast 
cancer at time of screening, hence, they were excluded from further analyses. Therefore, 
a total of 24,161 participants were used in this study. The Institutional Review Board at 
the National University of Singapore has approved this study. No informed consent was 
required as the data were analyzed anonymously. 
 
7.2.2 Density measurement 
MLO views of both breasts were used in this study. Original film mammograms 
collected during the SBCSP, and jointly owned by the Saw Swee Hock School of Public 
Health and National Cancer Centre, were digitized between February 2012 through 
February 2013 using the 2905 Laser Film Digitizer (Array Corporation, Model 2905, 
Tokyo, Japan), with a sampling pitch of 50 micrometers and a gray-scale contrast 
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resolution of 12 bits. Mammographic density was determined using a fully-automated 
thresholding method described previously in [231]. After images have been pre-
processed such that only the breast area remains on the image, 15 global thresholding 
approaches available in ImageJ were applied to each image to separate the areas of 
“dense” breast tissue (“regions of interest”) from the remaining area of the breast. The 
Analyze command in ImageJ was then used to count and measure objects in the 
thresholded images (for groups of objects divided into four size categories: 5+ in the 
case of the former preprocessed images; 1 to 100, 101 to 1,000, and 1,001+ pixels, in 
the case of the latter images that underwent background subtraction and  
watershedding). A variety of measurements were obtained for the breast as a whole, as 
well as for the "objects" of dense tissue, under each thresholding method. We also used 
the Analyze command in ImageJ, after applying the "find edges" filter in ImageJ to 
identify sharp changes in intensity, and binary thinning to find the centerlines of objects 
in the image (in place of thresholding). For each image, 1,008 measurements were 
obtained as output from ImageJ. Principal component analysis was applied on the 1,008 
measurements. 
Mammographic density measurements (PMD and absolute dense area) obtained 
by one trained observer using the semi-automated Cumulus software, currently the gold 
standard, were available for 2,035 images digitized using the same parameters in an 
independent Swedish study [231]. These measurements were used as a training set for 
model building with the principal components based on penalized estimation using the 
lasso (l1) penalty [553] for PMD and absolute dense area in two separate models. 
Estimates obtained from the respective models were then applied to estimate PMD and 
absolute dense area for all mammograms in the SBCSP dataset. The mean density of 
both breasts was calculated. 
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7.2.3 Genotype simulation 
 Since biological samples had not been collected from the participants during the 
original study, genotypes for the 75 loci were simulated for each woman using her breast 
cancer status and genotype frequencies from the Asian populations in the BCAC [439, 
520], while assuming that there is no interaction between SNPs, mammographic density 
and other established risk factors. Approximately 30 of the loci had been established in 
earlier GWAS, while the remaining were novel SNPs that have only been identified in the 
most recent BCAC findings [439]. A corresponding GRS was derived to represent the 
cumulative effect of all risk variants for a woman carrying a particular set of simulated 
genotypes. This is equivalent to the sum of (log OR of SNP) x (Number of risk alleles 
that the individual carries for SNP) across all 75 SNPs. A total of 1,000 virtual genotype 
datasets were generated and GRS were calculated for each dataset and saved for the 
analysis with prediction models.  
 
7.2.4 Case ascertainment 
Incident breast cancer and vital status of all participants as of 31 December 2011 
was obtained via electronic linkage with the population-based Singapore Cancer 
Registry [96]. Both invasive and in-situ cases were included. 
 
7.2.5 Statistical analyses 
 The SBCSP questionnaire contained demographic data, reproductive risk factors 
as well as information on family history and past breast biopsy. We followed the risk 
factor categories from the original Gail model [399], where possible: age (50-54, 55-59, 
60-64 years), age at menarche (≥14, 12-13, <12 years), age at first live birth (<20, 20-24, 
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25-29 or nulliparous, ≥30 years), number of first degree relatives (None, ≥1), and past 
breast biopsy (No, Yes), but used the corresponding coefficients from our study. 
Ethnicity (Chinese, Indian, Malay, Others) and BMI (<20, 20-23.9, 24-27.9, ≥28 kg/m2) 
were also considered in the model as they were relevant to our study population. 
Mammographic density was grouped into six dense area categories: ≤10, 11-20, 21-30, 
31-40, 41-50, 51-60 cm2, while GRS was treated as a continuous variable.  
 Cox proportional hazards (PH) models were used to build the predictive models 
including mammographic density and common genetic variants and compute 
(approximately) 10-year risk for each individual. The validity of proportional hazards 
assumption was assessed by Schoenfeld residuals and all variables were not subject to 
time-varying effects across all the models. Three models (Gail variables + BMI, Gail 
variables + BMI + Density, Gail variables + BMI + Density + GRS) were constructed and 
compared in terms of their ability to accurately assess each woman’s 10-year absolute 
risk. We note that Cox PH models leave the baseline hazard un-estimated and therefore 
we approximated 10-year cumulative baseline hazard to compute the absolute risk 
(explained below). The first model consisted of variables from the Gail model, ethnicity 
and BMI; the second included mammographic density; the third had mammographic 
density and GRS. In Cox PH models, the probability that a woman will survive beyond a 




where β’ was the corresponding effect size for each variable, and ∫ ℎ(𝑠)𝑑𝑠
𝑡
0
 was the 
cumulative baseline hazard for t years. In order to approximate the latter, we used the 
basehaz command in the survival R package, which implements the Nelson-Aalen 
estimator of the cumulative hazard for a person with specific covariate value x and 
reports the resulting survival probability estimate SNA(t | x). We computed this value for a 
person with X , average values for all covariates in the model (the reference group was 
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taken in the case of categorical variables), and approximated 10-year cumulative hazard 
as –log [SNA(t│ X )]/(e
β’ x ). Since each subject’s 10-year absolute risk is the desired 
score, an individual’s 10-year risk (with covariate X) of being diagnosed within ten years 
is 1- S (10│x).  
Improvement in the prediction performance was assessed by the changes in the 
AUC of the ROC for each model, as well as positive and negative predictive values at 
fixed 10-year absolute risk thresholds. We also computed the concordance probabilities 
using the Cox proportional hazard model fits as additional performance metric that is 
robust to censored data [554]. To account for overly-optimistic improvements in model 
performance when simulated genotypes are included, we used a 10-fold cross-validation 
in each of the 1,000 virtual datasets and averaged the ROCs over the 1,000 sets.  
All statistical analyses were performed using R version 2.13.0. Statistical tests 











 As of 31 December 2011, 680 women were diagnosed with either in-situ (n=106) 
or invasive (n=574) breast cancer. Table 7.1 shows the distribution of the study 
population by demographic, reproductive and other risk factors. The majority of the 
cases were 55 to 59 years old, more educated, have younger age at menarche, 
nulliparous or have their first child at a later age. They are also more likely to be current 
users of hormone replacement therapy, have a positive family history, previous breast 
biopsy, higher BMI and higher mammographic density. Based on the simulated 
genotypes, the corresponding GRS ranged from 2.75 to 7.01, with more cases being 
categorized in higher quintiles. The median follow-up time for cases and controls was 













Table 7.1 Distribution of baseline characteristics in breast cancer patients (cases) and 
healthy individuals (non-cases), the Singapore Breast Cancer Screening Programme. 
Demographics Cases (n= 680) Non-cases (n=23 481) P value 














Education level, n (%) 
No formal education 
Primary 






14 288 (60.8) 
   4390 (18.7) 











  36 (5.3) 
  38 (5.6) 
  23 (3.4) 
 
19 962 (85.0) 
   1146 (4.9) 
   1085 (4.6) 
   1288 (5.5) 
 
0.07 
Reproductive risk factors 
Age at menarche, n (%) 
≥ 14 





  39 (5.7) 
 
15 317 (65.2) 
   7429 (31.6) 
     735 (3.1) 
 
<0.001 
Age at first live birth, n (%) 
< 20 
20 – 24 
25 – 29 or nulliparous 
≥ 30 
 












Age at menopause, n (%) 
< 50 





  59 (8.7) 
 
11 064 (47.1) 
10 405 (44.3) 




Number of deliveries, n (%) 
0 
1 or 2 
3 or 4 
≥ 5 
 











Hormone Replacement Therapy 







  54 (7.9) 
  87 (12.8) 
 
 
20 349 (86.7) 
   1378 (5.9) 




Other risk factors 
Number of affected 1
st
 degree 







  34 (5.0) 
    2 (0.3) 
 
 
22 906 (97.6) 
     566 (2.4) 









  65 (9.6) 
 
22 266 (94.8) 
   1215 (5.2) 
 
<0.001 
Body mass index, n (%) 
< 20 
20 - < 24 
24 - < 28 
≥ 28 
 













Mean breast percent mammographic 
density, n (%) 
< 10% 
10% - < 25% 
25% - < 50% 
≥ 50% 
 
   
  57 (8.4) 
365 (53.7) 
246 (36.2) 
  12 (1.8) 
 
    
    3751(16.0) 
13 243 (56.4)  
   6232 (26.5) 





























  43 (6.3) 







  833 (3.5) 
 
<0.001 
Genetic Risk Score in quintiles, n (%) 
First       (2.75-4.22)      
Second  (4.23-4.43) 
Third      (4.44-4.62) 
Fourth    (4.63-4.84) 
Fifth       (4.85-7.01) 
 
  73 (10.7) 


























We evaluated the associations of the Gail model predictors, ethnicity, BMI, 
mammographic density and GRS with breast cancer risk. From Table 7.2, women who 
are 60 to 64 years old seemed to be at lower risk of breast cancer compared to those 
aged 50 to 54. This protective effect is no longer present after adjustment for breast 
density. The Malays reported about a 30% lower risk of disease in all three models 
compared to the Chinese, but this did not reach statistical significance. The established 
Gail model risk factors remained statistically significant even after accounting for BMI, 
density and GRS. Every increase of 0.1 in GRS corresponds to a 10% higher risk of 
breast cancer on average. BMI, mean dense area, and PMD (Table 7.3) also 
significantly increased one’s risk of disease by approximately 2 to 4 fold across all 








Variable vGail + BMI (95% CI) P value vGail + BMI + 
Density (95% CI) 
P value vGail + BMI + Density 
+ GRS (95% CI) 
P value 
Age, years 
50 – 54 




1.07 (0.90, 1.28) 







1.17 (0.98, 1.40) 







1.17 (0.98, 1.40) 












1.16 (0.82, 1.62) 
0.66 (0.43, 1.01) 








1.14 (0.81, 1.60) 
0.70 (0.46, 1.08) 








1.10 (0.78, 1.54) 
0.71 (0.46, 1.08) 
























1.13 (0.96, 1.33) 









1.14 (0.97, 1.34) 






Age at first live birth, 
years 
<20 
20 – 24 





1.21 (0.93, 1.57) 
1.85 (1.43, 2.40) 










1.16 (0.89, 1.51) 
1.66 (1.28, 2.15) 










1.14 (0.88, 1.49) 
1.63 (1.26, 2.12) 







Number of 1st degree 
relatives with breast 
cancer 
None 




















































Table 7.2 Association of conventional risk factors, BMI, mean breast dense area and GRS with breast cancer. 
 















Body mass index, 
kg/m2 
<20 
20 to <24 
24 to <28  




2.03 (1.44, 2.87) 
2.40 (1.70, 3.39) 










2.16 (1.53, 3.06) 
2.64 (1.86, 3.74) 










2.19 (1.55, 3.10) 
2.66 (1.88, 3.77) 















NA NA  
 
1.00 (ref) 
1.62 (1.23, 2.12) 
2.21 (1.67, 2.94) 
2.38 (1.74, 3.25) 
2.11 (1.43, 3.13) 












1.60 (1.22, 2.10) 
2.20 (1.65, 2.92) 
2.33 (1.71, 3.20) 
2.12 (1.43, 3.14) 









Genetic risk score 
(2.8 – 7.0) 







Variable vGail + BMI (95% CI) P value vGail + BMI 
+ %Density (95% CI) 
P value vGail + BMI + %Density 
+ GRS (95% CI) 
P value 
Age, years 
50 – 54 




1.07 (0.90, 1.28) 







1.17 (0.98, 1.40) 







1.17 (0.98, 1.39) 












1.16 (0.82, 1.62) 
0.66 (0.43, 1.01) 








1.19 (0.85, 1.67) 
0.73 (0.48, 1.12) 








1.15 (0.82, 1.61) 
0.73 (0.48, 1.12) 
























1.13 (0.96, 1.33) 









1.14 (0.97, 1.35) 






Age at first live birth, 
years 
<20 
20 – 24 





1.21 (0.93, 1.57) 
1.85 (1.43, 2.40) 










1.17 (0.89, 1.52) 
1.68 (1.29, 2.18) 










1.15 (0.88, 1.50) 
1.65 (1.27, 2.14) 







Number of 1st degree 
relatives with breast 
cancer 
None 




















































Table 7.3 Association of conventional risk factors, BMI, mean percent mammographic density and GRS with breast cancer. 
 















Body mass index, 
kg/m2 
<20 
20 to <24 
24 to <28  




2.03 (1.44, 2.87) 
2.40 (1.70, 3.39) 










2.25 (1.59, 3.18) 
2.84 (2.00, 4.03) 










2.27 (1.60, 3.22) 
2.86 (2.02, 4.07) 











10 - <25 
25 - <50 
≥50 




1.78 (1.34, 2.37) 
2.59 (1.90, 3.54) 












1.77 (1.33, 2.36) 
2.56 (1.88, 3.49) 








Genetic risk score 
(2.8 – 7.0) 
NA NA NA NA 1.10 (1.03, 1.16) <0.001 
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Performance in the three risk prediction models was examined by plotting ROC 
curves and comparing their areas under the curve. As genotypes were simulated, the 
average of 1,000 ROC curves for the model with GRS is reported in Figure 7.1. The 
model including Gail predictors, BMI, and mean dense area reported an AUC of 0.66 
(0.64 – 0.68), while an inclusion of GRS reported 0.68 (0.66 – 0.69). A similar 
observation in model performance was observed for the same model using PMD instead 
(Figure 7.2). Tables 7.4 and 7.5 show the concordance probabilities for the respective 




Figure 7.1 Three ROCs for predicting breast cancer: vGail + BMI (black), vGail + BMI + 
mean breast dense area (red), vGail + BMI + mean breast dense area + GRS (green). 
For the model with GRS, the average of 1000 ROCs is drawn. AUCs are 0.63, 0.66 and 




Figure 7.2 Three ROCs for predicting breast cancer: vGail + BMI (black), vGail + BMI + 
mean PMD (red), vGail + BMI + mean PMD + GRS (green). For the model with GRS, the 
average of 1000 ROCs is drawn. AUCs are 0.63, 0.65 and 0.67 respectively. The 
straight dashed line represents the ROC expected by chance only.   
 
Table 7.4 Concordance probabilities of the three risk prediction models (absolute dense 
area). 
Prediction Model Concordance Probability 95% CI 
vGail+BMI 0.62 0.60 - 0.64 
vGail+BMI+Density 0.65 0.63 - 0.66 
vGail+BMI+Density+GRS 0.66 0.65 - 0.68 
 
 
Table 7.5 Concordance probabilities of the three risk prediction models (percent 
mammographic density). 
Prediction Model Concordance Probability 95% CI 
vGail+BMI 0.62 0.60 - 0.64 
vGail+BMI+%Density 0.64 0.62 - 0.66 
vGail+BMI+%Density+GRS 0.66 0.65 - 0.68 
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 From Figures 7.3 and 7.4, we note a greater discrimination between cases and 
controls in terms of 10-year predicted absolute risk after the addition of mammographic 
density and GRS. As the risk thresholds (selected a priori) become more stringent from 
1% to 3%, the difference in the proportion of patients that are correctly identified 
between the modified models and the Gail model, increases in general (Tables 7.6 and 
7.7). In terms of accurately classifying healthy individuals, all models fared equally well 





Figure 7.3 Distribution of predicted 10-year absolute risk for patients (red) and healthy 
individuals (black) using the three prediction models. As mean breast dense area and 
GRS are added to the model, the discrimination between cases and non-cases 








Figure 7.4 Distribution of predicted 10-year absolute risk for patients (red) and healthy 
individuals (black) using the three prediction models. As mean percent mammographic 
density and GRS are added to the model, the discrimination between cases and non-


















Table 7.6. Positive and negative predictive values of the three risk prediction models at 

























































































Table 7.7 Positive and negative predictive values of the three risk prediction models at 
























































































Using a prospective cohort with baseline information on risk factors, 
mammographic density and simulated SNPs, we have observed better prediction of 10-
year cumulative risk in a low incidence environment. Models incorporating these 
additional predictors improved the area under the curve by 2% and 6% respectively, 
encouraging mammography screening and identification of more SNPs related to breast 
cancer risk. 
The Gail model has previously been shown to be poorly calibrated to the 
Singapore population, over-estimating an individual’s 10-year absolute risk by close to 
two-fold [550]. A recent study in 2012 reported that using a revised model which was 
country-specific improved model performance [555]. Here, we tested the use of 
mammographic density in improving the performance of the established risk prediction 
model. Similar to past studies in other populations [418, 421, 447], we report a modest 
increase in model performance from 0.63 to 0.66, and 0.63 to 0.65 for absolute dense 
area and percent density, respectively (Figures 7.1 and 7.2). This is slightly better than 
the 1% that was observed by Tice et al, who had assessed mammographic density with 
the more subjective BI-RADS tool, unlike the others who focused on percent density 
instead. Such errors in qualitative measurement tend to attenuate the association 
between mammographic density and risk of disease [476]. Although the best measure of 
mammographic density for risk assessment is still undetermined [237, 556, 557], the 
current study found no difference in AUC between the models that included either 
measure unless GRS was added too (Figures 7.1 and 7.2). Wider discrimination 
between cases and controls at various 10-year absolute risk thresholds (Figures 7.3 
and 7.4) highlights the potential application of our modified models in a clinical setting. 
These thresholds were set based on the 1.7% cumulative risk of women in Singapore at 
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age 50 [509], such that women at 3% were deemed to be at high risk. However, some of 
this effect could be due to the genotype data being generated independently of 
mammographic density and the other Gail model risk factors. The availability of a 
sufficient number of orthogonal predictors, each having limited predictive power, has the 
potential to improve the ROC curve. Given the low prevalence of breast cancer, our 
modified model could not enhance the existing performance of the Gail model 
substantially (Tables 7.6 and 7.7). The proportions obtained at 5.0% and 10.0% risk 
thresholds may not be reliable due to the small number of individuals at these cut-offs. 
Given the 1.7% cumulative risk, these thresholds may not be relevant in an Asian 
context. 
Breast cancer patients and healthy individuals were significantly different in all 
variables except ethnicity (Table 7.1). Due to the large size of the study population, the 
relevance of p values governing statistical significance is limited. Since the Chinese form 
approximately 75% of the local population, they may be over-represented in this study. 
Unexpectedly, ethnicity was not a statistically significant predictor in all three models as 
reported in earlier literature on the local population [513]. The change in association of 
BMI with breast cancer risk, after adjustment by mammographic density, is in agreement 
with our understanding on its negative confounding effect [558].   
To our knowledge, we are the first to consider the cumulative effect of the largest 
number of SNPs in breast cancer risk prediction for an Asian setting, using data from the 
only prospective trial conducted outside Europe and North America. Darabi et al have 
carried out a similar study recently, investigating the impact of BMI, PMD and 18 
common genetic variants on Swedish post-menopausal women [447]. Their results 
suggest an added value in using a larger pool of genetic markers, and a more obvious 
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shift of controls to a lower predicted risk category. Contrary to their findings, we saw a 
greater effect among our cases.  
Most groups have initially used estimation and subsequently computer-assisted 
methods to measure mammographic density. We have applied a fully-automated, high-
throughput method of measuring mammographic density, which can minimize any visual 
irreproducibility related to more subjective assessments. Also, this measure has been 
shown to be highly correlated with Cumulus, an established semi-automated tool [231].  
We have made a few assumptions in our study. Firstly, since cancer notification 
is mandatory in Singapore and all Singaporeans have a unique identification number, we 
expect the completeness of reporting to be close to 100% [559]. Secondly, we assume 
no correlation between mammographic density and SNPs, as well as between the 
various SNPs. Numerous groups have found common variants that contribute to the 
heritability of mammographic density [560-562], but the findings have either not been 
replicated or been countered [563, 564]. Thirdly, we have ignored the possible difference 
in screening behavior between the women in our study and those in the general 
population. Lastly, we have simulated the genotypes of our subjects while ignoring the 
linkage between certain loci that are relatively close together in the genome. Neglecting 
this point may result in an over-estimation of the impact of genetic variants.  
In this study, a cross-sectional simulation which is unrealistic has been 
implemented and no external validation has been done. However, the findings are in line 
with observations previously made in Chapter 6, which reported a modest improvement 
in risk assessment after including common genetic variants. Even with the over-
optimistic estimates reported here, the cumulative effect of common genetic variants 
does not seem to be very useful in enhancing risk model performance. 
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Although we had intended to compare our modified model with the Gail model, 
some of our study’s categories differed from the original model. Previous breast biopsy 
was recorded as “Yes/No” instead of the number and presence of atypical hyperplasia; 
family history was coded as “None/At least 1” instead of the actual number of affected 
first-degree relatives. However, we believe these minor coding differences will not affect 
our conclusion drastically [550]. 
The use of SNPs is dependent on the cost of genotyping, ease of collection of 
genetic material through blood samples or buccal swabs, as well as the identification of 
additional SNPs in future. As the women from the SBCSP were recruited in the 1990s, 
the results from this study may not be very relevant to a cohort of individuals two 
decades later where lifestyle patterns are more westernized. Further studies are 
required to gauge the applicability of the modified models on women younger than 50 
years. The modified model we propose will also not be very feasible in developing 
nations where resources for large-scale implementation of mammography screening and 







8 CONCLUSION AND FUTURE PERSPECTIVES 
 The work in this thesis contributes to the growing body of knowledge in breast 
cancer detection and risk assessment.  
We have presented the advantages of a novel method for visualizing breast 
images in 3D over conventional 2D mammography. The use of 3D SDM seemed to be 
most suited for detecting mass lesions by improving margin clarity. It also reduced the 
need for additional mammographic views but not ultrasound. With 3D SDM, 
abnormalities that are malignant or develop in denser breasts were more easily spotted.  
Although digital mammography can overcome sensitivity issues of traditional 
screen-film mammography especially in pre-menopausal women with 
mammographically dense breasts, it still faces limitations due to superimposed breast 
tissues that hamper detection of malignant lesions. The fact that breast thickness can be 
accounted for by 3D imaging makes it an attractive option in both diagnostic and 
screening settings. However, the high cost of this advanced technology may restrict its 
mass application. Large validation studies and formal cost-effectiveness analyses should 
be done before this new imaging technology is implemented in population-based 
initiatives. 
Risk assessment helps to determine if screening for a woman of intermediate risk 
should be performed at an earlier age or at shorter intervals. Mammographic density is 
an important risk factor of breast cancer and various groups have explored its inclusion 
in established risk models. However, the measure of mammographic density was not 
standardized, leading to mixed results. Also, most findings in the literature had been 
obtained from analogue screen-film mammography, which is gradually being phased out 
by digital technology. We have demonstrated the feasibility of using qualitative versus 
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quantitative measures of mammographic density from processed FFDM images for 
predicting a woman’s likelihood of developing breast cancer. Common density measures 
namely dense area and BI-RADS remain significantly associated with the disease when 
they are read from processed digital images. Together, dense and total area quartiles 
can replace BI-RADS as an objective and less labor-intensive alternative in risk 
estimation. While volumetric measures of mammographic density are not affected by the 
potential sources of error present in 2D mammography, they are less strongly 
associated with breast cancer and did not achieve better risk estimates [3].  
The launch of GWAS has identified numerous SNPs that influence breast cancer 
susceptibility but whose functions are unknown. It was expected that the majority of 
breast cancers would be explained by these common genetic variants and their addition 
to established models would yield more accurate risk estimates. As with other Western 
and Asian studies, we have shown that 51 SNPs can improve the current assessment of 
breast cancer risk in a Singapore Chinese population, but only modestly. Combining 
absolute dense area or PMD with SNPs and conventional risk factors can further 
increase model discriminatory power. For countries such as Singapore where breast 
cancer incidence is relatively low and mammography screening is not as well-received, 
cost-efficiency and ethical issues can be more aptly addressed. 
Our findings support evidence from the literature that common genetic variants 
and mammographic density add little to established risk models. Despite the hope that 
more genetic variants will be discovered via new, high-throughput sequencing methods, 
one should not anticipate any drastic enhancement in model performance. According to 
a simulation by Zitteren et al., an extra 50 SNPs with risk allele frequencies of 0.30 and 
ORs of 1.5 are needed to increase AUC from 0.68 to 0.8. Even when 100 more SNPs 
are added, effect sizes between 1.3 and 1.7 are required [565]. Rather than investing 
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resources exclusively in search of SNPs with declining effect sizes, it may be prudent to 
examine complex gene-gene and gene-environment interactions, as well as the 
relationship of breast cancer with biomarkers and epigenetic factors. Given the 
heterogeneous nature of the disease, specific risk models may have to be developed for 
each subtype to attain greater predictive accuracy.  
Screening is a double-edged sword that can cause more harm than good 
especially among younger, premenopausal women. Although screening in the general 
population is motivated by age, young females at higher risk of breast cancer should not 
be neglected. Conversely, older women at lower risk should not be exposed to 
unnecessary anxiety and medical procedures. Risk assessment serves to stratify 
individuals for tailored screening. However, these models have mostly been developed 
and validated in women who are postmenopausal or above the age of 50. As models 
may not be well-calibrated for populations with different incidence of breast cancer, it is 
imperative for prospective, cohort studies to be conducted in younger, premenopausal 
women. Even if a model is deemed suitable, it needs to be updated over time to account 
for temporal trends [458].  
Besides screening, risk assessment can also play a role in the primary 
prevention of breast cancer. Unfortunately, the performance of current models does not 
permit the suggestion of chemoprevention and prophylactic mastectomy. The accurate 
classification of risk is no doubt crucial, but having specific recommendations and clear 
communication of consequences for the respective risk categories should take 
precedence. Since a majority of established risk factors are not modifiable, women who 
are more susceptible can be encouraged to exercise frequently, keep a low-fat diet and 
reduce their consumption of alcohol. Although the association of these lifestyle factors 
with breast cancer is uncertain, its established relationship with other non-communicable 
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diseases such as cardiovascular disease and diabetes means that advocating these 
lifestyle changes is still beneficial.  
Epidemiological research on breast cancer has been focused on developed 
countries because databases are more accessible and complete. In regions where 
healthcare resources and infrastructure are scarce, calls for a personalized screening 
programme and 3D diagnostic imaging are irrelevant. Instead, educating people on the 
early symptoms of breast cancer, its risk factors and correct perception of personal risk, 
as well as routine CBE should be advised so that treatment can be administered 
promptly. 
Advanced therapeutics has reduced the burden of breast cancer by lowering 
mortality rates, but more needs to be done. Strategies that facilitate optimal treatment 
through more accurate and earlier detection, while minimizing the dangers of 
conventional screening, are currently being developed and refined in many populations. 
Unless contextual aspects are taken into account, neither screening nor treatment will be 
cost-effective. Concerted efforts should be made to improve the predictive ability of risk 
assessment models so that prophylactic interventions - even extreme ones, may be 
recommended with reasonable certainty. After all, as the old adage goes, “Prevention is 








The last two decades have witnessed accelerated progress in molecular biology 
and genetics. Since the sequencing of the human genome, the promise of genetics as a 
dominant explanatory agent in disease causation has been alluring. Causality of disease 
has been viewed as a close function of biology and distal relation to social organization 
[566]. This notion of social factors being antecedents to biological processes has 
facilitated the propagation of a biomedical fallacy - the sum of risk factors in all 
individuals is incorrectly thought to underlie disease causation in populations, and a 
population’s health being solely a consequence of the characteristics of the people that it 
contains [567]. Furthermore, this has initiated a search for innovative and sometimes 
sophisticated methodological frameworks to incorporate extensive genetic data into 
existing analyses.  
The work detailed in this thesis has shown that genetic information adds little to 
breast cancer risk assessment. This in turn raises issues on the dangers of using 
genetics indiscriminately especially in commercializable services. For example, 
23andMe, a personal genomics and biotechnology start-up, conducts direct-to-consumer 
genetic testing. Health-related claims from its reports could mislead consumers who are 
ill-informed about the limitations and reliability of current genetic tests, causing undue 
stress and unnecessary follow-up procedures akin to a false positive mammogram. In 
2013, the company terminated its health-related genetic testing services after a warning 
from the U.S. Food and Drug Administration agency [568]. .  
  To better understand breast cancer etiology and develop more effective 
preventive strategies, research on new biomarkers from blood or tissue is crucial. 
Investigations on epigenetic modifications, or circulating levels of hormones and growth 
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factors are likely to bear fruit in the near future, although their impact on existing risk 
assessment models remains to be evaluated [569].  
A holistic systems approach should perhaps be adopted too [570]. Despite 
resounding historical success, one should recognize that the conventional model of 
etiology had worked because contagious diseases were caused by a single necessary 
and sometimes, sufficient agent. This mono-causal model, however, is inappropriate for 
chronic diseases such as breast cancer, which depend on a multitude of factors that are 
neither necessary nor sufficient [571]. Numerous propositions for an integration of social 
and biomedical factors in health research have been made in recent years [572, 573]. 
Sadly, these proposals to incorporate a social side to epidemiology were nothing more 
than superficial as concrete discussions on the process have been limited [570]. One of 
the solutions that was described in greater detail was dynamic systems modeling [574]. 
This model allows the examination of behavior and relationships of many components in 
a defined population while it is functioning: interactions between multiple variables from 
the sub-cellular to the societal level, inter-dependence and feedback mechanisms 
between individuals, as well as changes over an individual’s course of life [570]. 
Although it has been used in physiology and infectious diseases, causal systems models 
have not been widely applied to chronic, non-communicable  diseases [574]. 
Hippocrates’ discourse, “Airs, Waters, Places” [575], has been a reference for 
learning about associations between the environment and the health of people in a 
population. Today, the scope of epidemiology has expanded to encompass  all “health-
related states or events” and the “control of health problems [576].” Regardless of its 
evolving definition, the ultimate aim of epidemiology - advance scientific knowledge, 
promote, protect, and restore health, remains and continues to put it at the centre of 
public health and preventive medicine. The emergence of distinct branches in 
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epidemiology and advanced statistical methods reflect the maturation of research in this 
field. To further its cause, epidemiology needs to integrate both science and art through 
multi-disciplinary collaborations. The former lies in its ability to predict and explain based 
on clinical and experimental knowledge, while the latter is the timely implementation of 
ingenious strategies to address specific health issues. Navigating a maze of complex 
interactions between health, genes and the environment is the challenge of this century. 
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